Multimerizer pharmaceutical compositions of rimiducid

Abstract

The technology relates in part to formulations of rimiducid, rimiducid family compounds and analogs thereof, and in part to formulations suitable for administration by injection and oral administration.

Description

[0001] MULTIMERIZER PHARMACEUTICAL COMPOSITIONS Cross-Reference to Related Patent Application This patent application claims priority to, and is a non-provisional of, U.S. provisional patent application numbers 63 / 519,466 (filed on August 14, 2023) and 63 / 620,542 (filed January 12, 2024). The entire content of the foregoing patent applications is incorporated herein by reference for all purposes, including all text, tables and drawings. Reference to a Sequence Listing This application contains a Sequence Listing in computer readable form. The computer readable form is incorporated herein by reference. The computer readable file is named Seqeuence.xml and was created on August 7, 2024 (9 kB size). Field The technology relates in part to formulations of rimiducid and analogs thereof, and relates in part to formulations suitable for administration by injection and oral administration. Background Chemically induced dimerization is a technology that allows for remote control of one or more signaling cascades among numerous signaling pathways within cells. The cells typically are genetically modified to express chimeric proteins that respond to a multimerizing ligand (also referred to herein as a “multimerizer” and “multimerizing agent”). There is a relatively small number of ligands suited for use in humans expressing multimerizable chimeric proteins. One such ligand is rimiducid, also referred to as AP1903, which is a homodimerizer having two identical binding sites and is 1411 Daltons in size. Rimiducid homodimerizes an analog of the human, prolyl isomerase protein, FKBP12, which can be genetically engineered into fusion proteins that are activated upon rimiducid-induced dimerization of the FKBP12 portions. This chemical-induced dimerization (CID) technology can be used to trigger a wide spectrum of downstream signaling cascades, and the use of rimiducid as a chemical dimerizer to trigger the caspase 9 apoptotic pathway has been clinically validated. Summary Described herein are pharmaceutical compositions that include an active ingredient containing a multimerizer. Non-limiting examples of a multimerizer active ingredient that can be included in such a pharmaceutical composition include a compound of Formula A, a compound of Formula B, a rimiducid analog (e.g., a compound of Formula C, D, E, F, F1, G, H, H1 or J) or a pharmaceutically acceptable salt, ester or amide thereof, as described herein. In certain aspects, provided is a pharmaceutical composition for administration by injection, such as subcutaneous (SQ) or intramuscular (IM) administration. In certain implementations, a pharmaceutical composition for administration by injection includes a multimerizer as an active ingredient and pharmaceutically acceptable excipients described herein. In certain aspects, provided is a pharmaceutical composition for oral administration (e.g., transdermal administration, transmucosal administration). In certain implementations, a pharmaceutical composition includes a multimerizer active ingredient, and pharmaceutically acceptable excipients described herein In certain aspects, provided is a method for manufacturing a pharmaceutical composition described herein. In certain aspects, provided is a composition comprising a compound according to Formula H, H1 or J, as defined herein, or a pharmaceutically acceptable salt thereof. In certain aspects, provided is a method for using a composition described herein for interaction of a multimerizer with a molecule that specifically binds to the multimerizer. Certain implementations are described further in the following description, examples and claims. Brief Description of the Drawings The drawings illustrate certain implementations of the technology and are not limiting. For clarity and ease of illustration, the drawings are not made to scale and, in some instances, various aspects may be shown exaggerated or enlarged to facilitate an understanding of particular implementations. FIG.1 shows mean particle size and polydispersity determined for particles in a representative SEDDS Formulation A containing the active ingredient rimiducid. FIG.2A shows rimiducid levels assessed over time after administration of a representative SEDDS Formulation A to rats, and FIG.2B shows rimiducid levels assessed over time after administration of the formulation to dogs. FIG.3 shows mean particle size and polydispersity determined for particles in a representative SEDDS Formulation D containing the active ingredient rimiducid. FIG.4A shows rimiducid levels assessed over time after administration of a representative SEDDS Formulation D to rats, and FIG.4B shows rimiducid levels assessed over time after administration of the formulation to dogs. FIG.5A, FIG.5B and FIG.5C depict a synthetic scheme for synthesizing the compound of Formula B. FIG.6A, FIG.6B and FIG.6C depict a synthetic scheme for synthesizing the compound of Formula H1. FIG.7A, FIG.7B, FIG.7C and FIG.7D depict a synthetic scheme for synthesizing a subset of compounds of Formula J. FIG.8A, FIG.8B, FIG.8C and FIG.8D depict a synthetic scheme for synthesizing a subset of compounds of Formula J. FIG.9A, FIG.9B and FIG.9C depict a synthetic scheme for synthesizing the compound of Formula F1. FIG.10A is a graph showing pharmacokinetic (PK) data after subcutaneous (SC) injection in mice of Formulation A. FIG.10B is a graph showing pharmacokinetic (PK) data after subcutaneous (SC) injection in mice of Formulation D. Detailed Description For a compound to reach systemic circulation, it must first be in solution, then permeate the cellular absorption barriers and finally escape intestinal / hepatic first-pass metabolism. Rimiducid is a multimerizer characterized as a class IV compound having low aqueous solubility (i.e., a volume of greater than 250 milliliters required to dissolve an effective dose), low gastrointestinal permeability (i.e., less than 10-5centimeters per second), high molecular weight and poor bioavailability (i.e., less than 90% of a dose administered by a non-intravenous route is absorbed, compared to an intravenous dose). Rimiducid is considered a poor candidate for oral administration and other routes of administration in view of these physical properties, as addressed in greater detail hereafter. An API possessing all physical properties identified according to Lipinski’s Rule of Five (RO5) is expected to have a relatively high probability of drug absorption from the intestinal track, and thereby a relatively high probability of oral bioavailability (Lipinski et al., Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26. doi: 10.1016 / s0169-409x(00)00129-0). According to the RO5, an API formulated for oral administration should have no more than one violation of the identified physical properties. The physical properties according to Lipinski's RO5 are: (1) no more than 5 hydrogen bond donors (the total number of nitrogen–hydrogen and oxygen–hydrogen bonds); (2) no more than 10 hydrogen bond acceptors (all nitrogen or oxygen atoms); (3) a molecular mass less than 500 Daltons (Da); and (4) an octanol-water partition coefficient (log P) that does not exceed 5. Rimiducid, having a structure according to Formula B herein and within the family of molecules defined by the structure according to Formula A herein, violates all of the physical properties according to Lipinsky’s Rule and therefore is not expected to display clinically relevant oral absorption. Rimiducid has 22 hydrogen bond donors (maximum allowed is 5), 24 hetero-atoms (O + N; maximum allowed is 10), a molecular mass of 1411.6 Da (maximum allowed is 500 Da) and a cLogP of 11.9 (maximum allowed is 5) (PubChem). Rimiducid has an extremely low water solubility of less than 0.5 µg / mL (Drug Bank Online), likely because it possesses no ionizable functional units. As such, rimiducid is categorized as a biopharmaceutical classification system (BCS) class IV drug. Although there are exceptions, BCS class IV compounds generally are viewed as poor candidates for oral delivery (Markovic et al., Pharmaceutics 2020, 12(12), 1175. doi.org / 10.3390 / pharmaceutics12121175). For a compound to be absorbed, it must first be in solution. Because of the extremely low water solubility, assuming an upper gastro-intestinal (GI) tract water content of approximately 500 mLs (if the dose were taken with 240 mLs of water), the theoretical maximal solubility of rimiducid within the upper GI tract likely is limited to less than 250 µg. Once solubilized, rimiducid must cross the plasma membranes of the intestinal tract to be absorbed. However, because of the extremely high number of hydrogen bond donors (22) possessed by rimiducid, the de-solvation energy required for lipid permeation would preclude passive permeability (Milanetti et al., Bioinformatics, 2016 April :32(8);1163–1169, doi.org / 10.1093 / bioinformatics / btv725). Because of the molecular weight of 1411.6 Da, passive absorption of rimiducid through the intestinal aqueous porin channels is unlikely (Dahlgren et al., Pharmaceutics.2019;11(8):411. Published 2019 Aug 13. doi:10.3390 / pharmaceutics11080411). Due to the challenging physical and chemical properties of rimiducid, a limited number of formulation excipients has been identified and route of administration is limited. In a clinical setting, rimiducid typically is infused slowly by intravenous (IV) administration to patients over a timespan covering two hours or longer. Rimiducid typically is stored in 25% Solutol HS15 / Kolliphor®HS15 (CAS# 70142-34-6) at 5 mg / ml, which is added to a 100-mL bag of saline. Solutol HS15 is associated with toxic side-effects when dosed intravenously, which is a primary reason for long infusion times. Due to risk of an infusion reaction to Solutol HS15, patients typically are treated prophylactically with the anti-histamine diphenhydramine and other anti-inflammatory agents. The labor intensity, slow infusion rate, and potential Solutol HS15 toxicity associated with Intravenous administration of rimiducid has limited it to a once-per-week dosing regimen, reducing its widespread applicability. It was not known whether a formulation of rimiducid and related analogs could be prepared for successful administration. Provided herein are formulations for injection (e.g., subcutaneous injection, intramuscular injection), or oral administration of rimiducid and related analogs. By obviating the requirement for intravenous administration and pre- and post-procedure measures to manage the possibility of infusion-based complications, the formulations provided herein can be considered for administration to a larger numbers of patients and for use in situations that could benefit from more frequent and / or longer exposure to the drug. Multimerizer active ingredient A pharmaceutical composition generally includes one or more active pharmaceutical ingredients (APIs), each of which can be referred to as an “active ingredient”. A pharmaceutical composition can include a multimerizer as an active ingredient. In certain implementations, an active ingredient in a pharmaceutical composition includes a rimiducid family molecule having a structure of Formula A. O O O O The rimiducid family of molecules having a structure according to Formula A includes rimiducid having a structure of Formula B. The compound having the structure of Formula B also is referred to as AP1903. An active ingredient in a pharmaceutical composition, in certain implementations, includes rimiducid having a structure of Formula B. An active ingredient in a pharmaceutical composition in certain instances can include a rimiducid analog. A rimiducid analog can include one or more atom modifications, one or more chemical group modifications and / or one or more linkage modifications relative to rimiducid or a rimiducid family compound. A modification may be a removal, substitution or addition, and sometime is a conservative or minor modification. A modification sometimes is in the linker or non-binding, peri- linker sides of the molecule having a structure of Formula A or Formula B that affects solubility or stability and not binding to a polypeptide (e.g., FKBP12-V36 polypeptide (e.g., polypeptide of SEQ ID NO:1 or SEQ ID NO:4). In certain instances, 1, 2, 3, 4 or 5 atoms, chemical groups and / or linkages in rimiducid or a rimiducid family compound are modified in a rimiducid analog. Non-limiting examples of rimiducid analogs include AP20187 and AP1510 (Formula C and Formula D), or a pharmaceutically acceptable salt thereof. Formula C (AP20187)

[0002] Another non-limiting example of a rimiducid analog is a compound of Formula E, in which two ester groups in rimiducid are substituted with amide groups, or a pharmaceutically acceptable salt thereof. Other non-limiting examples of rimiducid analogs are compounds of Formula F and Formula G, or pharmaceutically acceptable salts thereof, where substituents A, Y, Z, A' and Z' are defined in publication WO2019126344A1 (PCT / US2018 / 066532). Formula F

[0003] Formula G In certain implementations pertaining to compounds of Formula F and Formula G: Z and Z’ are the same or different and each independently is O, NR12, -N=, S, SO, SO2or CH2; Y is L, M or Q: R1, R2, R3, and R4are the same or different, and each is independently hydrogen, lower alkyl, heteroalkyl, perhaloalkyl, lower alkoxy, lower cycloalkyl, lower aryl, cycloalkyl, aryl, lower heterocycloalkyl, lower heteroaryl, heterocycloalkyl, or heteroaryl, which independently are optionally substituted with one or more substituents chosen from halogen, hydroxy, alkyl, heteroalkyl, haloalkyl, perhaloalkyl, perhaloalkoxy, alkoxy, haloalkoxy, alkoxyalkyl, acyl, oxo, acyloxy, carboxyl, amido, cyano, amino, alkylamino, alkylaminoalkyl, thiol, alkylthio, alkylthioalkyl, haloalkylthio, perhaloalkylthio, nitro, aryl, arylalkyl, cycloalkylalkyl, heterocycle- alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, alkylsulfonyl, sulfonamide, alkylsulfonamido and alkylsilyloxy; when Y is M, R1and R2together with -N-RL-N- may form a heterocyclic or heteroaryl ring optionally substituted with one or more substituents chosen from halogen, hydroxy, alkyl, heteroalkyl, haloalkyl, perhaloalkyl, perhaloalkoxy, alkoxy, haloalkoxy, alkoxyalkyl, acyl, oxo, acyloxy, carboxyl, amido, cyano, amino, alkylamino, alkylaminoalkyl, thiol, alkylthio, alkylthioalkyl, haloalkylthio, perhaloalkylthio, nitro, aryl, arylalkyl, cycloalkylalkyl, heterocycle- alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, alkylsulfonyl, sulfonamide, alkylsulfonamido and alkylsilyloxy; when Y is Q, R1and R2together with N+may form a heterocyclic or heteroaryl ring optionally substituted with one or more substituents chosen from halogen, hydroxy, alkyl, heteroalkyl, haloalkyl, perhaloalkyl, perhaloalkoxy, alkoxy, haloalkoxy, alkoxyalkyl, acyl, oxo, acyloxy, carboxyl, amido, cyano, amino, alkylamino, alkylaminoalkyl, thiol, alkylthio, alkylthioalkyl, haloalkylthio, perhaloalkylthio, nitro, aryl, arylalkyl, cycloalkylalkyl, heterocycle-alkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, alkylsulfonyl, sulfonamide, alkylsulfonamido and alkylsilyloxy; when Y is Q, R3and R4together with N+may form a heterocyclic or heteroaryl ring optionally substituted with one or more substituents chosen from halogen, hydroxy, alkyl, heteroalkyl, haloalkyl, perhaloalkyl, perhaloalkoxy, alkoxy, haloalkoxy, alkoxyalkyl, acyl, oxo, acyloxy, carboxyl, amido, cyano, amino, alkylamino, alkylaminoalkyl, thiol, alkylthio, alkylthioalkyl, haloalkylthio, perhaloalkylthio, nitro, aryl, arylalkyl, heterocycle-alkyl, cycloalkylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, alkylsulfonyl, sulfonamide, alkylsulfonamido and alkylsilyloxy; when Y is Q, R1and R3together with –N+-RL-N+- may form a heterocyclic or heteroaryl ring optionally substituted with one or more substituents chosen from halogen, hydroxy, alkyl, heteroalkyl, haloalkyl, perhaloalkyl, perhaloalkoxy, alkoxy, haloalkoxy, alkoxyalkyl, acyl, oxo, acyloxy, carboxyl, amido, cyano, amino, alkylamino, alkylaminoalkyl, thiol, alkylthio, alkylthioalkyl, haloalkylthio, perhaloalkylthio, nitro, aryl, arylalkyl, heterocycle-alkyl, cycloalkylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, alkylsulfonyl, sulfonamide, alkylsulfonamido and alkylsilyloxy; when Y is Q, R2and R4together with –N+-RL-N+- may form a heterocyclic or heteroaryl ring optionally substituted with one or more substituents chosen from halogen, hydroxy, alkyl, heteroalkyl, haloalkyl, perhaloalkyl, perhaloalkoxy, alkoxy, haloalkoxy, alkoxyalkyl, acyl, oxo, acyloxy, carboxyl, amido, cyano, amino, alkylamino, alkylaminoalkyl, thiol, alkylthio, alkylthioalkyl, haloalkylthio, perhaloalkylthio, nitro, aryl, arylalkyl, heterocycle-alkyl, cycloalkylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, alkylsulfonyl, sulfonamide, alkylsulfonamido and alkylsilyloxy; optionally, when Y is Q, one of the groups: R1, R2, R3and R4may be nonexistent. If one of the groups: R1, R2, R3or R4is non-existent, and Y is Q, the compound is a monosalt; RLis a lower alkylene, alkenylene, alkynylene, acyl, cycloalkyl, or aryl, in which none or one or more carbon atoms are replaced by O, NR13, S, SO, SO2, and which is optionally substituted with hydroxyl, alkoxyl, amino, alkylamino, thiol, thioalkyl, or halogen; A and A’ are the same or different and each independently are R6 R6 R6 , dialkyl thioether, lower dialkylamino, cyclopropylene, alkanylene, cycloalkanylene, alkenylene, cycloalkenylene, lower alkynylene, lower cycloalkynylene, carbamate, sulfanyl, sulfinyl, sulfonyl, thiocarbonyl, imino, or hydroxyimino, in which independently none or one or more carbon atoms are replaced by O, NR14, S, SO, SO2, and which is optionally substituted with hydroxyl, alkoxyl, amino, alkylamino, thiol, thioalkyl, or halogen; R12is hydrogen, lower alkyl, heteroalkyl, perhaloalkyl, lower alkoxy, lower cycloalkyl, lower aryl, cycloalkyl, aryl, lower heterocycloalkyl, lower heteroaryl, heterocycloalkyl, or heteroaryl, which independently are optionally substituted with one or more substituents chosen from halogen, hydroxy, alkyl, heteroalkyl, haloalkyl, perhaloalkyl, perhaloalkoxy, alkoxy, haloalkoxy, alkoxyalkyl, acyl, oxo, acyloxy, carboxyl, amido, cyano, amino, alkylamino, alkylaminoalkyl, thiol, alkylthio, alkylthioalkyl, haloalkylthio, perhaloalkylthio, nitro, aryl, arylalkyl, heterocycle-alkyl, cycloalkylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, alkylsulfonyl, sulfonamide, alkylsulfonamido and alkylsilyloxy; R13is hydrogen, lower alkyl, heteroalkyl, perhaloalkyl, lower alkoxy, lower cycloalkyl, lower aryl, cycloalkyl, aryl, lower heterocycloalkyl, lower heteroaryl, heterocycloalkyl, or heteroaryl, which independently are optionally substituted with one or more substituents chosen from halogen, hydroxy, alkyl, heteroalkyl, haloalkyl, perhaloalkyl, perhaloalkoxy, alkoxy, haloalkoxy, alkoxyalkyl, acyl, oxo, acyloxy, carboxyl, amido, cyano, amino, alkylamino, alkylaminoalkyl, thiol, alkylthio, alkylthioalkyl, haloalkylthio, perhaloalkylthio, nitro, aryl, arylalkyl, heterocycle-alkyl, cycloalkylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, alkylsulfonyl, sulfonamide, alkylsulfonamido and alkylsilyloxy; R14hydrogen, lower alkyl, heteroalkyl, perhaloalkyl, lower alkoxy, lower cycloalkyl, lower aryl, cycloalkyl, aryl, lower heterocycloalkyl, lower heteroaryl, heterocycloalkyl, or heteroaryl, which independently are optionally substituted with one or more substituents chosen from halogen, hydroxy, alkyl, heteroalkyl, haloalkyl, perhaloalkyl, perhaloalkoxy, alkoxy, haloalkoxy, alkoxyalkyl, acyl, oxo, acyloxy, carboxyl, amido, cyano, amino, alkylamino, alkylaminoalkyl, thiol, alkylthio, alkylthioalkyl, haloalkylthio, perhaloalkylthio, nitro, aryl, arylalkyl, heterocycle-alkyl, cycloalkylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, alkylsulfonyl, sulfonamide, alkylsulfonamido and alkylsilyloxy; X1, X2, X3, X4, X5and X6independently are carbon or nitrogen with the proviso that none, one, two or three of X1, X2, X3, X4, X5and X6are nitrogen; when X2, X3, X4, X5or X6is carbon, R5, R6, R7, R8or R9, respectively, independently is hydrogen, hydroxyl, halogen, C1-C2 alkyl or C1-C2 alkyl substituted with hydroxyl, halogen or NR10R11; R10and R11independently are hydrogen or C1-C2alkyl; when X2, X3, X4or X6is nitrogen, R5, R6, R7, R8or R9, respectively, is not present or is hydrogen, C1-C2 alkyl or C1-C2 alkyl substituted with hydroxyl, halogen or NR10R11; with the proviso that (i) Y is M or Q when A and A’ are phenyl and Z and Z' are oxygen, or (ii) A and A' are not the same, or one or both of A and A' are not phenyl, or Z and Z' are not the same, or one or both of Z and Z' are not oxygen, when Y is L and RL is –CH2-CH2-. In implementations pertaining to compounds of Formula F and Formula G, chemical groups are as commonly understood in the art. A non-limiting example of a rimiducid analog of Formula F is a compound of Formula F1, or a pharmaceutically acceptable salt thereof. O O non- are or O O H J from hydrogen or alkyl. The term “alkyl,” as used herein, alone or in combination, refers to a saturated straight-chain or branched-chain hydrocarbon radical containing from 1 to 20 carbon atoms. The term “straight-chain alkyl” refers to a saturated straight-chain hydrocarbon radical. The term “branched-chain alkyl” refers to a saturated branched-chain hydrocarbon radical. In certain embodiments, an alkyl includes 1 to 10 carbon atoms (C1-C10 alkyl), 1 to 8 carbon atoms (C1-C8 alkyl), 1 to 6 carbon atoms (C1-C6 alkyl), 1 to 5 carbon atoms (C1-C5alkyl), 1 to 4 carbon atoms (C1-C4alkyl), or 1 to 3 carbon atoms (C1-C3alkyl). Alkyl groups may be optionally substituted as defined herein. Non-limiting examples of alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, nonyl and the like. A non-limiting example of a rimiducid analog of Formula H is a compound of Formula H1, or a pharmaceutically acceptable salt thereof. Formula H1 comprising a pharmaceutically acceptable excipient) can be a compound of Formula C, D, E, F, F1, G, H, H1 or J, or a pharmaceutically acceptable salt thereof. A rimiducid analog sometimes is a Class IV compound, which is characterized by low aqueous solubility, low gastrointestinal permeability and poor bioavailability (as described herein). An active ingredient sometimes includes a pharmaceutically acceptable salt, ester or amide of a compound described herein. As used herein, the term “pharmaceutically acceptable salt” includes but is not limited to a carboxylate salt, amino acid addition salt or zwitterionic form thereof, known as suitable for use with humans and animals. (See, e.g., Gerge, S. M., et al, “Pharmaceutical Salts,” Pharm. Sci. (1977) 66:1-19). In cases where a compound (e.g., rimiducid analog) is sufficiently basic or acidic to form a stable nontoxic acid or base salt, an active ingredient sometimes includes a pharmaceutically acceptable salt of the compound. Non-limiting examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids that form a physiological acceptable anion, non-limiting examples of which include tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, [alpha]-ketoglutarate, and [alpha]- glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts. Pharmaceutically acceptable salts are obtained using standard procedures known in the art. For example, pharmaceutically acceptable salts may be obtained by reacting a sufficiently basic compound with a suitable acid affording a physiologically acceptable anion. Alkali metal (e.g., sodium, potassium or lithium) or alkaline earth metal (e.g., calcium, magnesium) salts of carboxylic acids and other anionic groups in molecules within a pharmaceutical composition also are contemplated. For an ester or amide of a compound, a carboxylic acid of a compound sometimes is modified to an amide or an ester, and sometimes an ester of a compound is converted to an amide. An active ingredient in a pharmaceutical composition in certain instances can include an isomer of rimiducid having a structure according to Formula B (e.g., an isomer of a compound of Formula A), or an isomer of a rimiducid analog (e.g., a compound of Formula C, D, E, F, F1, G, H, H1 or J) or a pharmaceutically acceptable salt thereof). Non-limiting examples of isomers are stereoisomers (e.g., diastereomers and enantiomers), and structural isomers (e.g., skeletal isomers, positional isomers (or regioisomers), functional isomers, tautomers, and structural topoisomers). An active ingredient in a pharmaceutical composition in certain instances can include a mixture that contains two or more stereoisomers of a compound of Formula A or Formula B, or two or more stereoisomers of a rimiducid analog. In certain instances, a mixture can include an stereoisomer of a compound of Formula A or Formula B, or a rimiducid analog, that predominates over other stereoisomers thereof (e.g., the molar amount of one stereoisomer represents about 60% or more of all isomers of a compound of Formula A or Formula B or a rimiducid analog (e.g., about 65% or more, about 70% or more, about 75% or more, about 80% or more, about 85% or more). An active ingredient in a pharmaceutical composition in certain instances can include an isomerically pure form of a compound of Formula A or Formula B or a rimiducid analog. For an isomerically pure form of an active ingredient, the molar amount of one isomer represents about 90% or more (e.g., about 91% or more, about 92% or more, about 93% or more, about 94% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, about 99% or more, about 99.5% or more or about 99.9% or more) of all isomers of the active ingredient (e.g., rimiducid having a structure of Formula B). Each component of a pharmaceutical composition (for example, multimerizer active ingredient and excipient components) typically is in an amount defined by weight. An amount by weight typically is referred to as a percent weight (%wt) amount, which is synonymous with a weight percent (wt%), percent weight to weight (%wt / wt), and a weight to weight percent (wt / wt%) amount herein. A %wt amount typically is weight in milligrams (mg) of a particular component of a pharmaceutical composition divided by the total weight in milligrams (mg) of the pharmaceutical composition. Where amounts of specific components (e.g., active ingredient and excipient components) are specified in ranges, the sum of the %wt of the components in the pharmaceutical composition does not exceed 100%. In certain instances, the sum of the %wt of the specified components in the pharmaceutical composition is 100%. In certain implementations, a compound of Formula A or Formula B or a rimiducid analog, or pharmaceutically acceptable salt thereof, is present in a pharmaceutical composition in a %wt amount of about 1% to about 25%, or about 1% to about 15%, about 5% to about 15%, or about 5% to about 10%, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25%. Additives A pharmaceutical composition can include an active ingredient and one or more pharmaceutical additives, including one or more pharmaceutically acceptable excipients. One or more pharmaceutically acceptable excipients in a pharmaceutical composition can form a carrier for the active ingredient. Pharmaceutical compositions provided herein include additives suitable for an injection route of administration (e.g., subcutaneous (SQ) or intramuscular (IM) route of administration) or oral route of administration, for example. Additives typically are pharmaceutically acceptable additives and non-limiting examples of additives include an oil component, surfactant component, solvent component, aqueous component, penetration enhancer component, solubility enhancer component, diluent, isotonic agent, buffering agent, stabilizer, preservative, vasoconstrictive agent, antibacterial agent, antifungal agent, adsorption delaying agents and the like). A pharmaceutical composition sometimes is prepared as a solid (e.g., powder) or liquid (e.g., aqueous solution, emulsion (e.g., micro-emulsion, nano- emulsion), dispersion (e.g., micro-dispersion, nano-dispersion), for example. One or more additives can be combined with an active ingredient for the manufacture of a pharmaceutical composition by methods known and described herein. Non-limiting examples of solvents and diluents, when utilized in a pharmaceutical composition, include water, saline, dextrose, ethanol, glycerol, oil, water-miscible organic cosolvents such as acetone or dimethyl sulfoxide (DMSO), and the like. Non-limiting examples of isotonic agents, when utilized in a pharmaceutical composition, include sodium chloride, dextrose, mannitol, glucose, sucrose, sorbitol, lactose, and the like. Non-limiting examples of buffering agents, when utilized in a pharmaceutical composition, include bicarbonate, phosphate, and the like. Phosphate- buffered saline (PBS), which may be buffered to provide a neutral pH, or in certain embodiments an acidic pH, sometimes is utilized. Non-limiting examples of stabilizers, when utilized in a pharmaceutical composition, include gelatin, albumin, and the like. Non-limiting examples of a preservatives, when utilized in a pharmaceutical composition, include gentamicin, merthiolate, chlorocresol and the like. Water or saline, when utilized in a pharmaceutical composition, may be buffered or not buffered. Non-limiting examples of saline solutions that can be used to prepare a pharmaceutical composition include lactated Ringer's solution, acetated Ringer's solution, intravenous sugar solutions (e.g., 5% dextrose in normal saline (D5NS), 10% dextrose in normal saline (D10NS), 5% dextrose in half-normal saline (D5HNS) and 10% dextrose in half-normal saline (D10HNS)). Non-limiting examples of buffered saline solutions and related solutions include phosphate buffered saline (PBS), TRIS-buffered saline (TBS), Hank's balanced salt solution (HBSS), Earle's balanced salt solution (EBSS), standard saline citrate (SSC), HEPES-buffered saline (HBS), and Gey's balanced salt solution (GBSS). A pharmaceutical composition consisting essentially of one or more of specified excipients and / or additives can include one or more other unspecified components that do not materially affect the basic and novel characteristics of the one or more specified excipients and / or additives. An unspecified component that does not materially affect the basic and novel characteristics of the one or more specified excipients and / or additives for a particular pharmaceutical composition typically alters the solubility of an active ingredient (e.g., rimiducid, rimiducid family compound or rimiducid analog) in the pharmaceutical composition by 5% or less. Pharmaceutical compositions for administration by injection Certain pharmaceutical compositions provided herein are for administration by injection, including subcutaneous (SQ) administration or intramuscular (IM) administration, and each is referred to herein as a “pharmaceutical composition for injection.” In certain implementations, a pharmaceutical composition for injection is not for intravenous injection. In certain implementations, an active ingredient in a pharmaceutical composition for injection includes a multimerizer active ingredient. An active ingredient sometimes is a compound of Formula A, which can be in an amount described herein. In certain implementations, an active ingredient in a pharmaceutical composition for injection includes a compound of Formula B, which can be in an amount described herein. In certain instances, an active ingredient in a pharmaceutical composition for injection includes a rimiducid analog, such as a rimiducid analog described herein, which can be in an amount described herein. In certain implementations, a total volume of a pharmaceutical composition for injection is about 0.1 mL to about 10 mL, or about 0.5 mL to about 5 mL, or about 1 mL to about 5 mL, or about 1 mL to about 3 mL, or about 2 mL. In certain implementations, a pharmaceutical composition provided herein for administration by injection is utilized to prepare a pharmaceutical composition for administration by infusion. For example, a pharmaceutical composition provided herein for administration by injection can be diluted in a solution suitable for infusion, such as a saline solution, for example, and the resulting preparation can be administered to a subject by infusion by a known infusion administration process. A pharmaceutical composition for administration by injection often includes one or more lipid excipient components (also referred to herein as lipid excipients). A lipid excipient component sometimes includes one type of lipid, or predominantly one type of lipid (e.g., 90% or more of one type of lipid over other types of lipids). A lipid excipient component sometimes includes multiple types of lipids. A lipid sometimes includes one or more types of fatty acids, each of which independently may be a saturated fatty acid or a fatty acid containing one or more un-saturations. Non-limiting examples of fatty acids that can be included in a lipid include a C6 fatty acid (e.g., caproic acid (C8 fatty acid; (CH3(CH2)4COOH)), (e.g., caprylic acid; (CH3(CH2)6COOH)), C10 fatty acid (e.g., capric acid; CH3(CH2)8COOH)), C12 fatty acid (e.g., lauric acid;CH3(CH2)10COOH), C14 fatty acid (e.g., myristic acid; CH3(CH2)12COOH), C16 fatty acid (e.g., palmitic acid; CH3(CH2)14COOH), C18 fatty acid (e.g., stearic acid; CH3(CH2)16COOH), C20 fatty acid (e.g., arachidic acid; CH3(CH2)18COOH), C22 fatty acid (e.g., behenic acid; CH3(CH2)20COOH), C24 fatty acid (e.g., lignoceric acid; CH3(CH2)22COOH) and C26 fatty acid (e.g., cerotic acid; CH3(CH2)24COOH). A lipid excipient component sometimes is a glyceride, which sometimes is a mono-glyceride, di- glyceride or tri-glyceride. A composition sometimes includes a mixture of glycerides, in which sometimes a majority of the glycerides is one type of glyceride and a minority of the glycerides is another type of glyceride. A lipid excipient component sometimes is an ester, which sometimes is a polyethylene glycol (PEG) ester or propylene glycol ester, and sometimes is a mono-ester or di-ester. Sometimes a composition includes a mixture of lipid esters, where a majority of the esters is one type of ester and a minority is another type of ester. In certain implementations, a lipid excipient component includes a mixture of glycerides and esters. A pharmaceutical composition for administration by injection can include multiple lipid excipients. In certain implementations, a pharmaceutical composition for administration by injection includes a lipid excipient combination containing a trigylcerides excipient and a PEG ether-modified trigylcerides excipient. The triglycerides excipient sometimes is a medium chain triglycerides (MCT) excipient, which can contain glycerides that include C6, C8, C10 and C12 fatty acids. The PEG ether-modified trigylcerides excipient sometimes is a modified vegetable oil, such as castor oil for example (e.g., polyethoxylated castor oil (PECO)). In certain implementations, a pharmaceutical composition containing a trigylcerides excipient and a PEG ether-modified trigylcerides excipient further includes a surfactant excipient. A surfactant excipient sometimes is a polysorbate (PS) surfactant, such as PS20, PS40, PS60 or PS80 for example. In certain implementations, a pharmaceutical composition containing a trigylcerides excipient and a PEG ether-modified trigylcerides excipient further includes ethanol. In certain implementations, a pharmaceutical composition for administration by injection includes a lipid excipient combination containing a trigylcerides excipient and a PEG ether-modified trigylcerides excipient, a surfactant excipient and a polyethylene glycol (PEG) excipient as described herein. In certain implementations, a pharmaceutical composition for administration by injection includes a trigylcerides excipient, a surfactant excipient and a polyethylene glycol (PEG) excipient as described herein. In certain implementations, a pharmaceutical composition that includes a PEG excipient optionally includes ethanol. In certain implementations, a pharmaceutical composition for administration by injection includes a lipid excipient combination containing a triglycerides excipient and a C8 fatty acid glyceride excipient, or a triglycerides excipient and one or more C8 fatty acid ester excipients. The triglycerides excipient sometimes is a medium chain triglycerides (MCT) excipient, which can contain glycerides that include C6, C8, C10 and C12 fatty acids. A C8 fatty acid glyceride excipient sometimes includes monoglycerides and diglycerides containing a C8 fatty acid. A C8 fatty acid glyceride excipient sometimes is a glyceryl monocaprylate excipient, which also can contain C10 fatty acid glycerides. A C8 fatty acid ester excipient sometimes includes propylene glycol esters of C8 fatty acids. A C8 fatty acid ester excipient sometimes is a propylene glycol monocaprylate excipient. A C8 fatty acid ester excipient sometimes is a propylene glycol dicaprylate excipient, which can include propylene glycol esters of C10 fatty acids. A C8 fatty acid ester excipient sometimes includes PEG esters, for example PEG monoesters and / or PEG diesters, of C8 fatty acids. A C8 fatty acid ester excipient sometimes is PEG-8 caprylic / capric glycerides excipient, which can include PEG esters of C10 fatty acids. In certain implementations, a pharmaceutical composition containing a lipid excipient combination containing a triglycerides excipient and a C8 fatty acid glyceride excipient, or a triglycerides excipient and a C8 fatty acid ester excipient, further includes a PEG ether-modified trigylcerides excipient. A PEG ether-modified trigylcerides excipient sometimes is a modified vegetable oil, such as castor oil for example (e.g., polyethoxylated castor oil (PECO)). In certain implementations, a pharmaceutical composition containing a lipid excipient combination containing a triglycerides excipient and a C8 fatty acid glyceride excipient, or a triglycerides excipient and a C8 fatty acid ester excipient, further includes a C18 fatty acid glycerides excipient. A C18 fatty acid glycerides excipient sometimes is a linoleoyl macrogol glycerides excipient, which often contains glycerides and PEG-6 (MW 300) esters of linoleic (C18:2) acid. In certain implementations, a pharmaceutical composition for injection is prepared as a self- emulsifying drug delivery system (SEDDS), which is referred to herein as a “SEDDS pharmaceutical composition.” A pharmaceutical composition for injection, such as a SEDDS pharmaceutical composition for example, sometimes contains no added water. In certain implementations, a pharmaceutical composition for injection is a liquid emulsion containing particles or a liquid dispersion containing particles, described in further detail herein. A liquid emulsion or a liquid dispersion can contain particles characterized by an average, mean, median, nominal or maximum diameter of about 500 nanometers (nm) or less, about 200 nm or less, or about 100 nm or less or about 60 nm or less, or about 50 nm or less, or about 40 nm or less. In certain implementations, a pharmaceutical composition for injection is a liquid emulsion containing particles or a liquid dispersion containing particles, and the amount of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof is about 8% wt / wt or less, or about 7% wt / wt or less, or about 6% wt / wt or less, or about 5% wt / wt or less, or about 0.1% wt / wt to about 10% wt / wt, or about 0.5% wt / wt to about 8% wt / wt, or about 0.5% wt / wt to about 5% wt / wt; or about 0.1% wt / wt, 0.2% wt / wt, 0.3% wt / wt, 0.4% wt / wt, 0.5% wt / wt, 0.6% wt / wt, 0.7% wt / wt, 0.8% wt / wt, 0.9% wt / wt, 1% wt / wt, 2% wt / wt, 3% wt / wt, 4% wt / wt, 5% wt / wt, 6% wt / wt, 7% wt / wt, 8% wt / wt, 9% wt / wt or 10% wt / wt. In certain implementations, a pharmaceutical composition for injection contains a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, and: (i) a triglycerides excipient, a PEG ether-modified triglycerides excipient, a surfactant excipient and optionally an ethanol excipient; (ii) a triglycerides excipient, a PEG ether-modified triglycerides excipient and a C8 fatty acid glyceride excipient; (iii) a triglycerides excipient, a PEG ether- modified triglycerides excipient, a C8 fatty acid glyceride excipient and a C18 fatty acid glycerides excipient; (iv) a triglycerides excipient, a PEG ether-modified triglycerides excipient and a C8 fatty acid ester excipient; (v) a triglycerides excipient, a PEG ether-modified triglycerides excipient, a C8 fatty acid glyceride excipient and a C8 fatty acid ester excipient; (vi) a triglycerides excipient, a C8 fatty acid glyceride excipient, a C8 fatty acid ester excipient, and a C18 fatty acid glycerides excipient; (vii) a triglycerides excipient, a PEG ether-modified triglycerides excipient and two or more C8 fatty acid ester excipients; (viii) a triglycerides excipient, and two or more C8 fatty acid ester excipients (e.g., one C8 fatty acid ester excipient and one or more additional C8 fatty acid ester excipients); (ix) a triglycerides excipient, a PEG ether-modified triglycerides excipient, a surfactant excipient, a PEG excipient, and optionally an ethanol excipient; or (x) a triglycerides excipient, a surfactant excipient, a PEG excipient, and optionally an ethanol excipient. In certain implementations, a pharmaceutical composition for injection contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 40% wt / wt triglycerides excipient, about 20% to about 60% wt / wt PEG ether-modified triglycerides excipient, about 10% to about 50% wt / wt surfactant excipient, and optionally an ethanol excipient. In certain implementations, a pharmaceutical composition for injection contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 30% wt / wt triglycerides excipient, about 30% to about 60% wt / wt PEG ether-modified triglycerides excipient, about 15% to about 30% wt / wt surfactant excipient, and optionally an ethanol excipient. In certain implementations, a pharmaceutical composition for injection contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 25% wt / wt triglycerides excipient, about 45% to about 50% wt / wt PEG ether-modified triglycerides excipient, and about 20% to about 25% wt / wt surfactant excipient. In certain implementations, a pharmaceutical composition for injection contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 25% wt / wt triglycerides excipient, about 35% to about 40% wt / wt PEG ether-modified triglycerides excipient, about 20% to about 25% wt / wt surfactant excipient and about 5% to about 10% wt / wt ethanol. In certain implementations, a pharmaceutical composition for injection contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient, about 15% to about 50% wt / wt PEG ether-modified triglycerides excipient and about 15% to about 60% wt / wt C8 fatty acid glyceride excipient. In certain implementations, a pharmaceutical composition for injection contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 30% wt / wt triglycerides excipient, about 15% to about 30% wt / wt PEG ether-modified triglycerides excipient and about 30% to about 55% wt / wt C8 fatty acid glyceride excipient. In certain implementations, a pharmaceutical composition for injection contains about 5% to about 15% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt triglycerides excipient, about 15% to about 20% wt / wt PEG ether-modified triglycerides excipient and about 40% to about 50% wt / wt C8 fatty acid glyceride excipient. In certain implementations, a pharmaceutical composition for injection contains about 5% to about 15% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt triglycerides excipient, about 25% to about 30% wt / wt PEG ether-modified triglycerides excipient and about 30% to about 40% wt / wt C8 fatty acid glyceride excipient. In certain implementations, a pharmaceutical composition for injection contains about 5% to about 15% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 20% wt / wt triglycerides excipient, about 20% to about 25% wt / wt PEG ether-modified triglycerides excipient and about 45% to about 55% wt / wt C8 fatty acid glyceride excipient. In certain implementations, a pharmaceutical composition for injection contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient, about 15% to about 50% wt / wt PEG ether-modified triglycerides excipient, about 5% to about 50% wt / wt C18 fatty acid glycerides excipient and about 15% to about 50% wt / wt C8 fatty acid glyceride excipient. In certain instances, a pharmaceutical composition for injection contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 35% wt / wt triglycerides excipient, about 15% to about 40% wt / wt PEG ether-modified triglycerides excipient, about 5% to about 30% wt / wt C18 fatty acid glycerides excipient and about 20% to about 50% wt / wt C8 fatty acid glyceride excipient. In certain implementations, a pharmaceutical composition for injection contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 18% to about 33% wt / wt triglycerides excipient, about 20% to about 40% wt / wt PEG ether-modified triglycerides excipient, about 10% to about 25% wt / wt C18 fatty acid glycerides excipient and about 25% to about 45% wt / wt C8 fatty acid glyceride excipient. In certain implementations, a pharmaceutical composition for injection contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 35% wt / wt triglycerides excipient, about 15% to about 30% wt / wt PEG ether-modified triglycerides excipient, about 5% to about 20% wt / wt C18 fatty acid glycerides excipient and about 20% to about 35% wt / wt C8 fatty acid glyceride excipient. In certain implementations, a pharmaceutical composition for injection contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt triglycerides excipient, about 20% to about 25% wt / wt PEG ether-modified triglycerides excipient, about 10% to about 15% wt / wt C18 fatty acid glycerides excipient and about 25% to about 30% wt / wt C8 fatty acid glyceride excipient. In certain implementations, a pharmaceutical composition for injection contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient, about 10% to about 35% wt / wt PEG ether-modified triglycerides excipient and about 25% to about 45% wt / wt C8 fatty acid ester excipient. In certain implementations, a pharmaceutical composition for injection contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt triglycerides excipient, about 25% to about 30% wt / wt PEG ether-modified triglycerides excipient and about 30% to about 40% wt / wt C8 fatty acid ester excipient. In certain implementations, a pharmaceutical composition for injection contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient, about 10% to about 30% wt / wt PEG ether-modified triglycerides excipient, about 10% to about 35% wt / wt C8 fatty acid glyceride excipient and about 5% to about 25% wt / wt C8 fatty acid ester excipient. In certain implementations, a pharmaceutical composition for injection contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt triglycerides excipient, about 20% to about 25% wt / wt PEG ether-modified triglycerides excipient, about 25% to about 30% wt / wt C8 fatty acid glyceride excipient and about 10% to about 15% wt / wt C8 fatty acid ester excipient. In certain implementations, a pharmaceutical composition for injection contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient, about 5% to about 50% wt / wt C18 fatty acid glycerides excipient, about 20% to about 50% wt / wt C8 fatty acid glyceride excipient and about 20% to about 50% wt / wt C8 fatty acid ester excipient. In certain implementations, a pharmaceutical composition for injection contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt triglycerides excipient, about 10% to about 15% wt / wt C18 fatty acid glycerides excipient, about 25% to about 30% wt / wt C8 fatty acid glyceride excipient and about 20% to about 25% wt / wt C8 fatty acid ester excipient. In certain implementations, a pharmaceutical composition for injection contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 40% wt / wt triglycerides excipient, about 20% to about 30% wt / wt PEG ether-modified triglycerides excipient, about 25% to about 50% wt / wt surfactant excipient and about 1% to about 20% wt / wt PEG excipient and optionally about 1% to about 10% wt / wt ethanol excipient. In certain implementations, a pharmaceutical composition for injection contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 25% wt / wt triglycerides excipient, about 20% to about 40% wt / wt surfactant excipient and about 1% to about 65% wt / wt PEG excipient and optionally about 1% to about 10% wt / wt ethanol excipient. In certain implementations, a pharmaceutical composition for injection contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient, about 10% to about 50% wt / wt PEG ether-modified triglycerides excipient, and two or more C8 fatty acid ester excipients each independently in an amount of about 1% to about 50% wt / wt. In certain implementations, a pharmaceutical composition for injection contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient, about 20% to about 50% wt / wt C8 fatty acid ester excipient, and one or two additional C8 fatty acid ester excipients each independently in an amount of about 1% to about 50%. A pharmaceutical composition sometimes includes two or more of the following excipients: a medium chain triglycerides (MCT) excipient, a polyethoxylated castor oil (PECO) excipient, polysorbate excipient (e.g., polysorbate 80), a polyethylene glycol excipient (PEG; e.g., PEG400), a linoleoyl macrogol glycerides excipient, a glyceryl monocaprylate excipient, a propylene glycol monocaprylate excipient, a propylene glycol dicaprylate excipient, a PEG-8 caprylic / capric glycerides excipient, and ethanol excipient. A medium chain triglycerides (MCT) excipient, when included in a pharmaceutical composition, typically contains 95% or more caprylic / capric triglyceride (saturated). A MCT excipient is commercially available under the tradename Captex 300 / EP / NF(ABITEC Corporation), for example, and the purity of an MCT excipient utilized to manufacture a pharmaceutical composition often is at least 90% (e.g., at least 95%; about 100%; USP grade). An amount of a MCT excipient by weight in a pharmaceutical composition can be about 5% to about 45% wt / wt, about 15% to about 40% wt / wt, about 5% to about 25% wt / wt, about 10% to about 30% wt / wt, about 15% to about 25% wt / wt, about 20% to about 30% wt / wt, about 15% to about 20% wt / wt, about 20% to about 25% wt / wt, about 25% to about 30% wt / wt, or about 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40 or 45% wt / wt. A polyethoxylated castor oil (PECO) excipient, which also is referred to herein as a polyoxyl 35 castor oil excipient, when included in a pharmaceutical composition, typically is a non-ionic solubilizer and emulsifier containing castor oil and ethylene oxide in a molar ratio of 1:35. A PECO excipient is commercially available under the tradename Acconon EL EP / NF (ABITEC Corporation), for example, and the purity of a PECO excipient utilized to manufacture a pharmaceutical composition often is at least 90% (e.g., at least 95%; about 100%; USP grade). An amount of a PECO excipient by weight in a pharmaceutical composition can be about 10% to about 55% wt / wt, about 15% to about 50% wt / wt, about 15% to about 30% wt / wt, about 15% to about 25% wt / wt, about 20% to about 30% wt / wt, about 25% to about 35% wt / wt, about 30% to about 40% wt / wt, about 35% to about 45% wt / wt, about 40% to about 50% wt / wt, about 45% to about 55% wt / wt, about 15% to about 20% wt / wt, about 20% to about 25% wt / wt, about 25% to about 30% wt / wt, about 35% to about 40% wt / wt, about 45% to about 50% wt / wt, or about 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or 55% wt / wt. A polysorbate (PS) excipient, when included in a pharmaceutical composition, sometimes is PS20, PS40, PS60 and / or PS80. Polysorbate 80 (PS80), for example, is a polyoxyethylene sorbitan fatty acid ester with a molecular weight of 1310 Da. A PS80 excipient is commercially available under the tradename Acconon PS80 EP / NF (ABITEC Corporation), for example, and the purity of a PS excipient utilized to manufacture a pharmaceutical composition often is at least 90% (e.g., at least 95%; about 100%; USP grade). An amount of a PS excipient by weight in a pharmaceutical composition can be about 10% to about 55% wt / wt, about 20% to about 50% wt / wt, about 15% to about 40% wt / wt, about 15% to about 30% wt / wt, about 20% to about 25% wt / wt, or about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or 55% wt / wt. A linoleoyl macrogol glycerides excipient, when included in a pharmaceutical composition, typically contains mono-, di- and triglycerides and PEG-6 (MW 300) mono- and diesters of linoleic (C18:2) acid. A linoleoyl macrogol glycerides excipient is commercially available under the tradename Acconon CMG-6 EP / NF (ABITEC Corporation), for example, and the purity of a linoleoyl macrogol glycerides excipient utilized to manufacture a pharmaceutical composition often is at least 90% (e.g., at least 95%; about 100%; USP grade). An amount of linoleoyl macrogol glycerides excipient by weight in a pharmaceutical composition can be about 5% to about 50% wt / wt, about 5% to about 40% wt / wt, about 5% to about 30%, about 5% to about 20% wt / wt, about 5% to about 15% wt / wt, about 10% to about 25%, about 10% to about 20%, about 10% to about 15% wt / wt or about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50% wt / wt. A glyceryl monocaprylate excipient, when included in a pharmaceutical composition, typically contains mono- and diglycerides of caprylic acid (C8) and capric acid (C10), with a majority of the monoester fraction. A glyceryl monocaprylate excipient is commercially available under the tradename Capmul MCM EP / NF (ABITEC Corporation), for example, and the purity of a glyceryl monocaprylate excipient utilized to manufacture a pharmaceutical composition often is at least 90% (e.g., at least 95%; about 100%; USP grade). An amount of a glyceryl monocaprylate excipient by weight in a pharmaceutical composition can be about 20% to about 55% wt / wt, about 15% to about 55% wt / wt, about 20% to about 35% wt / wt, about 20% to about 30% wt / wt, about 30% to about 40% wt / wt, about 40% to about 50% wt / wt, about 45% to about 55% wt / wt, about 25% to about 45% wt / wt, about 25% to about 40% wt / wt, about 25% to about 35% wt / wt, about 25% to about 30% wt / wt, about 35% to about 40% wt / wt, about 45% to about 55% wt / wt, or about 10, 15, 20, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 or 55% wt / wt. A propylene glycol monocaprylate excipient, when included in a pharmaceutical composition, typically contains propylene glycol esters of caprylic acid (C8), with a majority of mono-esters and minority of di-esters. A propylene glycol monocaprylate excipient is commercially available under the tradename Capmul PG-8 NF (ABITEC Corporation), for example, and the purity of a propylene glycol monocaprylate excipient utilized to manufacture a pharmaceutical composition often is at least 90% (e.g., at least 95%; about 100%; USP grade). An amount of a propylene glycol monocaprylate excipient by weight in a pharmaceutical composition can be about 0% to about 50% wt / wt, about 10% to about 40% wt / wt, about 20% to about 30% wt / wt, about 30% to about 40% wt / wt, about 30% to about 35% wt / wt, about 35% to about 40% wt / wt, or about 0, 10, 15, 20, 25, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, or 50% wt / wt. A propylene glycol dicaprylate excipient, when included in a pharmaceutical composition, typically contains propylene glycol esters of caprylic (C8) and capric (C10) acids. A propylene glycol dicaprylate excipient is commercially available under the tradename Captex 200 P (ABITEC Corporation), for example, and the purity of a propylene glycol dicaprylate excipient utilized to manufacture a pharmaceutical composition often is at least 90% (e.g., at least 95%; about 100%; USP grade). An amount of a propylene glycol dicaprylate excipient by weight in a pharmaceutical composition can be about 0% to about 50% wt / wt, about 10% to about 40% wt / wt, about 10% to about 30% wt / wt, about 10% to about 20% wt / wt, about 10% to about 15% wt / wt, or about 0, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50% wt / wt. A PEG-8 caprylic / capric glycerides excipient, when included in a pharmaceutical composition, typically contains a minority of mono-, di- and triglycerides and a majority of PEG-8 (MW 400) mono- and diesters of caprylic (C8) and capric (C10) acids. A PEG-8 caprylic / capric glycerides excipient is commercially available under the tradename Acconon MC8-2 EP / NF (ABITEC Corporation), for example, and the purity of a PEG-8 caprylic / capric glycerides excipient utilized to manufacture a pharmaceutical composition often is at least 90% (e.g., at least 95%; about 100%; USP grade). An amount of a PEG-8 caprylic / capric glycerides excipient by weight in a pharmaceutical composition can be about 20% to about 50% wt / wt, about 20% to about 40% wt / wt, about 20% to about 30% wt / wt, about 20% to about 25% wt / wt, or about 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, or 50% wt / wt. The purity of an ethanol excipient, when included in a pharmaceutical composition, sometimes is at least 90% (e.g., at least 95%; about 100%; USP grade). An amount of an ethanol excipient by weight in a pharmaceutical composition can be about 1% to about 15% wt / wt, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15% wt / wt. A polyethylene glycol (PEG) excipient, when included in a pharmaceutical composition, sometimes is PEG 300 or PEG400, for example. The PEG in PEG300 typically has an average molecular weight of 300 g / mol. The PEG in PEG400 typically has an average molecular weight of 400 g / mol and PEG-8 (PEG chains with 400 MW) often predominates. A PEG300 component or PEG400 component typically is not a mixture with non-PEG compounds (e.g., not typically a mixture of monoesters and diesters and / or diglycerides and triglycerides). A PEG excipient is commercially available under the tradename Kollisolv PEG 400 (BASF), for example, and the purity of a PEG excipient utilized to manufacture a pharmaceutical composition often is at least 90% (e.g., at least 95%; about 100%; USP grade). An amount of a PEG excipient by weight in a pharmaceutical composition can be about 1% to about 65% wt / wt, about 1% to about 20% wt / wt, about 35% to about 60% wt / wt, or about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 or 65% wt / wt. In certain implementations, a pharmaceutical composition contains a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, and: (i) a MCT excipient, a PECO excipient, a polysorbate excipient and optionally an ethanol excipient (e.g., MCT, PECO, PS80 and optionally ethanol); (ii) a MCT excipient, a PECO excipient, a linoleoyl macrogol glycerides excipient and a glyceryl monocaprylate excipient; (iii) a MCT excipient, a PECO excipient and a glyceryl monocaprylate excipient; (iv) a MCT excipient, a PECO excipient and a propylene glycol monocaprylate excipient; (v) a MCT excipient, a PECO excipient, a glyceryl monocaprylate excipient and a propylene glycol dicaprylate excipient; (vi) a MCT excipient, a linoleoyl macrogol glycerides excipient, a glyceryl monocaprylate excipient and a PEG-8 caprylic / capric glycerides excipient; (vii) a MCT excipient, a PECO excipient, a polysorbate excipient and a PEG excipient and optionally an ethanol excipient (e.g., MCT, PECO, PS80 and PEG400, and optionally ethanol); (viii) a MCT excipient, a polysorbate excipient and a PEG excipient and optionally an ethanol excipient (e.g., MCT, PS80 and PEG400, and optionally ethanol); (ix) a MCT excipient, a linoleoyl macrogol glycerides excipient, a glyceryl monocaprylate excipient and a PEG-8 caprylic / capric glycerides excipient; (x) a MCT excipient, a PECO excipient, and one or both of a propylene glycol monocaprylate excipient and a propylene glycol dicaprylate excipient; or (xi) a MCT excipient, a PEG-8 caprylic / capric glycerides excipient, and one or both of a propylene glycol monocaprylate excipient and a propylene glycol dicaprylate excipient. In certain implementations, a pharmaceutical composition contains about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 40% wt / wt MCT excipient, about 20% to about 60% wt / wt PECO excipient, about 10% to about 50% wt / wt PS80 excipient, and optionally an ethanol excipient. In certain instances, the MCT excipient, PECO excipient and polysorbate excipient are at a ratio of about 1 MCT excipient to about 2 PECO excipient to about 1 polysorbate excipient, and sometimes the polysorbate excipient comprises or is PS80. In certain implementations, a pharmaceutical composition contains about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 40% wt / wt MCT excipient, about 20% to about 60% wt / wt PECO excipient, about 10% to about 50% wt / wt PS80 excipient, and optionally an ethanol excipient. In certain instances, a pharmaceutical composition contains about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 30% wt / wt MCT excipient, about 30% to about 60% wt / wt PECO excipient, about 15% to about 30% wt / wt PS80 excipient, and optionally an ethanol excipient. In certain implementations, a pharmaceutical composition contains about 25% wt / wt or less (e.g. about 5% to about 20%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 25% wt / wt MCT excipient, about 40% to about 50% wt / wt PECO excipient, and about 20% to about 25% wt / wt PS80 excipient. In certain instances, a pharmaceutical composition contains about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 25% wt / wt MCT excipient, about 45% to about 50% wt / wt PECO excipient, and about 20% to about 25% wt / wt PS80 excipient. In certain implementations, a pharmaceutical composition contains about 5% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 23% to about 24% wt / wt MCT excipient, about 48% to about 49% wt / wt PECO excipient, and about 23% to about 24% wt / wt PS80 excipient, and optionally is a dispersion with a mean particle diameter of about 5 nm to about 100 nm or about 35 nm. In certain instances, a pharmaceutical composition contains about 10% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 22% to about 23% wt / wt MCT excipient, about 45% wt / wt PECO excipient, and about 22% to about 23% wt / wt PS80 excipient, and optionally is a dispersion with a mean particle diameter of about 100 nm to about 200 nm or about 143 nm. In certain implementations, a pharmaceutical composition contains about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% wt / wt MCT excipient, about 40% wt / wt PECO excipient, and about 20% wt / wt PS80 excipient, and optionally is a dispersion with a mean particle diameter of about 200 nm to about 300 nm or about 240 nm. In certain implementations, a pharmaceutical composition contains no ethanol excipient. In certain implementations, a pharmaceutical composition containing MCT, PECO and PS80 excipients contains about 20% wt / wt or less, about 15% wt / wt or less, or about 10% wt / wt or less, or about 9% wt / wt or less, or about 8% wt / wt or less, or about 7% wt / wt or less, or about 6% wt / wt or less, or about 5% wt / wt or less, or about 4% wt / wt or less, or about 3% wt / wt or less, or about 2% wt / wt or less, or about 1% wt / wt or less, of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof. In certain implementations, a pharmaceutical composition containing active ingredient and MCT, PECO and PS80 excipients contains particles having a mean particle diameter of about 100 nm or less, or about 90 nm or less, or about 80 nm or less, or about 70 nm or less, or about 60 nm or less, or about 50 nm or less, or about 45 nm or less, or about 40 nm or less, or about 35 nm or less, or about 30 nm or less.In certain implementations, a pharmaceutical composition contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 25% wt / wt MCT excipient, about 35% to about 40% wt / wt PECO excipient, about 20% to about 25% wt / wt PS80 excipient and about 5% to about 10% wt / wt ethanol. In certain implementations, a pharmaceutical composition contains about 5% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 23% to about 24% wt / wt MCT excipient, about 38% to about 39% wt / wt PECO excipient, about 23% to about 24% wt / wt PS80 excipient and about 8% to about 9% wt / wt ethanol, and optionally is a dispersion with a mean particle diameter of about 5 nm to about 300 nm, about 5 nm to about 100 nm, or about 35 nm. In certain implementations, a pharmaceutical composition contains about 25% wt / wt or less (e.g., about 1% to about 25%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt MCT excipient, about 15% to about 50% wt / wt PECO excipient, about 5% to about 50% wt / wt linoleoyl macrogol glycerides excipient and about 15% to about 50% wt / wt glyceryl monocaprylate excipient. In certain implementations, a pharmaceutical composition contains about 25% wt / wt or less (e.g., about 5% to about 20%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 35% wt / wt MCT excipient, about 20% to about 35%, about 15% to about 30%, about 15% to about 40% wt / wt PECO excipient, about 5% to about 30% wt / wt (or about 5% to about 20%) linoleoyl macrogol glycerides excipient and about 20% to about 50% wt / wt (or about 20% to about 35%) glyceryl monocaprylate excipient. In certain implementations, a pharmaceutical composition contains about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 18% to about 33% wt / wt MCT excipient, about 20% to about 40% wt / wt PECO excipient, about 10% to about 25% wt / wt linoleoyl macrogol glycerides excipient and about 25% to about 45% wt / wt glyceryl monocaprylate excipient. In certain implementations, a pharmaceutical composition contains about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 35% wt / wt MCT excipient, about 15% to about 30% wt / wt PECO excipient, about 5% to about 20% wt / wt linoleoyl macrogol glycerides excipient and about 20% to about 35% wt / wt glyceryl monocaprylate excipient. In certain implementations, a pharmaceutical composition contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt MCT excipient, about 20% to about 25% wt / wt PECO excipient, about 10% to about 15% wt / wt linoleoyl macrogol glycerides excipient and about 25% to about 30% wt / wt glyceryl monocaprylate excipient. In certain implementations, a pharmaceutical composition contains about 10% of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 27% wt / wt MCT excipient, about 22% to about 23% wt / wt PECO excipient, about 13% to about 14% wt / wt linoleoyl macrogol glycerides excipient and about 27% wt / wt glyceryl monocaprylate excipient, and optionally is a dispersion with a mean particle diameter of about 50 nm to about 100 nm or about 80 nm. In certain implementations, a pharmaceutical composition containing MCT, PECO, linoleoyl macrogol glycerides and glyceryl monocaprylate excipients contains about 20% wt / wt or less, about 15% wt / wt or less, or about 10% wt / wt or less, or about 9% wt / wt or less, or about 8% wt / wt or less, or about 7% wt / wt or less, or about 6% wt / wt or less, or about 5% wt / wt or less, or about 4% wt / wt or less, or about 3% wt / wt or less, or about 2% wt / wt or less, or about 1% wt / wt or less, of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof. In certain implementations, a pharmaceutical composition containing active ingredient and MCT, PECO, linoleoyl macrogol glycerides and glyceryl monocaprylate excipients contains particles having a mean particle diameter of about 100 nm or less, or about 90 nm or less, or about 80 nm or less, or about 70 nm or less, or about 60 nm or less, or about 50 nm or less, or about 45 nm or less, or about 40 nm or less, or about 35 nm or less, or about 30 nm or less. In certain implementations, a pharmaceutical composition contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt MCT excipient, about 15% to about 50% wt / wt PECO excipient and about 15% to about 60% wt / wt glyceryl monocaprylate excipient. In certain implementations, a pharmaceutical composition contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 30% wt / wt MCT excipient, about 15% to about 30% wt / wt PECO excipient and about 30% to about 55% wt / wt glyceryl monocaprylate excipient. In certain implementations, a pharmaceutical composition contains about 5% to about 15% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt MCT excipient, about 15% to about 20% wt / wt PECO excipient and about 40% to about 50% wt / wt glyceryl monocaprylate excipient. In certain implementations, a pharmaceutical composition contains about 10% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 27% wt / wt MCT excipient, about 18% wt / wt PECO excipient and about 45% wt / wt glyceryl monocaprylate excipient, and optionally is a dispersion with a mean particle diameter of about 50 nm to about 100 nm or about 82 nm. In certain implementations, a pharmaceutical composition contains about 5% to about 15% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt MCT excipient, about 25% to about 30% wt / wt PECO excipient and about 30% to about 40% wt / wt glyceryl monocaprylate excipient. In certain implementations, a pharmaceutical composition contains about 10% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 27% wt / wt MCT excipient, about 27% wt / wt PECO excipient and about 36% wt / wt glyceryl monocaprylate excipient, and optionally is a dispersion with a mean particle diameter of about 50 nm to about 100 nm or about 85 nm. In certain implementations, a pharmaceutical composition contains about 5% to about 15% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 20% wt / wt MCT excipient, about 20% to about 25% wt / wt PECO excipient and about 45% to about 55% wt / wt glyceryl monocaprylate excipient. In certain implementations, a pharmaceutical composition contains about 10% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 18% wt / wt MCT excipient, about 22% to about 23% wt / wt PECO excipient and about 49% to about 50% wt / wt glyceryl monocaprylate excipient, and optionally is a dispersion with a mean particle diameter of about 50 nm to about 100 nm or about 61 nm. In certain implementations, a pharmaceutical composition contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt MCT excipient, about 10% to about 35% wt / wt PECO excipient and about 25% to about 45% wt / wt propylene glycol monocaprylate excipient. In certain implementations, a pharmaceutical composition contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt MCT excipient, about 25% to about 30% wt / wt PECO excipient and about 30% to about 40% wt / wt propylene glycol monocaprylate excipient. In certain implementations, a pharmaceutical composition contains about 10% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 27% MCT excipient, about 27% wt / wt PECO excipient and about 36% wt / wt propylene glycol monocaprylate excipient, and optionally is a dispersion with a mean particle diameter of about 70 nm to about 120 nm or about 90 nm. In certain implementations, a pharmaceutical composition contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt MCT excipient, about 10% to about 30% wt / wt PECO excipient, about 10% to about 35% wt / wt glyceryl monocaprylate excipient and about 5% to about 25% wt / wt propylene glycol dicaprylate excipient. In certain implementations, a pharmaceutical composition contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt MCT excipient, about 20% to about 25% wt / wt PECO excipient, about 25% to about 30% wt / wt glyceryl monocaprylate excipient and about 10% to about 15% wt / wt propylene glycol dicaprylate excipient. In certain implementations, a pharmaceutical composition contains about 10% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 27% wt / wt MCT excipient, about 22% to about 23% wt / wt PECO excipient, about 27% wt / wt glyceryl monocaprylate excipient and about 13% to about 14% wt / wt propylene glycol dicaprylate excipient, and optionally is a dispersion with a mean particle diameter of about 50 nm to about 120 nm or about 75 nm. In certain implementations, a pharmaceutical composition contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt MCT excipient, about 5% to about 50% wt / wt linoleoyl macrogol glycerides excipient, about 20% to about 50% wt / wt glyceryl monocaprylate excipient and about 20% to about 50% wt / wt PEG-8 caprylic / capric glycerides excipient. In certain implementations, a pharmaceutical composition contains about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt MCT excipient, about 10% to about 15% wt / wt linoleoyl macrogol glycerides excipient, about 25% to about 30% wt / wt glyceryl monocaprylate excipient and about 20% to about 25% wt / wt PEG-8 caprylic / capric glycerides excipient. In certain implementations, a pharmaceutical composition contains about 10% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 27% wt / wt MCT excipient, about 13% to about 14% wt / wt linoleoyl macrogol glycerides excipient, about 27% wt / wt glyceryl monocaprylate excipient and about 22% to about 23% wt / wt PEG-8 caprylic / capric glycerides excipient, and optionally is a dispersion with a mean particle diameter of about 50 nm to about 120 nm or about 80 nm. In certain implementations, a pharmaceutical composition contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 40% wt / wt MCT excipient, about 20% to about 30% wt / wt PECO excipient, about 25% to about 50% wt / wt PS80 excipient and about 1% to about 20% wt / wt PEG excipient and optionally about 1% to about 10% wt / wt ethanol excipient. In certain implementations, a pharmaceutical composition contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 25% wt / wt MCT excipient, about 20% to about 40% wt / wt PS80 excipient and about 1% to about 65% wt / wt PEG excipient and optionally about 1% to about 10% wt / wt ethanol excipient. In certain implementations, a pharmaceutical composition contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt MCT excipient, about 10% to about 50% wt / wt PECO excipient, and one or both of about 1% to about 50% wt / wt propylene glycol monocaprylate excipient and about 1% to about 50% wt / wt propylene glycol dicaprylate excipient. In certain implementations, a pharmaceutical composition contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt MCT excipient, about 20% to about 50% wt / wt PEG-8 caprylic / capric glycerides excipient, and one or both of about 1% to about 50% wt / wt propylene glycol monocaprylate excipient and about 1% to about 50% wt / wt propylene glycol dicaprylate excipient. In the foregoing implementations, a rimiducid analog can be a compound of Formula C, D, E, F, F1, G, H, H1 or J, or a pharmaceutically acceptable salt thereof. In the foregoing implementations, a pharmaceutical composition for injection sometimes is a dispersion or emulsion with a mean particle diameter of about 5 nm to about 200 nm or about 5 nm to about 100 nm. In certain instances, a pharmaceutical composition for injection includes water, and sometimes about 0.1% to about 20% (e.g., about 0.5% to about 10%) by weight of an additive chosen from ethanol, propylene glycol, glycerol and polyethylene glycol (alone or a combination of two, three or all of the foregoing additives). In certain implementations, a pharmaceutical composition for injection contains no added water. In certain implementations, a pharmaceutical composition for injection includes about 1% to about 10% by weight of an antioxidant, non-limiting examples of which include butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), DL-alpha-tocopherol, ascorbyl palmitate and propyl gallate (alone or a combination of two, three, four or all of the foregoing antioxidants). Emulsions and Dispersions A pharmaceutical composition for injection that includes an oil component and aqueous component can be an oil-in-water emulsion containing particles (e.g. a nano-emulsion) or dispersion containing particles (e.g., a nano-dispersion). An oil-in-water emulsion or dispersion can contain a surfactant component, which can form micelles in the pharmaceutical composition. A surfactant component can include one or more surfactants described herein, such as PS80 and others described herein, for example. In certain instances the particles are defined by a mean particle diameter of about 1 nanometer (nm) to about 2000 nm. An emulsion or dispersion sometimes is characterized by a mean particle diameter of 200 nm or less, or 150 nm or less, or 100 nm or less, or 75 nm or less, or 50 nm or less. In certain instances, a standard deviation of the mean particle diameter is about 30 nm or less, or about 25 nm or less, or about 20 nm or less, or about 15 nm or less, or about 10 nm or less, or about 5 nm or less, or about 1 nm or less, or about 0.5 nm or less, or about 0.01 nm or less. Particles in an emulsion or dispersion sometimes are defined by dispersity. 'LVSHUVLW\^LV^WKH^VWDQGDUG^GHYLDWLRQ^^ı^^RI^WKH^ particle diameter distribution divided by the mean particle diameter and is alternatively referred to herein as polydispersity. In certain instances, the particles are defined by a dispersity of about 0.005 to about 0.50, or about 0.01 to about 0.40, or about 0.01 to about 0.30, or about 0.01 to about 0.25, or about 0.10 to about 0.25. In certain instances, a standard deviation of the dispersity is about 0.25 or less, about 0.20 or less, about 0.15 or less, about 0.10 or less, about 0.05 or less, about 0.01 or less, about 0.005 or less or about 0.001 or less. Particle size and dispersity can be determined using a suitable known technique, such as Dynamic Light Scattering (DLS), for example. Devices for DLS determination are commercially available (e.g., Zetasizer device (Malvern Panalytical Ltd., Malvern, United Kingdom). Dosage form of pharmaceutical composition for injection Pharmaceutical forms suitable for injection (e.g., subcutaneous or intramuscular administration) include pharmaceutical forms in sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. An injectable formulation often is sterile and often is fluid. A fluid sometimes is an emulsion or dispersion, such as an oil-in- water emulsion for example. An injectable pharmaceutical composition typically is stable under the conditions of manufacture and storage and is preserved against the contaminating action of microorganisms, such as bacteria and fungi. A pharmaceutical composition can be delivered to a subject via any suitable injection device, including without limitation, a syringe, needle or microneedle (e.g., including a syringe device for self-administration). An injectable formulation sometimes includes a carrier, which can be a solvent, excipient, and / or dispersion medium. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, other components described herein, and suitable mixtures thereof. Fluidity of an injectable formulation can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be affected by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In certain examples, isotonic agents, for example, sugars or sodium chloride may be included. Prolonged absorption of an injectable compositions can be affected by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin. A pharmaceutical composition may include a co- polymer such as, for example, a co-polymer selected from the group consisting of poly(vinyl alcohol), poly(vinyl pyrrolidone), and hypromellose acetate succinate. Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation include vacuum drying and freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions. In certain implementations, a pharmaceutical composition described herein sometimes is in subcutaneous administration dosage form (i.e., for subcutaneous administration) or sometimes is in intramuscular administration dosage form (i.e., for intramuscular administration). A pharmaceutical composition sometimes is in an auto-injector device, which can include a spring-loaded pre-filled syringe. An auto-injector device also is referred to herein as a pen device, and often is a one-use and disposable device. An auto-injector device often includes a cover that covers the needle of the syringe, and often includes a pre-loaded spring as a power source, where the spring and associated mechanical components form a one-shot linear actuator. When triggered an actuator can drive a sequence that includes (i) accelerating the syringe forward, puncturing the injection site; (ii) actuating the piston of the syringe, injecting the pharmaceutical composition; and (iii) deploying a shield that covers the needle. Auto-injection devices are known and non-limiting examples for different pharmaceutical compositions include SureClick® auto-injector; Rebiject®, Rebiject II® and Rebidose® auto-injectors; Anapen®, EpiPen®, Emerade®, and Auvi-Q® auto-injectors; subcutaneous sumatriptan auto-injector. Pharmaceutical compositions for oral administration Certain pharmaceutical compositions provided herein are for oral administration. In certain implementations, an active ingredient in a pharmaceutical composition for oral administration includes a multimerizer active ingredient. An active ingredient sometimes is a rimiducid analog, such as a rimiducid analog described herein, which can be in an amount described herein. In certain implementations, a pharmaceutical composition includes about 5% to about 25% of a rimiducid analog (or a pharmaceutically acceptable salt thereof) by weight (e.g., weight of rimiducid to total weight of the pharmaceutical composition (wt:wt)), such as a rimiducid analog of Formula C, D, E, F, F1, G, H, H1 or J. A pharmaceutical composition for oral administration often includes a lipid excipient component. Lipid excipient components are described herein. In certain implementations, a pharmaceutical composition for oral administration includes a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, a C8 fatty acid esters excipient and a C18 fatty acid glycerides excipient. A pharmaceutical composition sometimes includes about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt C8 fatty acid esters excipient and about 20% to about 80% wt / wt C18 fatty acid glycerides excipient. In certain implementations, a C8 fatty acid esters excipient includes polyethylene glycol (PEG) esters, and the PEG esters sometimes includes PEG-8. In certain implementations, a C8 fatty acid esters excipient includes C10 fatty acid esters. In certain instances, a C8 fatty acid esters excipient is a caprylocaproyl polyoxyl-8 glycerides excipient. In certain implementations, a C18 fatty acid glycerides excipient includes a monoglyceride majority glyceride. In certain implementations, a C18 fatty acid glycerides excipient includes oleic acid. In certain instances, a C18 fatty acid glycerides excipient is a glycerol monooleate (type 40) excipient. In certain implementations, a pharmaceutical composition for oral administration includes a rimiducid analog or pharmaceutically acceptable salt thereof, a caprylocaproyl polyoxyl-8 glycerides excipient and a glycerol monooleate (type 40) excipient, and sometimes includes about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt caprylocaproyl polyoxyl-8 glycerides excipient and about 20% to about 80% wt / wt glycerol monooleate (type 40) excipient. In certain implementations, a pharmaceutical composition for oral administration includes a rimiducid analog or pharmaceutically acceptable salt thereof, a C8 fatty acid esters excipient and C18 fatty acid esters excipient. In certain instances, the pharmaceutical composition includes about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt C8 fatty acid esters excipient and about 20% to about 80% wt / wt C18 fatty acid esters excipient. In certain instances, a C18 fatty acid esters excipient includes polyethylene glycol (PEG) esters, and sometimes the PEG esters comprise PEG-6. In certain implementations, a C18 fatty acid esters excipient includes oleic acid. In certain instances, a C18 fatty acid esters excipient is an oleoyl polyoxyl-6 glycerides excipient. In certain implementations, a C8 fatty acid esters excipient includes polyethylene glycol (PEG) esters, and the PEG esters sometimes include PEG-8. A C8 fatty acid esters excipient sometimes includes C10 fatty acid esters. In certain implementations, a C8 fatty acid esters excipient is a caprylocaproyl polyoxyl-8 glycerides excipient. In certain implementations, a pharmaceutical composition for oral administration includes a rimiducid analog or pharmaceutically acceptable salt thereof, a caprylocaproyl polyoxyl-8 glycerides excipient and an oleoyl polyoxyl-6 glycerides excipient, and sometimes includes about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt caprylocaproyl polyoxyl-8 glycerides excipient and about 20% to about 80% wt / wt oleoyl polyoxyl-6 glycerides excipient. In certain implementations, a pharmaceutical composition for oral administration includes a rimiducid analog or pharmaceutically acceptable salt thereof, a C8 fatty acid polyethylene glycol (PEG) esters excipient and C8 fatty acid propylene glycol (PG) esters excipient. A pharmaceutical composition sometimes includes about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt C8 fatty acid PEG esters excipient and about 20% to about 80% wt / wt C8 fatty acid PG esters excipient. In certain implementations PEG esters of the C8 fatty acid PEG esters excipient include PEG-8. A C8 fatty acid PEG esters excipient sometimes includes C10 fatty acid esters. A C8 fatty acid esters excipient sometimes is a caprylocaproyl polyoxyl-8 glycerides excipient. In certain implementations, a C8 fatty acid PG esters excipient includes monoesters and diesters with a majority of the monoesters. A C8 fatty acid PG esters excipient sometimes is a propylene glycol monocaprylate (type II) excipient. In certain implementations, a pharmaceutical composition for oral administration includes a rimiducid analog or pharmaceutically acceptable salt thereof, a caprylocaproyl polyoxyl-8 glycerides excipient and a propylene glycol monocaprylate (type II) excipient, and sometimes includes about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt caprylocaproyl polyoxyl-8 glycerides excipient and a propylene glycol monocaprylate (type II) excipient. In certain implementations, a pharmaceutical composition for oral administration includes a rimiducid analog or pharmaceutically acceptable salt thereof, a C8 fatty acid esters excipient and a C18 fatty acid esters excipient. A pharmaceutical composition sometimes includes about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt C8 fatty acid esters excipient and about 20% to about 80% wt / wt C18 fatty acid esters excipient. A C8 fatty acid esters excipient sometimes is a C8 fatty acid propylene glycol (PG) esters excipient comprising propylene glycol esters. A C8 fatty acid PG esters excipient can include monoesters and diesters with a majority of the monoesters. A C8 fatty acid PG esters excipient sometimes is a propylene glycol monocaprylate (type II) excipient. In certain implementations, a C18 fatty acid esters excipient includes polyethylene glycol (PEG) esters, and sometimes the PEG esters includes PEG-6. A C18 fatty acid esters excipient can include oleic acid, and sometimes a C18 fatty acid esters excipient is an oleoyl polyoxyl-6 glycerides excipient. In certain implementations, a pharmaceutical composition for oral administration includes a rimiducid analog or pharmaceutically acceptable salt thereof, a propylene glycol monocaprylate (type II) excipient and an oleoyl polyoxyl- 6 glycerides excipient, and sometimes includes about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt propylene glycol monocaprylate (type II) excipient and about 20% to about 80% wt / wt oleoyl polyoxyl-6 glycerides excipient. In the foregoing implementations, a lipid excipient component sometimes includes propylene glycol esters of caprylic acid (C8), which sometimes is composed of a majority of mono-esters and a minority of di-esters. In certain instances, a lipid excipient component includes glycerides (e.g., mono-, di- and tri-glycerides) of oleic acid (C18:1) (cis fatty acid) and PEG-6 (MW 300) esters (e.g., mono- and di-esters) of oleic acid. In certain implementations, a lipid excipient component includes glycerides (e.g., mono-, di- and tri-glycerides) of oleic acid (C18:1), in which sometimes a majority is mono-glycerides. In certain instances, a lipid excipient component includes glycerides (e.g., mono-, di- and tri-glycerides) of caprylic (C8) and capric (C10) acids and PEG-8 (MW 400) esters (e.g., mono- and diesters) of caprylic (C8) and capric (C10) acids, in which sometimes a majority is the PEG-8 esters of caprylic and capric acids and the minority is the glycerides of caprylic and capric acids. In certain implementations, a lipid excipient component includes propylene glycol esters (e.g., mono- and di- esters) of lauric acid (C12), in which sometimes a majority is mono-esters and a minority is di-esters. In certain instances, a lipid excipient component includes glycerides (e.g., mono-, di- and tri-glycerides) of linoleic (C18:2) and oleic (C18:1) acids, in which a majority sometimes is di-glyceride. In certain implementations, a pharmaceutical composition for oral administration includes one or more of the lipid excipient components depicted in the following Table A. A pharmaceutical composition for oral administration sometimes includes a mixture of two, three, four, five or all of lipid excipient components A, B, C, D, E and F shown in Table A. Table A: Non-limiting examples of lipid excipient components Example of Li id Exci ient Com onent USP Name EP Name Li id Exci ient Example of Lipid Excipient Component USP Name EP Name Lipid Excipient , p p , optionally about 0.1% to about 20% (e.g., about 0.5% to about 10%) by weight of an additive chosen from ethanol, propylene glycol, glycerol and polyethylene glycol (alone or a combination of two, three or all of the foregoing additives). In certain implementations, a pharmaceutical composition for oral administration contains no added water. In certain implementations, a pharmaceutical composition for oral administration includes about 1% to about 10% by weight of an antioxidant, non-limiting examples of which include butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), DL-alpha-tocopherol, ascorbyl palmitate and propyl gallate (alone or a combination of two, three, four or all of the foregoing antioxidants). In certain implementations, the pharmaceutical composition includes a taste-masking agent, which in certain instances can include peppermint oil and / or another taste-masking agent. In certain implementations, a pharmaceutical composition for oral administration or other pharmaceutical composition described herein does not include polyethylene glycol 15- hydroxystearate. In certain instances, a pharmaceutical composition for oral administration or other pharmaceutical composition described herein does not include 12-hydroxystearic acid-polyethylene glycol copolymer. In certain implementations, a pharmaceutical composition for oral administration or other pharmaceutical composition described herein does not include macrogol 15 hydroxystearate. In certain instances, a pharmaceutical composition for oral administration or other pharmaceutical composition described herein does not include polyethoxylated 12-hydroxystearic acid. In certain implementations, a pharmaceutical composition for oral administration or other pharmaceutical composition described herein does not include polyoxyl 15 hydroxystearate. In certain instances, a pharmaceutical composition for oral administration or other pharmaceutical composition described herein does not include a polyethylene glycol ether. In certain implementations a pharmaceutical composition for oral administration or other pharmaceutical composition described herein does not include a polyethylene glycol ether from castor oil. In certain implementations, a pharmaceutical composition for oral administration or other pharmaceutical composition described herein does not include a polyethylene glycol ester of ricinoleic acid. In certain implementations, a pharmaceutical composition for oral administration or other pharmaceutical composition described herein does not include a polyethylene glycol. In certain implementations, a pharmaceutical composition for oral administration or other pharmaceutical composition described herein does not include a polyethylene glycol ether of glycerol. In certain instances, a pharmaceutical composition for oral administration or other pharmaceutical composition described herein does not include stearic acid (C18 saturated fatty acid). In certain implementations, a pharmaceutical composition for oral administration or other pharmaceutical composition described herein does not include mono-, di- and triglycerides of stearic acid. In certain instances, a pharmaceutical composition for oral administration or other pharmaceutical composition described herein does not include PEG-15 mono- and diesters of stearic acid. Dosage form of pharmaceutical composition for oral administration A pharmaceutical composition for oral administration may be provided as a tablet (e.g., ingestible tablet, buccal tablet), troche, capsule (e.g., hard- or soft-shell gelatin capsule), drink, elixir, suspension, syrup, wafer, and the like, and / or may be incorporated directly in food or drink that is part of a subject’s diet. Such compositions and preparations sometimes contain at least 0.1% of active ingredient. The amount of active ingredient in a pharmaceutical composition is such that an effective dosage level will be obtained. Tablets, troches, pills, capsules, and the like may contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Any additive and material used in preparing a unit dosage form typically is pharmaceutically acceptable and substantially non-toxic in the amounts employed. Methods for manufacturing pharmaceutical compositions Any suitable known method can be used to manufacture a pharmaceutical composition described herein. An active ingredient, such as a rimiducid family compound of a structure of Formula A, rimiducid of a structure of Formula B, or a rimiducid analog (e.g., a compound of Formula C, D, E, F, F1, G, H, H1 or J) or a pharmaceutically acceptable salt thereof, for example, often is in a purified form. One or more or all components (e.g., excipient components), such as an oil component, solvent component (e.g., polar solvent component), aqueous component, surfactant component, for example, mixed with the active ingredient often are in a purified form. A purified form can be referred to as a refined form, and sometimes an active ingredient and one or more or all components mixed with the active ingredient are in a highly purified or highly refined form. A multimerizer active ingredient and one or more other components utilized to a prepare a pharmaceutical composition formulation each sometimes is at least 90% pure, and sometimes at least 95% pure (e.g., 90% pure or greater, 91% pure or greater, 92% pure or greater, 93% pure or greater, 94% pure or greater, 95% pure or greater, 96% pure or greater, 97% pure or greater, 98% pure or greater, 99% pure or greater, 99.5% pure or greater or 99.9% pure or greater). A percent purity of a multimerizer active ingredient or other component typically is an amount of the active ingredient or component in a reagent utilized to prepare a pharmaceutical composition, relative to other elements that may be present in the reagent. The amount sometimes is by weight, typically weight of the component to the overall weight of the reagent, and sometimes is by volume, typically volume of the component to the overall volume of the reagent. An active ingredient and one or more other components utilized to prepare a pharmaceutical composition formulation each sometimes is clinical grade, American Chemical Society (ACS) grade, Reagent grade, National Formulary (NF) grade, United States Pharmacopeia (USP) grade and / or GMP grade (i.e., manufactured according to Good Manufacturing Practice (GMP) or Current Good Manufacturing Practice (cGMP)). Provided in certain implementations is a method for preparing a pharmaceutical composition for injection that includes mixing a water miscible component with a water immiscible component to prepare a mixture; and combining the mixture with the compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof. In certain instances, the water immiscible component is a trigylcerides excipient, such as a medium chain triglycerides (MCT) excipient, for example, which can include C6, C8, C10 and C12 fatty acids. In certain implementations, the water miscible component comprises one or more of: a PEG ether-modified trigylcerides excipient, a surfactant excipient, ethanol, C8 fatty acid glyceride excipient, C8 fatty acid ester excipient, a C18 fatty acid glycerides excipient and a PEG excipient. In certain instances, the PEG ether-modified trigylcerides excipient is a modified vegetable oil, such as polyethoxylated castor oil (PECO) for example. A surfactant excipient sometimes is a polysorbate (PS) surfactant, and sometimes includes PS20, PS40, PS60 and / or PS80. In certain instances, a C8 fatty acid glyceride excipient includes monoglycerides and diglycerides containing a C8 fatty acid, and sometimes is a glyceryl monocaprylate excipient, which can include C10 fatty acid glycerides. In certain instances, a C8 fatty acid ester excipient includes propylene glycol esters of C8 fatty acids. A C8 fatty acid ester excipient sometimes includes a propylene glycol monocaprylate excipient and / or a propylene glycol dicaprylate excipient. A propylene glycol dicaprylate excipient can include propylene glycol esters of C10 fatty acids. In certain instances a C8 fatty acid ester excipient includes PEG esters, which can include PEG monoesters and / or PEG diesters of C8 fatty acids. A C8 fatty acid ester excipient sometimes includes a PEG-8 caprylic / capric glycerides excipient, which can include PEG esters of C10 fatty acids. In certain instances, a C18 fatty acid glycerides excipient includes a linoleoyl macrogol glycerides excipient, which can include glycerides and PEG-6 (MW 300) esters of linoleic (C18:2) acid. A PEG excipient sometimes includes a PEG400 excipient and / or a PEG300 excipient. In certain implementations, a rimiducid analog is a compound of Formula C, D, E, F, F1, G, H, H1 or J, or a pharmaceutically acceptable salt thereof. For implementations in which an oil component is utilized, a composition prepared often is an emulsion or dispersion containing particles, and sometimes is an oil-in-water emulsion including particles. For example, a composition prepared by mixing an oil mixture with an aqueous mixture often is an oil-in-water emulsion including particles. In certain implementations, an emulsion containing particles is formed, and the method of manufacture does not include exposing the particles to conditions that reduce the size of the particles. In certain implementations, an emulsion containing particles is formed, and the method of manufacture includes exposing the particles to conditions that reduce the size of the particles. In the latter implementations, any suitable conditions that reduce the size of the particles can be utilized, non-limiting examples of which include sonication conditions, micro-fluidization conditions, ball-milling conditions, or the like, or a combination thereof. In certain manufacturing processing implementations, which can include or not include exposing particles to conditions that reduce the size of particles, the particles in an intermediate composition, or in a final pharmaceutical composition, can have one or more of the following characteristics: (i) a mean particle diameter of 200 nm or less, or 150 nm or less, or 100 nm or less, or 75 nm or less, or 50 nm or less. In certain instances, (ii) a standard deviation of the mean particle diameter of about 30 nm or less, or about 25 nm or less, or about 20 nm or less, or about 15 nm or less, or about 10 nm or less, or about 5 nm or less, or about 1 nm or less, or about 0.5 nm or less or about 0.01 nm or less; (iii) a dispersity of about 0.005 to about 0.50, or about 0.01 to about 0.40, or about 0.01 to about 0.30, or about 0.01 to about 0.25, or about 0.10 to about 0.25; or (iv) a standard deviation of the dispersity of about 0.25 or less, about 0.20 or less, about 0.15 or less, about 0.10 or less, about 0.05 or less, about 0.01 or less, about 0.005 or less or about 0.001 or less. Certain implementations of methods for manufacturing pharmaceutical compositions include preparing a pharmaceutical composition in a dosage form. A dosage form sometimes is a subcutaneous administration dosage form (i.e., a dosage form for subcutaneous administration), and sometimes is an intramuscular administration dosage form (i.e., a dosage form for intramuscular administration). Certain implementations of a method of manufacture include loading a pharmaceutical composition into an auto-injector device (e.g., auto-injector pen device). A dosage form sometimes is a topical administration dosage form (i.e., a dosage form for topical administration). Use of pharmaceutical compositions A pharmaceutical composition described herein can be administered to cells to which a therapeutic agent has been administered. In some embodiments, a therapeutic agent includes a polynucleotide encoding a polypeptide that interacts with a multimerizer active ingredient (also referred to as a “multimerizing agent”) in a pharmaceutical composition described herein. In certain implementations, a polypeptide encoded by a polynucleotide of a therapeutic agent can facilitate cell elimination. In certain instances, a polypeptide encoded by a polynucleotide of a therapeutic agent can facilitate cell activation (e.g., immunogenic cell activation). A therapeutic agent sometimes includes a polynucleotide that encodes a chimeric polypeptide, which also is referred to herein as a fusion protein. A chimeric polypeptide sometimes is a non-naturally occurring polypeptide, or exogenous polypeptide, and sometimes is a polypeptide containing two or more different polypeptides or portions thereof that are not joined in nature. A chimeric polypeptide often includes a polypeptide portion that interacts with (e.g., binds to) a multimerizer active ingredient in a pharmaceutical composition described herein. A chimeric polypeptide often can multimerize upon interaction with a multimerizer in a pharmaceutical composition described herein (referred to as “induced multimerization”). A chimeric polypeptide may be inactive or exhibit low baseline activity, and activity of the chimeric polypeptide can be induced and / or significantly increased by induced multimerization of two or more molecules of the chimeric polypeptide (e.g., in a cell). Multimerization of a chimeric polypeptide in a cell can be facilitated by contacting the cell with a multimerizing active ingredient in a pharmaceutical composition described herein. A cell expressing a chimeric polypeptide may be contacted by a multimerizing agent by administering a multimerizing agent to a cell (e.g., administering a multimerizing agent to a population of cells containing one or more cells expressing a chimeric polypeptide) or to a subject containing the cell. A multimerizing agent administered to induce a chimeric polypeptide activity can be in a pharmaceutical composition described herein. In certain implementations, the multimerizer (i.e., multimerizing agent) is a compound having a structure of Formula A (rimiducid family compound), a compound having a structure of Formula B (rimiducid), a rimiducid analog (e.g., a compound of Formula C, D, E, F, F1, G, H, H1 or J) or a pharmaceutically acceptable salt thereof. Provided in certain implementations is a method that includes administering a pharmaceutical composition described herein to cells containing a polypeptide (e.g., a chimeric polypeptide, a fusion protein) encoded by a polynucleotide of a therapeutic agent, where the polypeptide is capable of interacting with an active ingredient in the pharmaceutical composition. In certain instances, provided is a method that includes administering a pharmaceutical composition described herein to a subject in need thereof, where cells of the subject (e.g., a subset of cells in the subject) contain a polypeptide (e.g., a chimeric polypeptide, a fusion protein) encoded by a polynucleotide of a therapeutic agent and the polypeptide is capable of interacting with a multimerizing active ingredient in the pharmaceutical composition. A pharmaceutical composition may be administered in vitro, ex vivo or in vivo, and a may include as a multimerizing active ingredient a compound having a structure of Formula A (rimiducid family molecule), a compound having a structure of Formula B (rimiducid), a rimiducid analog (e.g., a compound of Formula C, D, E, F, F1, G, H, H1 or J) or a pharmaceutically acceptable salt thereof. In some embodiments, a therapeutic agent includes a polynucleotide encoding a polypeptide capable of inducing cell death, such as a pro-apoptotic (or apoptosis-facilitating) polypeptide, for example. In certain implementations, a therapeutic agent includes a polynucleotide encoding a chimeric polypeptide that includes a pro-apoptotic (or apoptosis-facilitating) polypeptide portion. The term pro-apoptotic polypeptide generally refers to a polypeptide that can directly or indirectly induce, promote, and / or cause apoptosis (i.e., programmed cell death). Pro-apoptotic polypeptides generally participate in a cascade that is triggered in response to pro-apoptotic signals, which culminates in cleavage of certain proteins / polypeptides, resulting in disassembly of the cell. Non-limiting examples of pro-apoptotic polypeptides include caspases (e.g., caspase-1, caspase-2, caspase-3, caspase-6, caspase-7, caspase-8, caspase-9, caspase-10, caspase-11, caspase-12), apoptosis-inducing factor (AIF), amyloid-beta-peptide, the pro-apoptotic bcl-2 subfamily of proteins (e.g., BAX, BID, BAK, BAD), granzymes (e.g., granzyme A, B), Caspase-binding adapter molecules (e.g., apoptotic protease activating factor 1 (APAF1), Fas, Fas-associated death domain (FADD)-containing protein, and death domain-containing protein (CRADD)), p53, death domain-containing members of the tumor necrosis factor receptor (TNFR) family (e.g., Fas and TNFR1) and certain heat shock proteins. Non-limiting examples of polypeptides capable of facilitating cell elimination are described in Savrou et al., Molecular Therapy 26(5), 1266-1276 (2018); Duong et al., Molecular Therapy: Oncolytics 12, 124-137 (2019); and U.S. Patent Application Publication No. US20160166613A1, each of which is incorporated by reference herein. In some embodiments, a therapeutic agent includes a senolytic agent. The term senolytic agent generally refers to an agent that can selectively induce, promote, and / or cause death (e.g., apoptosis (i.e., programmed cell death)) of senescent cells. In some embodiments, a therapeutic agent includes a polynucleotide encoding a senolytic polypeptide or a functional variant or fragment thereof. In certain implementations, a therapeutic agent includes a polynucleotide encoding a chimeric polypeptide that includes a senolytic polypeptide portion. In some embodiments, a therapeutic agent includes a senescent cell-specific promoter. For example, a therapeutic agent may include a nucleic acid construct containing (1) a polynucleotide encoding pro-apoptotic polypeptide and (2) a senescent cell-specific promoter. Senescent cell-specific promoters may include one or more regulatory regions (e.g., a promoter region, or variant thereof, or fragment thereof) from a gene that is upregulated in senescent cells compared to non-senescent cells. Genes that are upregulated in senescent cells include cyclin-dependent kinase (CDK) inhibitors (e.g., p16INK4a), cyclin-dependent kinase inhibitor 1 (p21Cip1), senescence-DVVRFLDWHG^ȕ-galactosidase (SA-ȕ-gal), transcription factor, E2F7, transcription factor regulator, BTG2, and others. A senolytic agent may be useful for treating one or more skin conditions, skin diseases, skin lesions, and / or skin disorders. For example, a senolytic agent may be used to treat actinic keratosis, Bowen’s disease, and the like. In some embodiments, a therapeutic agent includes a polynucleotide encoding a caspase. In some embodiments, a therapeutic agent includes a polynucleotide encoding caspase-9. Caspase-9 is an enzyme encoded by the CASP9 gene (in humans). Caspase-9 belongs to a family of caspases, cysteine-aspartic proteases involved in apoptosis and cytokine signaling. Apoptotic signals promote the release of cytochrome c from mitochondria and activation of apaf-1 (apoptosome), which then cleaves the pro-enzyme of caspase-9 into the active dimer form. Caspase-9 has three domains: N- terminal pro-domain, large subunit, and a small subunit. The N-terminal pro-domain contains the caspase activation domain (CARD) motif and is linked to a catalytic domain by a linker loop. The large subunit and small subunit both include the catalytic domain. In some embodiments, a therapeutic agent includes a polynucleotide encoding a caspase-9 polypeptide fragment lacking a CARD domain. In some embodiments, a therapeutic agent includes a polynucleotide encoding an inducible caspase- 9, which is referred to herein as “iCasp9” or “iC9”. In certain implementations, a therapeutic agent includes a polynucleotide encoding a chimeric polypeptide containing an inducible caspase-9 polypeptide portion. In some embodiments, a therapeutic agent includes a polynucleotide encoding an inducible caspase-9 (iCasp9) polypeptide fragment lacking a CARD domain. An inducible caspase 9 may be generated by modifying caspase-9 and fusing it with a polypeptide that binds to a multimerizing agent in a chimeric polypeptide (e.g., fusion protein). Such a modification sometimes is performed by linking a first polynucleotide encoding a caspase-9 to a second polynucleotide encoding a polypeptide that binds to a multimerizing agent. The first polynucleotide may be linked directly to the second polynucleotide or may be linked via a linker, for example. A non-limiting example of a polypeptide that binds to a multimerizing agent is FK506-binding protein or variant thereof (e.g., FKBP12, FKBP12-V36, FRB or variant of the foregoing). A multimerizing agent can bind to the protein fused to the modified caspase-9, dimerizing and activating caspase-9, which triggers cell death. In some embodiments, an inducible caspase-9 is induced by a multimerizing agent (e.g., a dimerizer). In some embodiments, a therapeutic agent includes a polynucleotide encoding a homodimerizer- based inducible caspase-9 (iCasp9). Non-limiting examples of inducible caspase-9 systems are described in Fan et al., Hum. Gene Ther.10(14):2273-85 (1999); and Straathof et al., Blood 105(11):4247-54 (2005), each of which is incorporated by reference herein. In some embodiments, a therapeutic agent includes a polynucleotide encoding an inducible caspase-9 (iCasp9) construct (e.g., chimeric polypeptide, fusion protein). Non-limiting examples of inducible caspase-9 (iCasp9) construct components are provided in the Table B herein. In some embodiments, a therapeutic agent includes a polynucleotide encoding an inducible caspase- 9 (iCasp9) construct comprising a first polypeptide and a second polypeptide (i.e., chimeric polypeptide, fusion protein). In some embodiments, the first polypeptide is a FKBP12-V36 polypeptide. In some embodiments, the first polypeptide is a human FKBP12-V36 polypeptide. In some embodiments, the first polypeptide includes a polypeptide that is at least 90% identical to SEQ ID NO:1. In some embodiments, the first polypeptide includes a polypeptide that is at least 95% identical to SEQ ID NO:1. In some embodiments, the first polypeptide includes a polypeptide that is at least 99% identical to SEQ ID NO:1. In some embodiments, the first polypeptide includes the polypeptide of SEQ ID NO:1. In some embodiments, the second polypeptide is a dCasp9 (5' truncated Casp9) polypeptide. In some embodiments, the second polypeptide is a dCasp9 (5' truncated human Casp9) polypeptide. In some embodiments, the second polypeptide includes a polypeptide that is at least 90% identical to SEQ ID NO:3. In some embodiments, the second polypeptide includes a polypeptide that is at least 95% identical to SEQ ID NO:3. In some embodiments, the second polypeptide includes a polypeptide that is at least 99% identical to SEQ ID NO:3. In some embodiments, the second polypeptide includes the polypeptide of SEQ ID NO:3. In some embodiments, a linker is located between the first polypeptide and the second polypeptide. In some embodiments, the linker is a GS linker. In some embodiments, the linker includes about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids. In some embodiments, the linker includes about 6 amino acids. In some embodiments, the linker includes the peptide of SEQ ID NO:2. A chimeric polypeptide (e.g., fusion protein) encoded by a therapeutic agent nucleic acid sometimes includes a FKBP12-V36 portion that lacks an N-terminal methionine when the FKBP12-V36 portion is not located at the N-terminus of the chimeric polypeptide (SEQ ID NO:4). In certain implementations, a therapeutic agent encodes or includes a binding domain that binds to rapamycin or a rapamycin analog, such as a FKBP-rapamycin-binding (FRB) domain, for example. In certain implementations, the first polypeptide is located at the N-terminus of the chimeric polypeptide (e.g., fusion protein), the first polypeptide is located closer to the N-terminus of the chimeric polypeptide (e.g., fusion protein) than the second polypeptide, the second polypeptide is located closer to the N-terminus of the chimeric polypeptide (e.g., fusion protein) than the first polypeptide, or the second polypeptide is located at the C-terminus of the chimeric polypeptide. In certain implementations, a therapeutic agent includes a polynucleotide encoding a chimeric polypeptide (e.g., fusion protein) that includes (i) a polypeptide portion capable of interacting with (e.g., binding to) a multimerizing agent, and (ii) one or more polypeptide portions capable of activating a cell, such as an immune system cell. Non-limiting examples of immune system cells include T-cells (e.g., alpha-beta T-cells, gamma-delta T-cells), NK cells and the like. A chimeric polypeptide (e.g., fusion protein) can include a suitable type of polypeptide portion capable of activating a cell, such as an immune cell, non-limiting examples of which include CD3-zeta, CD19, 41BB, OX40, MyD88, CD40, a portion thereof and combinations of the foregoing. In certain implementations, a chimeric polypeptide (e.g., fusion protein) includes MyD88 or a truncated form of MyD88. A MyD88 sometimes is a polypeptide product of the myeloid differentiation primary response gene 88 (NCBI Gene ID 4615). A truncated MyD88 polypeptide is shorter than the full- length MyD88 polypeptide and sometimes lacks a domain or portion of a domain, such as the TIR domain, for example. A non-limiting example of a truncated MyD88 polypeptide has a structure according to SEQ ID NO:5. In certain implementations, a chimeric polypeptide (e.g., fusion protein) includes CD40 (e.g., human CD40) or a truncated form of CD40. A truncated CD40 polypeptide is shorter than the full-length CD40 polypeptide and sometimes lacks a domain, such as the extracellular domain and / or transmembrane domain, or portion of such a domain, for example. A non-limiting example of a truncated CD40 polypeptide referred to as “cytoplasmic CD40” has a structure according to SEQ ID NO:6. A chimeric polypeptide (e.g., fusion protein) encoded by a therapeutic agent nucleic acid sometimes includes a first polypeptide, a second polypeptide and a third polypeptide. In some embodiments, the first polypeptide is a truncated MyD88 polypeptide or MyD88 polypeptide. In some embodiments, the first polypeptide is a truncated human MyD88 polypeptide. In some embodiments, the first polypeptide includes a polypeptide that is at least 90% identical to SEQ ID NO:5. In some embodiments, the first polypeptide includes a polypeptide that is at least 95% identical to SEQ ID NO:5. In some embodiments, the first polypeptide includes a polypeptide that is at least 99% identical to SEQ ID NO:5. In some embodiments, the first polypeptide includes the polypeptide of SEQ ID NO:5. In some embodiments, the second polypeptide is a CD40 polypeptide or cytoplasmic CD40 polypeptide. In some embodiments, the second polypeptide is a human cytoplasmic CD40 polypeptide. In some embodiments, the second polypeptide includes a polypeptide that is at least 90% identical to SEQ ID NO:6. In some embodiments, the second polypeptide includes a polypeptide that is at least 95% identical to SEQ ID NO:6. In some embodiments, the second polypeptide includes a polypeptide that is at least 99% identical to SEQ ID NO:6. In some embodiments, the second polypeptide includes the polypeptide of SEQ ID NO:6. In some embodiments, the third polypeptide is a FKBP12-V36 polypeptide. In some embodiments, the third polypeptide is a human FKBP12-V36 polypeptide. In some embodiments, the third polypeptide includes a polypeptide that is at least 90% identical to SEQ ID NO:4. In some embodiments, the third polypeptide includes a polypeptide that is at least 95% identical to SEQ ID NO:4. In some embodiments, the third polypeptide includes a polypeptide that is at least 99% identical to SEQ ID NO:4. In some embodiments, the third polypeptide includes the polypeptide of SEQ ID NO:4. In certain implementations, a therapeutic agent encodes or includes a binding domain that binds to rapamycin or a rapamycin analog, such as a FKBP-rapamycin-binding (FRB) domain, for example. In certain embodiments, the cytoplasmic polypeptide (e.g., fusion protein) includes the following polypeptides in the following order: N-terminus – first polypeptide – second polypeptide – third polypeptide – C-terminus, where there optionally is a linker between the first polypeptide and the second polypeptide and there optionally is a linker between the second polypeptide and the third polypeptide. Any suitable linker can be incorporated, such as a linker containing about 10 or fewer contiguous amino acids (e.g., a linker that includes about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids), non-limiting examples which include a GS linker (e.g., SEQ ID NO:2), a linker containing or consisting of the amino acids LN, RT, VG (designated by the one-letter amino acid code), and the like. A chimeric polypeptide (e.g., fusion protein) encoded by a therapeutic agent nucleic acid sometimes includes a polypeptide portion that associates with a portion of a cell membrane, which can facilitate membrane localization and multimerization of multiple molecules of the chimeric polypeptide. A non-limiting example of a membrane association polypeptide portion is a myristoyl-association polypeptide portion, which can have structure according to SEQ ID NO:7. In certain implementations, a chimeric polypeptide (e.g., fusion protein) includes a myristoyl-association polypeptide at least 90% identical to SEQ ID NO:7, or a myristoyl-association polypeptide at least 95% identical to SEQ ID NO:7, or a myristoyl-association polypeptide at least 99% identical to SEQ ID NO:7, or the myristoyl-association polypeptide of SEQ ID NO:7. A membrane-association polypeptide portion of a chimeric polypeptide (e.g., fusion protein) sometimes is located at the N- terminus of the chimeric polypeptide, and sometimes is spaced from an adjacent domain in the chimeric polypeptide by a linker containing 10 or fewer contiguous amino acids (e.g., a GS linker (e.g., SEQ ID NO:2), or a linker containing or consisting of LN, RT, VG, and the like). Table B: polypeptide sequences Polypeptide Polypeptide sequence K I T P E D Polypeptide Polypeptide sequence l m nt F S , (e.g., iC9) is incorporated in cells using methodology known in the art (e.g., transduction, transfection and the like), and the chimeric polypeptide is encoded in cells by the incorporated polynucleotide. In certain instances, a therapeutic polynucleotide encoding a chimeric polypeptide is incorporated into cell nucleic acid using a known genome editing process. In some embodiments, a therapeutic agent includes a polynucleotide encoding a genome-editing polypeptide, genome-editing enzyme, or genome-editing system. In some embodiments, a therapeutic agent includes a polynucleotide encoding a gene-editing polypeptide, gene-editing enzyme, or gene-editing system. In some embodiments, a gene-editing system includes one or more gene-editing polypeptides, gene- editing enzymes, and / or a gene-editing fusion protein. A gene-editing polypeptide, gene-editing enzyme, or gene-editing system generally has one or more capabilities chosen from DNA binding, DNA cleaving, DNA modification, DNA deletion, DNA insertion, and DNA replacement. Often, gene-editing systems target the binding, cleaving, modification, deletion, insertion, and / or replacement to site-specific locations (e.g., specific location(s) in the genome; specific gene(s)). Non-limiting examples of gene-editing polypeptides and / or gene-editing enzymes include CRISPR (clustered regularly interspaced short palindromic repeats) associated proteins (Cas) (e.g., Cas3, Cas9, Cas10), CRISPR-associated endonuclease in Prevotella and Francisella 1 (Cpf1), transcription activator-like effector (TALE) proteins, transcription activator-like effector nucleases (TALENs), zinc finger proteins, endonucleases, integrases, recombinases, transposases, restriction enzymes, hybrid proteins such as a nuclease-inactivated Cas9 polypeptide fused to a Clo51 endonuclease (e.g., Cas-CLOVER), and the like. In some embodiments, a gene-editing system further includes a polynucleotide encoding a guide RNA (gRNA). Guide RNA can help one or more gene-editing enzymes bind specific sequences of DNA in a genome. Guide RNA may be of any suitable length (e.g., about 10 to 50 nucleotides in length, about 15 to 30 nucleotides in length, about 18 to 22 nucleotides in length, or about 20 nucleotides in length). A gene-editing system herein may be useful for treating one or more genetic conditions, genetic diseases, and / or genetic disorders. For example, a gene-editing system herein may be used for treating hair loss / baldness (e.g., by knocking out one or more genes encoding an androgen receptor in cells associated with hair growth (e.g., basal epidermal cells, hair follicle cells). A pharmaceutical composition sometimes is administered to multimerize a chimeric polypeptide (e.g., fusion protein) that includes a polypeptide that binds to a multimerizing active ingredient (e.g., a compound having a structure of Formula A (rimiducid family molecule), a compound having a structure of Formula B (rimiducid), a rimiducid analog (e.g., a compound of Formula (e.g., a compound of Formula C, D, E, F, F1, G, H, H1 or J) or a pharmaceutically acceptable salt thereof). A non-limiting example of a polypeptide that can bind to rimiducid (i.e., a compound of Formula B) is FKBP12-V36. A FKBP12-V36 polypeptide sometimes includes the polypeptide of SEQ ID NO:1 or SEQ ID NO:4. A chimeric polypeptide (e.g., fusion protein) sometimes includes a polypeptide capable of inducing cell death (e.g., apoptosis), such as a caspase-9 polypeptide, for example. A caspase-9 polypeptide incorporated in chimeric polypeptide (e.g., a fusion protein) sometimes is a truncated caspase-9 polypeptide, such as a polypeptide of SEQ ID NO:3, for example. A chimeric polypeptide (e.g., fusion protein) sometimes includes the polypeptides of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, which can be presented in the foregoing order in a chimeric polypeptide (e.g., fusion protein) in the N-terminal to C-terminal direction. A chimeric polypeptide (e.g., fusion protein) often is expressed in cells, where the cells sometimes occur in vitro or ex vivo, or are in vivo. A pharmaceutical composition sometimes is administered as part of a chimeric antigen receptor (CAR) molecule treatment. In a CAR molecule treatment, a subject often is administered immunologic cells containing a nucleic acid encoding a CAR molecule and / or a CAR molecule encoded by the nucleic acid. Where the immunologic cells administered are T-cells, the treatment typically is referred to as a CAR-T treatment. A pharmaceutical composition sometimes is administered for elimination of cells containing a fusion protein, wherein the fusion protein contains a polypeptide that binds to the compound having the structure of Formula A, or Formula B or a rimiducid analog and often contains a polypeptide capable of inducing cell death (e.g., apoptosis). A pharmaceutical composition sometimes is administered as part of a treatment of a cell proliferative condition. A cell proliferative condition sometimes is a cancer. Non-limiting examples of cancers include an adrenal gland tumor, an AIDS-associated cancer, an alveolar soft part sarcoma, an astrocytic tumor, bladder cancer, bone cancer, a brain cancer, a spinal cord cancer, a metastatic brain tumor, a breast cancer, a carotid body tumors, a cervical cancer, a chondrosarcoma, a chordoma, a chromophobe renal cell carcinoma, a clear cell carcinoma, a colon cancer, a colorectal cancer, a cutaneous benign fibrous histiocytoma, a desmoplastic small round cell tumor, an ependymoma, a Ewing’s tumor, an extraskeletal myxoid chondrosarcoma, a fibrogenesis imperfecta ossium, a fibrous dysplasia of the bone, a gallbladder or bile duct cancer, gastric cancer, a gestational trophoblastic disease, a germ cell tumor, a head and neck cancer, hepatocellular carcinoma, an islet cell tumor, a Kaposi’s Sarcoma, a kidney cancer, a leukemia, a lipoma / benign lipomatous tumor, a liposarcoma / malignant lipomatous tumor, a liver cancer, a lymphoma, a lung cancer, a medulloblastoma, a melanoma, a meningioma, a multiple endocrine neoplasia, a multiple myeloma, a myelodysplastic syndrome, a neuroblastoma, a neuroendocrine tumors, an ovarian cancer, a pancreatic cancer, a papillary thyroid carcinoma, a parathyroid tumor, a pediatric cancer, a peripheral nerve sheath tumor, a phaeochromocytoma, a pituitary tumor, a prostate cancer, a posterior uveal melanoma, a rare hematologic disorder, a renal metastatic cancer, a rhabdoid tumor, a rhabdomyosarcoma, a sarcoma, a skin cancer, a soft-tissue sarcoma, a squamous cell cancer, a stomach cancer, a synovial sarcoma, a testicular cancer, a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer. A pharmaceutical composition sometimes is administered as part of a treatment of a skin condition. Non-limiting examples of skin conditions include a skin lesion, actinic keratosis, skin carcinoma and Bowen’s disease. A pharmaceutical composition sometimes is administered as part of a treatment of a pathogen condition. A pathogen condition sometimes is a viral condition, fungal condition, parasitic condition or bacterial condition. Non-limiting examples of pathogen conditions include those characterized the presence of Epstein Barr virus, Hepatitis A Virus (HAV); Hepatitis B Virus (HBV); Hepatitis C Virus (HCV); herpes viruses (e.g. HSV-1, HSV-2, HHV-6, CMV), Human Immunodeficiency Virus (HIV), Vesicular Stomatitis Virus (VSV), Bacilli, Citrobacter, Cholera, Diphtheria, Enterobacter, Gonococci, Helicobacter pylori, Klebsiella, Legionella, Meningococci, mycobacteria, Pseudomonas, Pneumococci, rickettsia bacteria, Salmonella, Serratia, Staphylococci, Streptococci, Tetanus, Aspergillus (A. fumigatus, A. niger, etc.), Blastomyces dermatitidis, Candida (C. albicans, C. krusei, C. glabrata, C. tropicalis, etc.), Cryptococcus neoformans, Genus Mucorales (mucor, absidia, rhizopus), Sporothrix schenkii, Paracoccidioides brasiliensis, Coccidioides immitis, Histoplasma capsulatum, Leptospirosis, Borrelia burgdorferi, helminth parasite (hookworm, tapeworms, flukes, flatworms (e.g. Schistosomia), Giardia lambia, trichinella, Dientamoeba Fragilis, Trypanosoma brucei, Trypanosoma cruzi, or Leishmania donovani. A pharmaceutical composition can be administered to a mammalian patient or subject, such as a human patient or nonhuman animal, in a variety of forms adapted to the chosen route of administration. The terms “patient” or “subject” are interchangeable, and include without limitation a mammal, including, e.g., a human, non-human primate (e.g., monkey), mouse, pig, cow, goat, rabbit, rat, guinea pig, hamster, horse, monkey, sheep, or other non-human mammal; a non-mammal, including, e.g., a non-mammalian vertebrate, such as a bird (e.g., a chicken or duck) or a fish, and a non-mammalian invertebrate. Provided hereafter is a non-limiting representative application of pharmaceutical compositions described herein. The following representative application pertains to eradication of modified cells that express a therapeutic protein in a sub-population of subjects receiving a treatment. In a specific representative application, a large portion of the population has been exposed to an infectious virus. There is an identified monoclonal antibody (MAb) that neutralizes the virus, but there is not enough purified MAb available for the entire at-risk population. Instead, there is a delivery system available that carries nanoparticles (NPs) encapsulating transposase mRNA plus integrating transposon plasmids that encodes the antibody. Upon administration of the particles, MAbs are released systemically at effective levels after genetic modification occurs in cells of the subject. Once the risk of infection has abated or a counterindication occurs for systemic and constitutive MAb production, genetically engineered skin cells may need to be eliminated. In addition, a subset of individuals may present an adverse reaction associated with the genetically modified cells or antibodies they produce. For example, certain individuals may have a rare cross-reactivity to a hepatocyte surface marker due to the MAb. To increase safety and terminate MAb expression when obsolete, an inducible safety switch chimeric polypeptide (e.g., fusion protein), containing FKBP12V36 and a truncated caspase-9 (iC9), is co-expressed with the MAb. To activate the pro-apoptotic iC9 switch, the individuals will be administered, or self-administer, a rimiducid pharmaceutical composition described herein, such as a pharmaceutical composition in unit dosage form for example (e.g., administered by a pen- injection device), leading to apoptosis of genetically modified cells and termination of MAb expression. Certain Implementations Following are non-limiting examples of certain implementations of the technology. A1. A pharmaceutical composition, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, a trigylcerides excipient and a PEG ether-modified trigylcerides excipient. A2. The pharmaceutical composition of embodiment A1, wherein the triglycerides excipient is a medium chain triglycerides (MCT) excipient. A3. The pharmaceutical composition of embodiment A2, wherein the triglycerides excipient comprises triglycerides that include C6, C8, C10 and C12 fatty acids. A4. The pharmaceutical composition of any one of embodiments A1-A3, wherein the PEG ether- modified trigylcerides excipient is a modified vegetable oil. A5. The pharmaceutical composition of embodiment A4, wherein the PEG ether-modified trigylcerides excipient is polyethoxylated castor oil (PECO). A6. The pharmaceutical composition of any one of embodiments A1-A5, comprising a surfactant excipient. A7. The pharmaceutical composition of embodiment A6, wherein the surfactant excipient is a polysorbate (PS) surfactant. A8. The pharmaceutical composition of embodiment A7, wherein the PS surfactant is chosen from PS20, PS40, PS60 or PS80. A9. The pharmaceutical composition of any one of embodiments A1-A8, comprising ethanol. A10. The pharmaceutical composition of any one of embodiments A1-A9, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, a triglycerides excipient, a PEG ether-modified triglycerides excipient, a surfactant excipient and optionally an ethanol excipient. A10.1. The pharmaceutical composition of embodiment A10, wherein the triglycerides excipient, PEG ether-modified triglycerides excipient, and surfactant excipient are at a ratio of about 1 triglycerides excipient, to about 2 PEG ether-modified triglycerides excipient, to about 1 surfactant excipient. A11. The pharmaceutical composition of embodiment A10 or A11, comprising about 25% wt / wt or less (e.g., about 1% to about 25%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof. A12. The pharmaceutical composition of any one of embodiments A10-A11, comprising about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 40% wt / wt triglycerides excipient, about 20% to about 60% wt / wt PEG ether-modified triglycerides excipient, about 10% to about 50% wt / wt surfactant excipient, and optionally an ethanol excipient. A13. The pharmaceutical composition of any one of embodiments A10-A11, comprising about 25% wt / wt of less (e.g., about 5% to about 20%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 30% wt / wt triglycerides excipient, about 30% to about 60% wt / wt PEG ether-modified triglycerides excipient, about 15% to about 30% wt / wt surfactant excipient, and optionally an ethanol excipient. A14. The pharmaceutical composition of any one of embodiments A10-A11, comprising about 25% wt / wt or less (e.g., about 5% to about 25%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 25% wt / wt triglycerides excipient, about 40% to about 50% wt / wt PEG ether-modified triglycerides excipient, and about 20% to about 25% wt / wt surfactant excipient. A15. The pharmaceutical composition of any one of embodiments A10-A11, comprising about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 25% wt / wt triglycerides excipient, about 45% to about 50% wt / wt PEG ether-modified triglycerides excipient, and about 20% to about 25% wt / wt surfactant excipient. A16. The pharmaceutical composition of any one of embodiments A10-A11, comprising about 25% wt / wt or less (e.g., about 5% to about 20%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 25% wt / wt triglycerides excipient, about 35% to about 40% wt / wt PEG ether-modified triglycerides excipient, about 20% to about 25% wt / wt surfactant excipient and about 5% to about 10% wt / wt ethanol. A17. A pharmaceutical composition of any one of embodiments A1-A16, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, and a MCT excipient, a PECO excipient, a polysorbate excipient and optionally an ethanol excipient. A18. The pharmaceutical composition of embodiment A17, wherein the MCT excipient, PECO excipient and polysorbate excipient are at a ratio of about 1 MCT excipient to about 2 PECO excipient to about 1 polysorbate excipient. A19. The pharmaceutical composition of embodiment A17 or A18, wherein the polysorbate excipient comprises PS80. A20. The pharmaceutical composition of embodiment A17, comprising about 25% wt / wt or less (e.g., about 1% to about 20%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 40% wt / wt MCT excipient, about 20% to about 60% wt / wt PECO excipient, about 10% to about 50% wt / wt PS80 excipient, and optionally an ethanol excipient. A21. The pharmaceutical composition of embodiment A17, comprising about 25% wt / wt or less (e.g., about 5% to about 20%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 30% wt / wt MCT excipient, about 30% to about 60% wt / wt PECO excipient, about 15% to about 30% wt / wt PS80 excipient, and optionally an ethanol excipient. A22. The pharmaceutical composition of embodiment A17, comprising about 25% wt / wt or less (e.g., about 5% to about 20%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 25% wt / wt MCT excipient, about 40% to about 50% wt / wt PECO excipient, and about 20% to about 25% wt / wt PS80 excipient. A23. The pharmaceutical composition of embodiment A17, comprising about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 25% wt / wt MCT excipient, about 45% to about 50% wt / wt PECO excipient, and about 20% to about 25% wt / wt PS80 excipient. A24. The pharmaceutical composition of embodiment A17, comprising about 5% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 23% to about 24% wt / wt MCT excipient, about 48% to about 49% wt / wt PECO excipient, and about 23% to about 24% wt / wt PS80 excipient, and optionally is a dispersion with a mean particle diameter of about 5 nm to about 100 nm or about 35 nm. A25. The pharmaceutical composition of embodiment A17, comprising about 5% to about 20% wt / wt (e.g., about 10% wt / wt )of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 22% to about 23% wt / wt MCT excipient, about 45% wt / wt PECO excipient, and about 22% to about 23% wt / wt PS80 excipient, and optionally is a dispersion with a mean particle diameter of about 100 nm to about 200 nm or about 143 nm. A26. The pharmaceutical composition of embodiment A17, comprising about 10% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% wt / wt MCT excipient, about 40% wt / wt PECO excipient, and about 20% wt / wt PS80 excipient, and optionally is a dispersion with a mean particle diameter of about 200 nm to about 300 nm or about 240 nm. A27. The pharmaceutical composition of any one of embodiments A1-A15 and A17-A26, comprising no ethanol excipient. A28. The pharmaceutical composition of embodiment A17, comprising about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 25% wt / wt MCT excipient, about 35% to about 40% wt / wt PECO excipient, about 20% to about 25% wt / wt PS80 excipient and about 5% to about 10% wt / wt ethanol. A29. The pharmaceutical composition of embodiment A17, comprising about 10% wt / wt or less (e.g., about 5%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 23% to about 24% wt / wt MCT excipient, about 38% to about 39% wt / wt PECO excipient, about 23% to about 24% wt / wt PS80 excipient and about 8% to about 9% wt / wt ethanol, and optionally is a dispersion with a mean particle diameter of about 5 nm to about 100 nm or about 35 nm. A30. The pharmaceutical composition of any one of embodiments A1-A37, comprising about 10% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof. A31. The pharmaceutical composition of any one of embodiments A1-A37, comprising about 8% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof. A32. The pharmaceutical composition of any one of embodiments A1-A37, comprising about 6% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof. A33. The pharmaceutical composition of any one of embodiments A1-A37, comprising about 5% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof. A34. The pharmaceutical composition of any one of embodiments A1-A33, comprising particles having a mean particle diameter of about 100 nm or less. A35. The pharmaceutical composition of any one of embodiments A1-A33, comprising particles having a mean particle diameter of about 60 nm or less. A36. The pharmaceutical composition of any one of embodiments A1-A33, comprising particles having a mean particle diameter of about 50 nm or less. A37. The pharmaceutical composition of any one of embodiments A1-A33, comprising particles having mean particle diameter of about 40 nm or less. B1. A pharmaceutical composition, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, and: a triglycerides excipient and a C8 fatty acid glyceride excipient, or a triglycerides excipient and one or more C8 fatty acid ester excipients. B2. The pharmaceutical composition of embodiment B1, wherein the triglycerides excipient is a medium chain triglycerides (MCT) excipient. B3. The pharmaceutical composition of embodiment B2, wherein the triglycerides excipient comprises C6, C8, C10 and C12 fatty acids. C1. The pharmaceutical composition of any one of embodiments B1-B3, wherein the C8 fatty acid glyceride excipient comprises monoglycerides and diglycerides containing a C8 fatty acid. C2. The pharmaceutical composition of embodiment C1, wherein the fatty acid glyceride excipient is a glyceryl monocaprylate excipient. C3. The pharmaceutical composition of embodiment C2, wherein the glyceryl monocaprylate excipient comprises C10 fatty acid glycerides. D1. The pharmaceutical composition of any one of embodiments B1-B3, wherein the C8 fatty acid ester excipient comprises propylene glycol esters of C8 fatty acids. D2. The pharmaceutical composition of embodiment D1, wherein the C8 fatty acid ester excipient is a propylene glycol monocaprylate excipient. D3. The pharmaceutical composition of embodiment D2, wherein the C8 fatty acid ester excipient is a propylene glycol dicaprylate excipient. D4. The pharmaceutical composition of embodiment D3, wherein the propylene glycol dicaprylate excipient comprises propylene glycol esters of C10 fatty acids. D5. The pharmaceutical composition of any one of embodiments B1-B3, wherein the C8 fatty acid ester excipient comprises PEG esters. D6. The pharmaceutical composition of embodiment D5, wherein the PEG esters comprise PEG monoesters and / or PEG diesters of C8 fatty acids. D7. The pharmaceutical composition of embodiment D5 or D6, wherein the C8 fatty acid ester excipient is PEG-8 caprylic / capric glycerides excipient. D8. The pharmaceutical composition of embodiment D7, wherein the PEG-8 caprylic / capric glycerides excipient comprises PEG esters of C10 fatty acids. D9. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3 and D1- D12, further comprising a PEG ether-modified trigylcerides excipient. D10. The pharmaceutical composition of embodiment D9, wherein the PEG ether-modified trigylcerides excipient is a modified vegetable oil. D11. The pharmaceutical composition of embodiment D10, wherein the modified vegetable oil is a modified castor oil. D12. The pharmaceutical composition of embodiment D11, wherein the PEG ether-modified trigylcerides excipient is polyethoxylated castor oil (PECO). E1. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3 and D1- D12, further comprising a C18 fatty acid glycerides excipient. E2. The pharmaceutical composition of embodiment E1, wherein the C18 fatty acid glycerides excipient is a linoleoyl macrogol glycerides excipient. E3. The pharmaceutical composition of embodiment E2, wherein the linoleoyl macrogol glycerides excipient comprises glycerides and PEG-6 (MW 300) esters of linoleic (C18:2) acid. F1. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12 and E1-E3, comprising a triglycerides excipient, a PEG ether-modified triglycerides excipient and a C8 fatty acid glyceride excipient. F2. The pharmaceutical composition of embodiment F1, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient, about 15% to about 50% wt / wt PEG ether-modified triglycerides excipient and about 15% to about 60% wt / wt C8 fatty acid glyceride excipient. F3. The pharmaceutical composition of embodiment F1, comprising about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 30% wt / wt triglycerides excipient, about 15% to about 30% wt / wt PEG ether-modified triglycerides excipient and about 30% to about 55% wt / wt C8 fatty acid glyceride excipient. F4. The pharmaceutical composition of embodiment F1, comprising about 5% to about 15% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt triglycerides excipient, about 15% to about 20% wt / wt PEG ether-modified triglycerides excipient and about 40% to about 50% wt / wt C8 fatty acid glyceride excipient. F5. The pharmaceutical composition of embodiment F1, comprising about 5% to about 15% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt triglycerides excipient, about 25% to about 30% wt / wt PEG ether-modified triglycerides excipient and about 30% to about 40% wt / wt C8 fatty acid glyceride excipient. F6. The pharmaceutical composition of embodiment F1, comprising about 5% to about 15% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 20% wt / wt triglycerides excipient, about 20% to about 25% wt / wt PEG ether-modified triglycerides excipient and about 45% to about 55% wt / wt C8 fatty acid glyceride excipient. F7. The pharmaceutical composition of embodiment F1, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, and a MCT excipient, a PECO excipient, and a glyceryl monocaprylate excipient. F8. The pharmaceutical composition of embodiment F7, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt MCT excipient, about 15% to about 50% wt / wt PECO excipient and about 15% to about 60% wt / wt glyceryl monocaprylate excipient. F9. The pharmaceutical composition of embodiment F7, comprising about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 30% wt / wt MCT excipient, about 15% to about 30% wt / wt PECO excipient and about 30% to about 55% wt / wt glyceryl monocaprylate excipient. F10. The pharmaceutical composition of embodiment F7, comprising about 5% to about 15% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt MCT excipient, about 15% to about 20% wt / wt PECO excipient and about 40% to about 50% wt / wt glyceryl monocaprylate excipient. F11. The pharmaceutical composition of embodiment F7, comprising about 10% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 27% wt / wt MCT excipient, about 18% wt / wt PECO excipient and about 45% wt / wt glyceryl monocaprylate excipient, and optionally is a dispersion with a mean particle diameter of about 50 nm to about 100 nm or about 82 nm. F12. The pharmaceutical composition of embodiment F7, comprising about 5% to about 15% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt MCT excipient, about 25% to about 30% wt / wt PECO excipient and about 30% to about 40% wt / wt glyceryl monocaprylate excipient. F13. The pharmaceutical composition of embodiment F7, comprising about 10% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 27% wt / wt MCT excipient, about 27% wt / wt PECO excipient and about 36% wt / wt glyceryl monocaprylate excipient, and optionally is a dispersion with a mean particle diameter of about 50 nm to about 100 nm or about 85 nm. F14. The pharmaceutical composition of embodiment F7, comprising about 5% to about 15% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 20% wt / wt MCT excipient, about 20% to about 25% wt / wt PECO excipient and about 45% to about 55% wt / wt glyceryl monocaprylate excipient. F15. The pharmaceutical composition of embodiment F7, comprising about 10% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 18% wt / wt MCT excipient, about 22% to about 23% wt / wt PECO excipient and about 49% to about 50% wt / wt glyceryl monocaprylate excipient, and optionally is a dispersion with a mean particle diameter of about 50 nm to about 100 nm or about 61 nm. G1. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12 and E1-E3, comprising a triglycerides excipient, a PEG ether-modified triglycerides excipient, a C8 fatty acid glyceride excipient and a C18 fatty acid glycerides excipient. G2. The pharmaceutical composition of embodiment G1, comprising about 25% wt / wt or less (e.g., about 1% to about 25%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient, about 15% to about 50% wt / wt PEG ether-modified triglycerides excipient, about 5% to about 50% wt / wt C18 fatty acid glycerides excipient and about 15% to about 50% wt / wt C8 fatty acid glyceride excipient. G3. The pharmaceutical composition of embodiment G1 or G2, comprising about 25% wt / wt or less (e.g. about 5% to about 20%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient (e.g. about 20%), about 15% to about 50% wt / wt PEG ether-modified triglycerides excipient (e.g., about 30%) , about 5% to about 50% wt / wt C18 fatty acid glycerides excipient (e.g. about 20%) and about 15% to about 50% wt / wt C8 fatty acid glyceride excipient (e.g. about 20% to about 35%). G4. The pharmaceutical composition of embodiment G1, comprising about 25% wt / wt or less (e.g. about 5% to about 20%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 35% wt / wt triglycerides excipient, about 15% to about 40% wt / wt PEG ether-modified triglycerides excipient, about 5% to about 30% wt / wt C18 fatty acid glycerides excipient and about 20% to about 50% wt / wt C8 fatty acid glyceride excipient. G5. The pharmaceutical composition of embodiment G1, comprising about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 18% to about 33% wt / wt triglycerides excipient, about 20% to about 40% wt / wt PEG ether-modified triglycerides excipient, about 10% to about 25% wt / wt C18 fatty acid glycerides excipient and about 25% to about 45% wt / wt C8 fatty acid glyceride excipient. G6. The pharmaceutical composition of embodiment G1, comprising about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 35% wt / wt triglycerides excipient, about 15% to about 30% wt / wt PEG ether-modified triglycerides excipient, about 5% to about 20% wt / wt C18 fatty acid glycerides excipient and about 20% to about 35% wt / wt C8 fatty acid glyceride excipient. G7. The pharmaceutical composition of embodiment G1, comprising about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt triglycerides excipient, about 20% to about 25% wt / wt PEG ether-modified triglycerides excipient, about 10% to about 15% wt / wt C18 fatty acid glycerides excipient and about 25% to about 30% wt / wt C8 fatty acid glyceride excipient. G8. The pharmaceutical composition of embodiment G1, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, and a MCT excipient, a PECO excipient, a linoleoyl macrogol glycerides excipient and a glyceryl monocaprylate excipient. G9. The pharmaceutical composition of embodiment G8, comprising about 25% wt / wt or less (e.g., about 1% to about 25%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt MCT excipient, about 15% to about 50% wt / wt PECO excipient, about 5% to about 50% wt / wt linoleoyl macrogol glycerides excipient and about 15% to about 50% wt / wt glyceryl monocaprylate excipient. G10. The pharmaceutical composition of embodiment G8, comprising about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 15% to about 35% wt / wt MCT excipient, about 15% to about 40% wt / wt PECO excipient, about 5% to about 30% wt / wt linoleoyl macrogol glycerides excipient and about 20% to about 50% wt / wt glyceryl monocaprylate excipient. G11. The pharmaceutical composition of embodiment G8, comprising about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 18% to about 33% wt / wt MCT excipient, about 20% to about 40% wt / wt PECO excipient, about 10% to about 25% wt / wt linoleoyl macrogol glycerides excipient and about 25% to about 45% wt / wt glyceryl monocaprylate excipient. G12. The pharmaceutical composition of embodiment G8, comprising about 25% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 35% wt / wt MCT excipient, about 15% to about 30% wt / wt PECO excipient, about 5% to about 20% wt / wt linoleoyl macrogol glycerides excipient and about 20% to about 35% wt / wt glyceryl monocaprylate excipient. G13. The pharmaceutical composition of embodiment G8, comprising about 25% wt / wt or less (e.g., about 5% to about 20%) of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt MCT excipient, about 20% to about 25% wt / wt PECO excipient, about 10% to about 15% wt / wt linoleoyl macrogol glycerides excipient and about 25% to about 30% wt / wt glyceryl monocaprylate excipient. G14. The pharmaceutical composition of embodiment G8, comprising about 10% of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 27% wt / wt MCT excipient, about 22% to about 23% wt / wt PECO excipient, about 13% to about 14% wt / wt linoleoyl macrogol glycerides excipient and about 27% wt / wt glyceryl monocaprylate excipient, and optionally is a dispersion with a mean particle diameter of about 50 nm to about 100 nm or about 80 nm. G15. The pharmaceutical composition of any one of embodiments G1-G14, comprising about 10% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof. G16. The pharmaceutical composition of any one of embodiments G1-G14, comprising about 8% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof. G17. The pharmaceutical composition of any one of embodiments G1-G14, comprising about 6% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof. G18. The pharmaceutical composition of any one of embodiments G1-G14, comprising about 5% wt / wt or less of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof. G19. The pharmaceutical composition of any one of embodiments G1-G18, comprising particles having a mean particle diameter of about 100 nm or less. G20. The pharmaceutical composition of any one of embodiments G1-G18, comprising particles having a mean particle diameter of about 60 nm or less. G21. The pharmaceutical composition of any one of embodiments G1-G18, comprising particles having a mean particle diameter of about 50 nm or less. G22. The pharmaceutical composition of any one of embodiments G1-G18, comprising particles having mean particle diameter of about 40 nm or less. H1. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12 and E1-E3, comprising a triglycerides excipient, a PEG ether-modified triglycerides excipient and a C8 fatty acid ester excipient. H2. The pharmaceutical composition of embodiment H1, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient, about 10% to about 35% wt / wt PEG ether-modified triglycerides excipient and about 25% to about 45% wt / wt C8 fatty acid ester excipient. H3. The pharmaceutical composition of embodiment H1, comprising about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt triglycerides excipient, about 25% to about 30% wt / wt PEG ether-modified triglycerides excipient and about 30% to about 40% wt / wt C8 fatty acid ester excipient. H4. The pharmaceutical composition of embodiment H1, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, a MCT excipient, a PECO excipient and a propylene glycol monocaprylate excipient. H5. The pharmaceutical composition of embodiment H4, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt MCT excipient, about 10% to about 35% wt / wt PECO excipient and about 25% to about 45% wt / wt propylene glycol monocaprylate excipient. H6. The pharmaceutical composition of embodiment H4, comprising about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt MCT excipient, about 25% to about 30% wt / wt PECO excipient and about 30% to about 40% wt / wt propylene glycol monocaprylate excipient. H7. The pharmaceutical composition of embodiment H4, comprising about 10% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 27% MCT excipient, about 27% wt / wt PECO excipient and about 36% wt / wt propylene glycol monocaprylate excipient, and optionally is a dispersion with a mean particle diameter of about 70 nm to about 120 nm or about 90 nm. J1. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12 and E1-E3, comprising a triglycerides excipient, a PEG ether-modified triglycerides excipient, a C8 fatty acid glyceride excipient and a C8 fatty acid ester excipient. J2. The pharmaceutical composition of embodiment J1, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient, about 10% to about 30% wt / wt PEG ether-modified triglycerides excipient, about 10% to about 35% wt / wt C8 fatty acid glyceride excipient and about 5% to about 25% wt / wt C8 fatty acid ester excipient. J3. The pharmaceutical composition of embodiment J1, comprising about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt triglycerides excipient, about 20% to about 25% wt / wt PEG ether-modified triglycerides excipient, about 25% to about 30% wt / wt C8 fatty acid glyceride excipient and about 10% to about 15% wt / wt C8 fatty acid ester excipient. J4. The pharmaceutical composition of embodiment J1, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, a MCT excipient, a PECO excipient, a glyceryl monocaprylate excipient and a propylene glycol dicaprylate excipient. J5. The pharmaceutical composition of embodiment J4, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt MCT excipient, about 10% to about 30% wt / wt PECO excipient, about 10% to about 35% wt / wt glyceryl monocaprylate excipient and about 5% to about 25% wt / wt propylene glycol dicaprylate excipient. J6. The pharmaceutical composition of embodiment J4, comprising about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt MCT excipient, about 20% to about 25% wt / wt PECO excipient, about 25% to about 30% wt / wt glyceryl monocaprylate excipient and about 10% to about 15% wt / wt propylene glycol dicaprylate excipient. J7. The pharmaceutical composition of embodiment J4, comprising about 10% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 27% wt / wt MCT excipient, about 22% to about 23% wt / wt PECO excipient, about 27% wt / wt glyceryl monocaprylate excipient and about 13% to about 14% wt / wt propylene glycol dicaprylate excipient, and optionally is a dispersion with a mean particle diameter of about 50 nm to about 120 nm or about 75 nm. K1. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12 and E1-E3, comprising a triglycerides excipient, a C8 fatty acid glyceride excipient, a C8 fatty acid ester excipient, and a C18 fatty acid glycerides excipient. K2. The pharmaceutical composition of embodiment K1, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient, about 5% to about 50% wt / wt C18 fatty acid glycerides excipient, about 20% to about 50% wt / wt C8 fatty acid glyceride excipient and about 20% to about 50% wt / wt C8 fatty acid ester excipient. K3. The pharmaceutical composition of embodiment K1, comprising about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt triglycerides excipient, about 10% to about 15% wt / wt C18 fatty acid glycerides excipient, about 25% to about 30% wt / wt C8 fatty acid glyceride excipient and about 20% to about 25% wt / wt C8 fatty acid ester excipient. K4. The pharmaceutical composition of embodiment K1, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, a MCT excipient, a linoleoyl macrogol glycerides excipient, a glyceryl monocaprylate excipient and a PEG-8 caprylic / capric glycerides excipient. K5. The pharmaceutical composition of embodiment K4, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt MCT excipient, about 5% to about 50% wt / wt linoleoyl macrogol glycerides excipient, about 20% to about 50% wt / wt glyceryl monocaprylate excipient and about 20% to about 50% wt / wt PEG-8 caprylic / capric glycerides excipient. K6. The pharmaceutical composition of embodiment K4, comprising about 5% to about 20% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 30% wt / wt MCT excipient, about 10% to about 15% wt / wt linoleoyl macrogol glycerides excipient, about 25% to about 30% wt / wt glyceryl monocaprylate excipient and about 20% to about 25% wt / wt PEG-8 caprylic / capric glycerides excipient. K7. The pharmaceutical composition of embodiment K4, comprising about 10% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 27% wt / wt MCT excipient, about 13% to about 14% wt / wt linoleoyl macrogol glycerides excipient, about 27% wt / wt glyceryl monocaprylate excipient and about 22% to about 23% wt / wt PEG-8 caprylic / capric glycerides excipient, and optionally is a dispersion with a mean particle diameter of about 50 nm to about 120 nm or about 80 nm. L1. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12 and E1-E3, comprising a triglycerides excipient, a PEG ether-modified triglycerides excipient and two or more C8 fatty acid ester excipients. L2. The pharmaceutical composition of embodiment L1, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient, about 10% to about 50% wt / wt PEG ether-modified triglycerides excipient, and two or more C8 fatty acid ester excipients each independently in an amount of about 1% to about 50% wt / wt. L3. The pharmaceutical composition of embodiment L1, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, a MCT excipient, a PECO excipient, and one or both of a propylene glycol monocaprylate excipient and a propylene glycol dicaprylate excipient. L4. The pharmaceutical composition of embodiment L4, comprising In certain implementations, a pharmaceutical composition contains about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt MCT excipient, about 10% to about 50% wt / wt PECO excipient, and one or both of about 1% to about 50% wt / wt propylene glycol monocaprylate excipient and about 1% to about 50% wt / wt propylene glycol dicaprylate excipient. M1. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12 and E1-E3, comprising a triglycerides excipient, and two or more C8 fatty acid ester excipients. M2. The pharmaceutical composition of embodiment M1, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt triglycerides excipient, about 20% to about 50% wt / wt C8 fatty acid ester excipient, and one or two additional C8 fatty acid ester excipients each independently in an amount of about 1% to about 50%. M3. The pharmaceutical composition of embodiment M1, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, a MCT excipient, a PEG-8 caprylic / capric glycerides excipient, and one or both of a propylene glycol monocaprylate excipient and a propylene glycol dicaprylate excipient. M4. The pharmaceutical composition of embodiment M3, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 35% wt / wt MCT excipient, about 20% to about 50% wt / wt PEG-8 caprylic / capric glycerides excipient, and one or both of about 1% to about 50% wt / wt propylene glycol monocaprylate excipient and about 1% to about 50% wt / wt propylene glycol dicaprylate excipient. N1. A pharmaceutical composition, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, a trigylcerides excipient, a PEG ether- modified trigylcerides excipient, a surfactant excipient and a polyethylene glycol (PEG), and optionally ethanol. N2. The pharmaceutical composition of embodiment N1, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 40% wt / wt triglycerides excipient, about 20% to about 30% wt / wt PEG ether-modified triglycerides excipient, about 25% to about 50% wt / wt surfactant excipient and about 1% to about 20% wt / wt PEG excipient and optionally about 1% to about 10% wt / wt ethanol excipient. N3. A pharmaceutical composition, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, a trigylcerides excipient, a surfactant excipient and a polyethylene glycol (PEG) excipient, and optionally ethanol. N4. The pharmaceutical composition of embodiment N3, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 25% wt / wt triglycerides excipient, about 20% to about 40% wt / wt surfactant excipient and about 1% to about 65% wt / wt PEG excipient and optionally about 1% to about 10% wt / wt ethanol excipient. N5. The pharmaceutical composition of any one of embodiments N1-N4, wherein the triglycerides excipient is a medium chain triglycerides (MCT) excipient. N6. The pharmaceutical composition of embodiment N5, wherein the triglycerides excipient comprises triglycerides that include C6, C8, C10 and C12 fatty acids. N7. The pharmaceutical composition of any one of embodiments N1-N6, wherein the PEG ether- modified trigylcerides excipient is a modified vegetable oil. N8. The pharmaceutical composition of embodiment N7, wherein the PEG ether-modified trigylcerides excipient is polyethoxylated castor oil (PECO). N9. The pharmaceutical composition of any one of embodiments N1-N8, wherein the surfactant excipient is a polysorbate (PS) surfactant. N10. The pharmaceutical composition of embodiment N9, wherein the PS surfactant is chosen from PS20, PS40, PS60 or PS80. N11. The pharmaceutical composition of embodiment N1 or N3, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, a MCT excipient, a PECO excipient, a polysorbate excipient and a PEG excipient and optionally an ethanol excipient. N12. The pharmaceutical composition of embodiment N11, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 25% to about 40% wt / wt MCT excipient, about 20% to about 30% wt / wt PECO excipient, about 25% to about 50% wt / wt PS80 excipient and about 1% to about 20% wt / wt PEG excipient and optionally about 1% to about 10% wt / wt ethanol excipient. N13. The pharmaceutical composition of embodiment N1 or N3, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, a MCT excipient, a polysorbate excipient and a PEG excipient and optionally an ethanol excipient. N14. The pharmaceutical composition of embodiment N13, comprising about 1% to about 25% wt / wt of a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, about 10% to about 25% wt / wt MCT excipient, about 20% to about 40% wt / wt PS80 excipient and about 1% to about 65% wt / wt PEG excipient and optionally about 1% to about 10% wt / wt ethanol excipient. N15. The pharmaceutical composition of any one of embodiments N1-N14, wherein the PEG excipient is a PEG400 excipient. P1. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12, E1-E3, F1-F15, G1-G22, H1-H7, J1-J7, K1-K7, L1-L4, M1-M4 and N1-N15, prepared as a self- emulsifying drug delivery system (SEDDS). P2. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12, E1-E3, F1-F15, G1-G22, H1-H7, J1-J7, K1-K7, L1-L4, M1-M4, N1-N15 and P1, comprising no added water. P3. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12, E1-E3, F1-F15, G1-G22, H1-H7, J1-J7, K1-K7, L1-L4, M1-M4, N1-N15 and P1, comprising water. P4. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12, E1-E3, F1-F15, G1-G22, H1-H7, J1-J7, K1-K7, L1-L4, M1-M4, N1-N15 and P1-P3, which is a liquid emulsion containing particles or a liquid dispersion containing particles. P5. The pharmaceutical composition of embodiment P4, wherein the particles have a mean diameter of about 500 nanometers (nm) or less. P6. The pharmaceutical composition of embodiment P4, wherein the mean diameter is about 200 nm or less. P7. The pharmaceutical composition of embodiment P6, wherein the mean diameter is about 100 nm or less. P8. The pharmaceutical composition of any one of embodiments P1-P7, comprising about 0.1% to about 20% wt / wt of an additive chosen from ethanol, propylene glycol, glycerol and polyethylene glycol. P9. The pharmaceutical composition of any one of embodiments P1-B8, comprising about 1% to about 10% wt / wt of an antioxidant P10. The pharmaceutical composition of embodiment P9, wherein the antioxidant is chosen from butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), DL-alpha-tocopherol, ascorbyl palmitate and propyl gallate, or two or more thereof. P11. The pharmaceutical composition of any one of embodiments P1-P10, wherein the rimiducid analog is a compound of Formula C, D, E, F, F1, G, H, H1 or J, or a pharmaceutically acceptable salt thereof. P12. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12, E1-E3, F1-F15, G1-G22, H1-H7, J1-J7, K1-K7, L1-L4, M1-M4, N1-N15 and P1-P11, in unit dosage form. P13. A device, comprising the pharmaceutical composition of any one of embodiments A1-A37, B1- B3, C1-C3, D1-D12, E1-E3, F1-F15, G1-G22, H1-H7, J1-J7, K1-K7, L1-L4, M1-M4, N1-N15 and P1-P12. P14. The device of embodiment P13, which is an injectable device or which is not an injectable device. P15. The device of embodiment P14, which is an auto-injection device. P16. The device of embodiment P15, which is a pen auto-injection device. P17. The pharmaceutical composition or device of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12, E1-E3, F1-F15, G1-G22, H1-H7, J1-J7, K1-K7, L1-L4, M1-M4, N1-N15 and P1-P17, for administration by injection or infusion. P18. The pharmaceutical composition or device of embodiment P17, for subcutaneous or intramuscular administration. Q1. A method for preparing a pharmaceutical composition of any one of embodiments A1-A37, B1- B3, C1-C3, D1-D12, E1-E3, F1-F15, G1-G22, H1-H7, J1-J7, K1-K7, L1-L4, M1-M4, N1-N15 and P1-P12, comprising: mixing a water miscible component with a water immiscible component to prepare a mixture; and combining the mixture with the compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof. Q2. The method of embodiment Q1, wherein the water immiscible component is a trigylcerides excipient. Q3. The method of embodiment Q2, wherein the triglycerides excipient is a medium chain triglycerides (MCT) excipient. Q4. The method of embodiment Q3, wherein the triglycerides excipient comprises triglycerides that include C6, C8, C10 and C12 fatty acids. Q5. The method of any one of embodiments Q1-Q4, wherein the water miscible component comprises one or more of: a PEG ether-modified trigylcerides excipient, a surfactant excipient, ethanol, C8 fatty acid glyceride excipient, C8 fatty acid ester excipient, a C18 fatty acid glycerides excipient and a PEG excipient. Q6. The method of embodiment Q5, wherein the PEG ether-modified trigylcerides excipient is a modified vegetable oil. Q7. The method of embodiment Q5, wherein the PEG ether-modified trigylcerides excipient is polyethoxylated castor oil (PECO). Q8. The method of embodiment Q5, wherein the surfactant excipient is a polysorbate (PS) surfactant. Q9. The method of embodiment Q8, wherein the PS surfactant is chosen from PS20, PS40, PS60 or PS80. Q10. The method of embodiment Q5, wherein the C8 fatty acid glyceride excipient comprises monoglycerides and diglycerides containing a C8 fatty acid. Q11. The method of embodiment Q5, wherein the fatty acid glyceride excipient is a glyceryl monocaprylate excipient. Q12. The method of embodiment Q5, wherein the glyceryl monocaprylate excipient comprises C10 fatty acid glycerides. Q13. The method of embodiment Q5, wherein the C8 fatty acid ester excipient comprises propylene glycol esters of C8 fatty acids. Q14. The method of embodiment Q5, wherein the C8 fatty acid ester excipient is a propylene glycol monocaprylate excipient. Q15. The method of embodiment Q5, wherein the C8 fatty acid ester excipient is a propylene glycol dicaprylate excipient. Q16. The method of embodiment Q15, wherein the propylene glycol dicaprylate excipient comprises propylene glycol esters of C10 fatty acids. Q17. The method of embodiment Q5, wherein the C8 fatty acid ester excipient comprises PEG esters. Q18. The method of embodiment Q17, wherein the PEG esters comprise PEG monoesters and / or PEG diesters of C8 fatty acids. Q19. The method of embodiment Q5, wherein the C8 fatty acid ester excipient is PEG-8 caprylic / capric glycerides excipient. Q20. The method of embodiment Q19, wherein the PEG-8 caprylic / capric glycerides excipient comprises PEG esters of C10 fatty acids. Q21. The method of embodiment Q5, wherein the C18 fatty acid glycerides excipient is a linoleoyl macrogol glycerides excipient. Q22. The method of embodiment Q21, wherein the linoleoyl macrogol glycerides excipient comprises glycerides and PEG-6 (MW 300) esters of linoleic (C18:2) acid. Q23. The method of embodiment Q5, wherein the PEG excipient is a PEG400 excipient. Q24. The method of any one of embodiments Q1-A23, wherein the rimiducid analog is a compound of Formula C, D, E, F, F1, G, H, H1 or J, or a pharmaceutically acceptable salt thereof. Q25. A pharmaceutical composition obtainable by a method of any one of embodiments Q1-Q24. R1. A pharmaceutical composition, comprising a compound of Formula A or Formula B or a rimiducid analog or pharmaceutically acceptable salt thereof, a C8 fatty acid esters excipient and a C18 fatty acid glycerides excipient. R2. The pharmaceutical composition of embodiment R1, comprising about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt C8 fatty acid esters excipient and about 20% to about 80% wt / wt C18 fatty acid glycerides excipient. R3. The pharmaceutical composition of embodiment R1 or R2, wherein the C8 fatty acid esters excipient comprises polyethylene glycol (PEG) esters. R4. The pharmaceutical composition of embodiment R3, wherein the PEG esters comprise PEG-8. R5. The pharmaceutical composition of any one of embodiments R1-R4, wherein the C8 fatty acid esters excipient comprises C10 fatty acid esters. R6. The pharmaceutical composition of any one of embodiments R1-R5, wherein the C8 fatty acid esters excipient is a caprylocaproyl polyoxyl-8 glycerides excipient. R7. The pharmaceutical composition of any one of embodiments R1-R6, wherein the C18 fatty acid glycerides excipient comprises a monoglyceride majority glyceride. R8. The pharmaceutical composition of embodiment R7, wherein the C18 fatty acid glycerides excipient comprises oleic acid. R9. The pharmaceutical composition of any one of embodiments R1-R8, wherein the C18 fatty acid glycerides excipient is a glycerol monooleate (type 40) excipient. R10. The pharmaceutical composition of any one of embodiments R1-R9, comprising a rimiducid analog or pharmaceutically acceptable salt thereof, a caprylocaproyl polyoxyl-8 glycerides excipient and a glycerol monooleate (type 40) excipient. R11. The pharmaceutical composition of embodiment R10, comprising about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt caprylocaproyl polyoxyl-8 glycerides excipient and about 20% to about 80% wt / wt glycerol monooleate (type 40) excipient. S1. A pharmaceutical composition, comprising a rimiducid analog or pharmaceutically acceptable salt thereof, a C8 fatty acid esters excipient and C18 fatty acid esters excipient. S2. The pharmaceutical composition of embodiment S1, comprising about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt C8 fatty acid esters excipient and about 20% to about 80% wt / wt C18 fatty acid esters excipient. S3. The pharmaceutical composition of embodiment S1 or S2, wherein the C18 fatty acid esters excipient comprises polyethylene glycol (PEG) esters. S4. The pharmaceutical composition of embodiment S3, wherein the PEG esters comprise PEG-6. S5. The pharmaceutical composition of any one of embodiments S1-S4, wherein the C18 fatty acid esters excipient comprises oleic acid. S6. The pharmaceutical composition of any one of embodiments S1-S5, wherein the C18 fatty acid esters excipient is an oleoyl polyoxyl-6 glycerides excipient. S7. The pharmaceutical composition of any one of embodiments S1-S5, wherein the C8 fatty acid esters excipient comprises polyethylene glycol (PEG) esters. S8. The pharmaceutical composition of embodiment S7, wherein the PEG esters comprise PEG-8. S9. The pharmaceutical composition of any one of embodiments S1-S8, wherein the C8 fatty acid esters excipient comprises C10 fatty acid esters. S10. The pharmaceutical composition of any one of embodiments S1-S9, wherein the C8 fatty acid esters excipient is a caprylocaproyl polyoxyl-8 glycerides excipient. S11. The pharmaceutical composition of any one of embodiments S1-S10, comprising a rimiducid analog or pharmaceutically acceptable salt thereof, a caprylocaproyl polyoxyl-8 glycerides excipient and an oleoyl polyoxyl-6 glycerides excipient. S12. The pharmaceutical composition of embodiment S11, comprising about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt caprylocaproyl polyoxyl-8 glycerides excipient and about 20% to about 80% wt / wt oleoyl polyoxyl- 6 glycerides excipient. T1. A pharmaceutical composition, comprising a rimiducid analog or pharmaceutically acceptable salt thereof, a C8 fatty acid polyethylene glycol (PEG) esters excipient and C8 fatty acid propylene glycol (PG) esters excipient. T2. The pharmaceutical composition of embodiment T1, comprising about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt C8 fatty acid PEG esters excipient and about 20% to about 80% wt / wt C8 fatty acid PG esters excipient. T3. The pharmaceutical composition of embodiment T1 or T2, wherein the PEG esters of the C8 fatty acid PEG esters excipient comprise PEG-8. T4. The pharmaceutical composition of any one of embodiments T1-T3, wherein the C8 fatty acid PEG esters excipient comprises C10 fatty acid esters. T5. The pharmaceutical composition of any one of embodiments T1-T4, wherein the C8 fatty acid esters excipient is a caprylocaproyl polyoxyl-8 glycerides excipient. T6. The pharmaceutical composition of any one of embodiments T1-T5, wherein the C8 fatty acid PG esters excipient comprises monoesters and diesters with a majority of the monoesters. T7. The pharmaceutical composition of any one of embodiments T1-T6, wherein the C8 fatty acid PG esters excipient is a propylene glycol monocaprylate (type II) excipient. T9. The pharmaceutical composition of any one of embodiments T1-T7, comprising a rimiducid analog or pharmaceutically acceptable salt thereof, a caprylocaproyl polyoxyl-8 glycerides excipient and a propylene glycol monocaprylate (type II) excipient. T10. The pharmaceutical composition of embodiment T9, comprising about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt caprylocaproyl polyoxyl-8 glycerides excipient and a propylene glycol monocaprylate (type II) excipient. U1. A pharmaceutical composition, comprising a rimiducid analog or pharmaceutically acceptable salt thereof, a C8 fatty acid esters excipient and a C18 fatty acid esters excipient. U2. The pharmaceutical composition of embodiment U1, comprising about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt C8 fatty acid esters excipient and about 20% to about 80% wt / wt C18 fatty acid esters excipient. U3. The pharmaceutical composition of embodiment U1 or U2, wherein the C8 fatty acid esters excipient is a C8 fatty acid propylene glycol (PG) esters excipient comprising propylene glycol esters. U4. The pharmaceutical composition of embodiment U3, wherein the C8 fatty acid PG esters excipient comprises monoesters and diesters with a majority of the monoesters. U5. The pharmaceutical composition of any one of embodiments U1-U4, wherein the C8 fatty acid PG esters excipient is a propylene glycol monocaprylate (type II) excipient U6. The pharmaceutical composition of any one of embodiments U1-U5, wherein the C18 fatty acid esters excipient comprises polyethylene glycol (PEG) esters. U7. The pharmaceutical composition of embodiment U6, wherein the PEG esters comprise PEG-6. U8. The pharmaceutical composition of any one of embodiments U1-U7, wherein the C18 fatty acid esters excipient comprises oleic acid. U9. The pharmaceutical composition of any one of embodiments U1-U8, wherein the C18 fatty acid esters excipient is an oleoyl polyoxyl-6 glycerides excipient. U10. The pharmaceutical composition of any one of embodiments U1-U9, comprising a rimiducid analog or pharmaceutically acceptable salt thereof, a propylene glycol monocaprylate (type II) excipient and an oleoyl polyoxyl-6 glycerides excipient. U11. The pharmaceutical composition of embodiment U10, comprising about 5% to about 25% wt / wt of the rimiducid analog or pharmaceutically acceptable salt thereof, about 20% to about 80% wt / wt propylene glycol monocaprylate (type II) excipient and about 20% to about 80% wt / wt oleoyl polyoxyl-6 glycerides excipient. V1. The pharmaceutical composition of any one of embodiments R1-R11, S1-S12, T1-T10 and U1- U11, comprising water. V2. The pharmaceutical composition of any one of embodiments R1-R11, S1-S12, T1-T10 and U1- U11 comprising no added water. V3. The pharmaceutical composition of any one of embodiments R1-R11, S1-S12, T1-T10, U1-U11, V1 and V2, comprising about 0.1% to about 20% wt / wt of an additive chosen from ethanol, propylene glycol, glycerol and polyethylene glycol. V4. The pharmaceutical composition of any one of embodiments R1-R11, S1-S12, T1-T10, U1-U11, and V1-V3, comprising about 1% to about 10% wt / wt of an antioxidant V5. The pharmaceutical composition of embodiment V4, wherein the antioxidant is chosen from butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), DL-alpha-tocopherol, ascorbyl palmitate and propyl gallate, or two or more thereof. V6. The pharmaceutical composition of any one of embodiments R1-R11, S1-S12, T1-T10, U1-U11, and V1-V5, comprising a flavoring. V7. The pharmaceutical composition of any one of embodiments R1-R11, S1-S12, T1-T10, U1-U11, and V1-V6, wherein the rimiducid analog is a compound of Formula C, D, E, F, F1, G, H, H1 or J, or a pharmaceutically acceptable salt thereof. V8. The pharmaceutical composition of any one of embodiments R1-R11, S1-S12, T1-T10, U1-U11, and V1-V7, which is a liquid emulsion containing particles or a liquid dispersion containing particles. V9. The pharmaceutical composition of embodiment V8, wherein the particles have a mean diameter of about 500 nanometers (nm) or less. V10. The pharmaceutical composition of embodiment V8, wherein the mean diameter is about 200 nm or less. V11. The pharmaceutical composition of embodiment V8, wherein the mean diameter is about 100 nm or less. V12. The pharmaceutical composition of any one of embodiments R1-R11, S1-S12, T1-T10, U1- U11, and V1-V11, in unit dosage form. V13. The pharmaceutical composition of any one of embodiments R1-R11, S1-S12, T1-T10, U1- U11, and V1-V12, for oral administration. V14. A method for preparing a pharmaceutical composition of any one of embodiments R1-R11, S1- S12, T1-T10, U1-U11, and V1-V13, comprising combining and mixing the excipients to form a mixture, and combing the rimiducid analog with the mixture. V15. A pharmaceutical composition obtainable by a method of embodiment V14. W1. A composition comprising a compound of Formula H1 or a pharmaceutically acceptable salt thereof. W2. A composition comprising a compound of Formula H or a pharmaceutically acceptable salt thereof, wherein R1and R2each independently is hydrogen or alkyl. W3. A composition comprising a compound of Formula J or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3and R4each independently is hydrogen or alkyl. W4. A composition comprising a compound of any one of embodiments W1-W3 or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. X1. The pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12, E1-E3, F1-F15, G1-G22, H1-H7, J1-J7, K1-K7, L1-L4, M1-M4, N1-N15, P1-P18, R1-R11, S1-S12, T1-T10, U1-U11, V1-V14 and S4 or composition of any one of embodiments W1-W3, for multimerization of a fusion protein, wherein the fusion protein comprises a polypeptide that binds to the compound having the structure of Formula A, the compound having the structure of Formula B, or a rimiducid analog. X2. A method for administering a pharmaceutical composition of any one of embodiments A1-A37, B1-B3, C1-C3, D1-D12, E1-E3, F1-F15, G1-G22, H1-H7, J1-J7, K1-K7, L1-L4, M1-M4, N1-N15, P1-P18, R1-R11, S1-S12, T1-T10, U1-U11, V1-V14 and S4 or composition of any one of embodiments W1-W3 to cells comprising a fusion protein, wherein the fusion protein comprises a polypeptide that binds to the compound having the structure of Formula A, the compound having the structure of Formula B, or a rimiducid analog. X3. The method of embodiment X2, wherein the pharmaceutical composition or composition is administered to a subject in need thereof. X4. The pharmaceutical composition or composition of embodiment X1 or the method of embodiment X2 or X3, wherein the polypeptide that binds to the compound having the structure of Formula A, the compound having the structure of Formula B, or the rimiducid analog, is FKBP12- V36. X5. The pharmaceutical composition or composition or the method of embodiment X4, wherein the FKBP12-V36 comprises the polypeptide of SEQ ID NO:1 or SEQ ID NO:4, or a polypeptide at least 90% identical to the polypeptide of SEQ ID NO:1 or SEQ ID NO:4. X6. The pharmaceutical composition or the composition or the method of any one of embodiments X1-X5, wherein the fusion protein comprises a polypeptide capable of inducing cell death. X7. The pharmaceutical composition or the composition or the method of embodiment X6, wherein the polypeptide capable of inducing cell death is caspase-9. X8. The pharmaceutical composition or the composition or the method of embodiment X7, wherein the caspase-9 is a truncated caspase-9. X9. The pharmaceutical composition or the composition or the method of embodiment X8, wherein the truncated caspase-9 comprises the polypeptide of SEQ ID NO:3, or a polypeptide at least 90% identical to SEQ ID NO:3. X10. The pharmaceutical composition of the method of any one of embodiments X1-X9, wherein the fusion protein comprises the polypeptides of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, or polypeptides at least 90% identical to the polypeptides of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3. X11. The pharmaceutical composition or the composition or the method of embodiment X10, wherein the fusion protein comprises, in the N-terminus to C-terminus direction, the polypeptides of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, or polypeptides at least 90% identical to the polypeptides of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3. X12. The pharmaceutical composition or method of any one of embodiments X1-X11, wherein the fusion protein comprises a polypeptide capable of activating immune cells. X13. The pharmaceutical composition or the composition or the method of embodiment X12, wherein the polypeptide capable of activating immune cells comprises a MyD88 polypeptide or truncated MyD88 polypeptide. X14. The pharmaceutical composition or method of embodiment X13, wherein the truncated MyD88 polypeptide comprises the polypeptide of SEQ ID NO:5, or a polypeptide at least 90% identical to SEQ ID NO:5. X15. The pharmaceutical composition or the composition or the method of any one of embodiments X12-X14, wherein the polypeptide capable of activating immune cells comprises a CD40 polypeptide or cytoplasmic CD40 polypeptide. X16. The pharmaceutical composition or method of embodiment X15, wherein the cytoplasmic CD40 polypeptide comprises the polypeptide of SEQ ID NO:6, or a polypeptide at least 90% identical to SEQ ID NO:7. X17. The pharmaceutical composition or the composition or the method of any one of embodiments X12-X16, wherein the fusion protein comprises the polypeptides of SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, or polypeptides at least 90% identical to the polypeptides of SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. X18. The pharmaceutical composition or the composition or the method of embodiment X17, wherein the fusion protein comprises, in the N-terminus to C-terminus direction, the polypeptides of SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:4, or polypeptides at least 90% identical to the polypeptides of SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:4. X19. The pharmaceutical composition or the composition or the method of embodiment X18, wherein: there is a linker peptide between (i) the polypeptide of SEQ ID NO:5, or the polypeptide at least 90% identical to SEQ ID NO:5, and (ii) the polypeptide of SEQ ID NO:6, or the polypeptide at least 90% identical to SEQ ID NO:6; or there is a linker peptide between (i) the polypeptide of SEQ ID NO:6, or the polypeptide at least 90% identical to SEQ ID NO:6, and (ii) the polypeptide of SEQ ID NO:4, or the polypeptide at least 90% identical to SEQ ID NO:4. X20. The pharmaceutical composition of the method of any one of embodiments X1-X19, wherein the fusion protein comprises a membrane association polypeptide. X21. The pharmaceutical composition of the method of embodiment X20, wherein the fusion protein comprises a myristoyl association polypeptide. X22. The pharmaceutical composition or the composition or the method of embodiment X21, wherein the fusion protein comprises a membrane association polypeptide of SEQ ID NO:7, or a polypeptide at least 90% identical to the polypeptide of SEQ ID NO:7. X23. The pharmaceutical composition or the composition or the method of any one of embodiments X20-X22, wherein the membrane association polypeptide is positioned at the N-terminus of the fusion protein. X24. The pharmaceutical composition or the composition or the method of embodiment X23, wherein the fusion protein optionally contains a linker peptide at the C-terminus of the membrane association polypeptide. X25. The pharmaceutical composition of the method of any one of embodiments X1-X24, wherein the fusion protein is expressed in cells. X26. The pharmaceutical composition or the composition or the method of embodiment X25, wherein the cells are in vitro or ex vivo. X27. The pharmaceutical composition of the method of embodiment X25, wherein the cells are in vivo. X28. The pharmaceutical composition or the composition or the method of any one of embodiments X1-X27, for eliminating cells containing a fusion protein, wherein the fusion protein comprises a polypeptide that binds to the compound having the structure of Formula A or Formula B or a rimiducid analog. X29. The pharmaceutical composition or the composition or the method of any one of embodiments X1-X28, for treatment of a cell proliferative condition. X30. The pharmaceutical composition or the composition or the method of embodiment X29, wherein the condition is a cancer. X31. The pharmaceutical composition or the composition or the method of any one of embodiments X1-X30, for treatment of a skin condition. X32. The pharmaceutical composition or the composition or the method of embodiment X31, wherein the skin condition is chosen from skin lesion, actinic keratosis, skin carcinoma and Bowen’s disease. X33. The pharmaceutical composition or the composition or the method of any one of embodiments X1-X28, for treatment of a pathogen condition. X34. The pharmaceutical composition of the method of embodiment X33, wherein the pathogen condition is a viral condition or bacterial condition. Examples The examples set forth below illustrate certain implementations and do not limit the technology. Example 1: Synthesis of compound of Formula B Following is a synthetic scheme (see FIG.5A, FIG.5B and FIG.5C) for synthesizing the compound of Formula B, referred to as rimiducid herein. A -78°C solution of commercially available 3, 4, 5- trimethoxyphenyl acetic acid 1 in THF was treated with 2.2 equivalents of tert-butyllithium. After an appropriate period, a solution of ethyl iodide was added and the product 2 was isolated. Compound 2 was resolved to give it’s (S) enantiomer 3. Acid 3 was amidated with (S) pipecolic acid methyl ester, using a reagent like HATU, PyBop or EEDQ, to give the amide 4. Hydrolysis of 4 with potassium carbonate in aqueous methanol, followed by acidification, gave the carboxylic acid 5. Commercially available 3-hydroxyacetophenone 6 was condensed via acid catalyzed aldol reaction, dehydration and water removal, with 3,4-dimethoxybenzaldehyde, to give eneone 7. Catalytic hydrogenation using a palladium catalyst under a hydrogen atmosphere afforded ketone 8. Alkylation of 8 with tert-butylbromoacetate in the presence of a basic promoter like potassium carbonate gave keto-phenoxy ester 9. Reduction of 9 with a chirally modified reducing agent, followed by resolution to remove the minor enantiomer, gives hydroxy-phenoxy ester 10 bearing the depicted (R) absolute stereochemistry. Esterification of 10 to give compound 11 was carried out via acid chloride formation of 5 using oxalyl chloride in the presence of catalytic amounts of DMF in dichloromethane solution, followed by addition to 10 in the presence of a soluble base like triethylamine. Diester 11 was converted to ester acid 12 by the action of TFA in a solvent like DCM. Amidation of 12 with a large excess of ethylene diamine using an amidation agent like HATU, PyBop or EEDQ affords an aminoethyl amide intermediate (not shown) which, when exposed to a second equivalent of 12 under the same conditions, gives the final product 13 (rimiducid; Formula B). Example 2: Synthesis of compound of Formula H1 Following is a synthetic scheme (see FIG.6A, FIG.6B and FIG.6C) for synthesizing the compound of Formula H1. While the scheme shown in this example is for synthesizing the compound of Formula H1, the scheme can be adapted generally to synthesize compounds of Formula H. For the synthetic scheme shown in this Example, the keto phenoxy ester 1 is reduced with a chirally modified reducing agent, followed by resolution, affording the hydroxy-phenoxy ester 2 having the depicted absolute stereochemistry. Treatment of 2 with diphenylphosphoryl azide gives the azido-phenoxy ester 3 with the depicted absolute stereochemistry. Staudinger reduction of 3 with triphenylphosphine then gives amino-phenoxy ester 4 with retention of stereochemistry. Acylation of 4 with the depicted pipecolic acid derivative by the action of an amidation reagent like HATU, PyBop or EEDQ produces the acylamino-phenoxy ester 5. De-esterification of 5 using TFA then gives the acylamino phenoxy carboxylic acid 6. Reduction of the carboxylic acid functionality in 6 with borane-dimethylsulfide affords the alkylamino alcohol 11. Reaction of 11 with p- toluenesulfonyl chloride then generates the acylamino phenoxy tosylate 8, which is reacted with 1,4- dimethyl-ethylene diamine to give the acylamino phenoxy diamine 9. Further reaction of 13 with another equivalent of 8 gives the compound of Formula H1. Example 3: Synthesis of compounds of Formula J Following is a synthetic scheme (see FIG.7A, FIG.7B, FIG.7C and FIG.7D) for synthesizing a subset of compounds of Formula J. Positions R1and R2in the synthetic scheme shown in this Example correspond to R1and R2in Formula J. For the synthetic scheme shown above in this Example, commercially available 3-(N- dibenzylamino)acetophenone (1) is condensed with 3,4-dimethoxybenzaldehyde via a base promoted aldol reaction using potassium tert-butoxide, followed by neutralization and dehydration, to form eneone 2. Catalytic hydrogenation of 2 using a palladium-on-carbon catalyst removes the benzyl groups and reduces the eneone to give anilino-ketone 3. Alkylation of 3 with allyl bromoacetate in the presence of potassium carbonate in a solvent like DMF affords the keto-amino ester 4. Reaction of 4 with Boc anhydride in the presence of an acylation catalyst like DMAP yields the N-protected keto-amino ester 5. Reduction of 5 with a chirally modified reducing agent followed by resolution affords the N- protected hydroxy-amino ester 6 having the depicted absolute stereochemistry. Treatment of 6 with diphenylphosphoryl azide yields the N-protected azido-amino ester 7 having the depicted absolute stereochemistry. Staudinger reduction of 7 with triphenylphosphine yields N-monoprotected diamino-ester 8 with retention of stereochemistry. Acylation of 8 with the depicted pipecolic acid derivative by the action of an amidation reagent like HATU, PyBop or EEDQ produces the acylamino N-protected ester 9. Ester de-allylation using a palladium catalyst like palladium (II) acetate yields the acylamino N-protected carboxylic acid 10. Reduction of the carboxylic acid functionality in 10 with borane-dimethylsulfide yields acylamino N-protected alcohol 11. Reaction of 11 with p-toluenesulfonyl chloride will lead to N-protected tosylate 12. Reaction of 12 with ethylene diamine, a 1-substitued derivative of ethylene diamine (R1= H, R2 = alkyl) or a 1,4-disubstitued derivative of ethylene diamine (R1, R2 = independently alkyl) yields the acylamino N-protected diamine 13. Further reaction of 13 with another equivalent of 12 yields a fully assembled N,N-diprotected-tetra amine intermediate (not shown) which, when treated with TFA, affords the final compound 14. Example 4: Synthesis of compounds of Formula J Following is a synthetic scheme (see FIG.8A, FIG.8B, FIG.8C and FIG.8D) for synthesizing a subset of compounds of Formula J. The positions of R1, R2, R3 and R4 in the synthetic scheme shown in this Example differ from the positions of R1, R2, R3and R4in Formula J, where R1in Formula J is R3in compound 14 shown in the scheme, R2in Formula J is R4in compound 14 shown in the scheme, R3in Formula J is R1in compound 14 shown in the scheme, and R4in Formula J is R2 in compound 14 shown in the scheme. For the synthetic scheme shown above in this Example, commercially available 3-benzylamino acetophenone 1 is combined with a solution of an aldehyde in THF and stirred for an hour. Solid sodium triacetoxyborohydride will be added and the mixture stirred until the reaction is complete, giving 3-(alkylbenzylamino)acetophenone 2. Compound 2 is subjected to base promoted aldol condensation with 3,4-dimethoxybenzaldehyde, followed by neutralization to give eneone 3. Catalytic hydrogenation using palladium-on-carbon removes the benzyl group and reduces the eneone to give alkylamino ketone 4. Ketone 4 is alkylated with tert-butyl bromoacetate to give the keto-alkylamino ester 5. Reduction of 5 with a chirally modified reducing agent followed by resolution affords the hydroxy- alkylamino ester 6 with the depicted absolute stereochemistry. Treatment of 6 with diphenylphosphoryl azide yields the azido-alkylamino ester 7 with the depicted absolute stereochemistry. Staudinger reduction of 7 with triphenylphosphine then gives amino-alkylamino- ester 8 with retention of stereochemistry. Acylation of 8 (R1= alkyl) with the depicted pipecolic acid derivative by the action of an amidation reagent like HATU, PyBop or EEDQ produces the acylamino-alkylamino ester 9. De-esterification of 9 using TFA then gives the acylamino alkylamino carboxylic acid 10. Reduction of the carboxylic acid functionality in 10 with borane-dimethylsulfide affords the alkylamino alcohol 11. Reaction of 11 with p-toluenesulfonyl chloride then generates the alkylamino tosylate 12, which is promptly reacted with ethylene diamine, a 1-substitued derivative of ethylene diamine (R3 = H, R4 = alkyl) or a 1,4-disubstitued derivative of ethylene diamine (R3, R4= independently alkyl) to give the acylamino alkylamino triamine 13. Further reaction of 13 with an equivalent of freshly generated 12 then gives a fully assembled tetra-amine final compound 14. Example 5: Synthesis of compound of Formula F1 Following is a process for synthesizing a compound of Formula F1, as reported in published PCT application no. WO2019126344A1, according to the following scheme (see FIG.9A, FIG.9B and FIG.9C). A suspension of LiAlH4(1.41 g, 37.18 mmol, 0.2 vol.) in THF (tetrahydrofuran) (74 mL, 9.0 vol.) is cooled to 0 °C. To this suspension is added a solution of [3[(1R)-3-(3,4-dimethoxyphenyl)-1- hydroxyphenyl]phenoxy]-acetic acid (6, 8.05 g, 23.24 mmol; compounds 6 and 14 may be prepared as provided in the present application) in THF (60 mL, 7.5 vol.) while maintaining the internal temperature below 20 °C. The reaction is stirred for a further 2 hours at room temperature. [IPC TLC (in process check: thin layer chromatography) (SiO2: EtOAc / Hexane 50:50) 6: Rf 0.15, 19: Rf 0.26]. Upon completion, the reaction mixture is cooled to 0 °C and water (1.5 mL) is added dropwise followed by 15% NaOH aq. (1.5 mL) and water (3 mL) while maintaining the internal temperature below 30 °C. The quenched reaction is then diluted with TBME (tert-Butyl methyl ether) (100 mL, 12.0 vol.) and stirring continues for 30 minutes. The reaction mixture is dried with MgSO4, filtered and solvent is removed by rotary evaporation. The crude product 3-(3,4-dimethoxyphenyl)-1-[3-(2- hydroxyethoxy)phenyl]propan-1-one 19 (7.10 g, 21.38 mmol, 92% yield) is obtained as a colorless oil and was used directly in the next step without further purification. 3-(3,4-dimethoxyphenyl)-1-[3-(2-hydroxyethoxy)phenyl]propan-1-one (19, 68.6 g, 206.5 mmol) is dissolved in DCM (Dichloromethane) (590 mL, 8.5 vol.). Triethylamine (43.2 mL, 309.8 mmol, 1.5 eq.) is added followed by 4-toluenesulfonyl chloride (39.4 g, 206.5 mmol, 1.0 eq.). The reaction mixture is stirred at room temperature for 18 hours. [IPC TLC (SiO2: EtOAc / Hexane 50:50) 19: Rf 0.26, 20-OTs: Rf 0.52, TsCl: Rf 0.76]. Upon completion, the DCM is removed by rotary evaporation and exchanged for EtOAc (500 mL, 7.1 vol.). The organic layer is washed with HCl aq.1M (3 x 100 mL, 1.4 vol.), NaHCO3sat. aq. (2 x 10 mL, 1.4 vol.), brine (70 mL, 1.0 vol.), dried over MgSO4then filtered and solvent is removed by rotary evaporation. The crude residue is purified by BIOTAGE (340 g SNAP Ultra column; 30-90% EtOAc in Hexane) to provide 2-{3-[3-(3,4- dimethoxyphenyl)propanoyl]phenoxy}ethyl 4-methylbenzenesulfonate, 20-OTs (63.6 g, 130.7 mmol, 63% yield) as a colorless oil. This material is used directly in the following step. 2-{3-[3-(3,4-dimethoxyphenyl)propanoyl]phenoxy}ethyl 4-methylbenzenesulfonate 20-OTs (3.93 g, 8.08 mmol) and N,N'-dimethyl-ethylenediamine (0.36 g, 4.04 mmol, 0.5 eq.) are dissolved in MeCN (acetonitrile) (20 mL, 5.0 vol.). To this solution is added K2CO3 (2.23 g, 16.16 mmol, 2.0 eq.) and KI (0.67 g, 4.04 mmol, 0.5 eq.). The reaction mixture is heated to 70 °C and stirred for 16 hours. [IPC TLC (SiO2: EtOAc / Hexane 50:50) 20-OTs: Rf 0.26, 13-(CH2)2-: Rf baseline]. Upon completion, MeCN is removed by rotary evaporation and exchanged for EtOAc (50 mL, 12.0 vol.). The organic layer is washed with water (2 x 20 mL, 5.0 vol.) and NaHCO3 sat. aq. (2 x 20 mL, 5.0 vol.). The desired product is then extracted into the aqueous layer with HCl 1M aq. (2 x 30 mL, 7.5 vol.) and the aqueous phase is washed with EtOAc (2 x 20 mL, 5.0 vol.). The aqueous phase is then basified with NaHCO3 sat. aq. (90 mL, 22.5 vol.) and extracted with EtOAc (3 x 30 mL, 7.5 vol.). The organic phase is then washed with brine (20 mL, 5.0 vol.), dried over MgSO4, filtered and solvent is removed by rotary evaporation to provide 13-(CH2)2- (2.75 g, 3.83 mmol, 95% yield). The crude material is used directly in the next step without further purification. 13-(CH2)2- (2.47 g, 3.45 mmol) and 14 (2.77 g, 7.59 mmol, 2.2 eq.) are dissolved in DCM (35 mL, 14.0 vol.) and the solution cooled to -15 °C. To the reaction mixture is added EDCI (1-Ethyl-3-(3- dimethylaminopropyl)carbodiimide) (1.59 g, 8.28 mmol, 2.4 eq.) followed by DMAP (4- Dimethylaminopyridine) (1.86 g, 15.18 mmol, 4.4 eq.). The reaction is stirred overnight at -15 °C. After 24 hours the internal temperature of the reaction was increased to -4 °C and the reaction left to stir for a further 24 hours. [IPC TLC (SiO2: MeOH / DCM 5:95) 15-(CH2)2-: Rf 0.15, 14: Rf 0.37, compound of Formula F1: Rf 0.66]. Upon completion, the reaction is quenched by addition of 5M HCl sol. (10 mL, 4.0 vol.) to the reaction mixture at -4 °C. DCM is then removed by vacuum distillation while maintaining the internal temperature below 20 °C. The residue is diluted with EtOAc (50 mL, 20.0 vol.) and the organic layer washed sequentially with 1M HCl sol. (2 x 10 mL, 4.0 vol.), NaHCO3 sol. (10 mL, 4.0 vol.) and brine (10 mL, 4.0 vol.). The organic layer is dried with MgSO4, filtered and solvent removed by rotary evaporation. The crude residue is purified by BIOTAGE (50 g SNAP Ultra, 0- 10% MeOH in DCM) to provide a compound of Formula F1 (2.09 g, 1.48 mmol, 43% yield) as an amorphous white solid. MS: (+ESI): calculated for C80H106N4018 [M+H]+1411.7575, found 1411.7982. The compound of Formula F1 is (1R,1'R)-((((ethane-1,2- diylbis(methylazanediyl))bis(ethane-2,1-diyl))bis(oxy))bis(3,1-phenylene))bis(3-(3,4- dimethoxyphenyl)propane-1,1-diyl) (2S,2'S)-bis(1-((S)-2-(3,4,5- trimethoxyphenyl)butanoyl)piperidine-2-carboxylate). Example 6: HPLC Solubility Testing High-performance liquid chromatography (HPLC) is used to measure the solubility of rimiducid and rimiducid analogs in various formulations (formulations also are referred to as pharmaceutical compositions). Solvent A is HPLC grade water containing 0.1% trifluoro acetic acid (TFA) and Solvent B is acetonitrile containing 0.1% TFA. A gradient HPLC method is utilized for quantifying rimiducid content and rimiducid analog content from the formulations. A gradient of 5% Solvent B to 100% Solvent B, the other portion being made up of Solvent A, is run on HPLC over the course of 10 minutes. A standard curve is generated with solutions of known concentrations (standard solutions in sample diluent (60:40 acetonitrile:water)) of rimiducid and rimiducid analogs and analyzing the standard solutions using an identical gradient HPLC method. An ultraviolet (UV) detector set to a wavelength of 275 nanometers (nm) is used to detect the compounds run in the gradient HPLC method. The UV peaks are integrated, and peak areas are calculated. The peak areas (y-axis) are then plotted versus the concentrations of the standard solutions (x-axis) and a linear curve is fitted. To test the solubility of the rimiducid and rimiducid analogs in the formulations, sample formulations are synthesized (as described below), centrifuged to pellet undissolved rimiducid, and the supernatant fractions are diluted in sample diluent to extract all rimiducid from the formulations. The extracted rimiducid or rimiducid analog is then analyzed using an identical HPLC gradient method as the standard solution. The peak area of the extracted rimiducid or rimiducid analog is then integrated and the solubility is calculated using the equation derived from the peak areas of standard solutions. Example 7: Pharmacokinetics Testing Pharmacokinetic testing (PK) is performed in mice and / or rats for the rimiducid or rimiducid analog formulations. The formulations are dosed intraperitonially (IP), subcutaneously (SC), intramuscularly (IM), orally (PO), or intravenously (IV). Blood draws, sample processing, and sample analysis are irrespective of route of administration (ROA) or animal species. At time zero of a particular study, rimiducid or rimiducid analog formulations are dosed. Following formulation dosing, at pre-determined time points, blood is drawn either retro-orbitally (RO) or using the saphenous vein into EDTA-coated blood tubes. After blood draws, the blood tubes are centrifuged at 10,000 x g for 10 minutes in a cooled (4°C) centrifuge to separate plasma. After centrifugation, 50 µL of plasma is removed from the blood tube and pipetted into a 1.5-mL microcentrifuge tube and placed on ice. To extract rimiducid or rimiducid analog from the plasmid, 50 µL of internal standard solution (ISS) is added to the plasma. The plasma / ISS mixture is vortexed for 30 seconds to ensure complete extraction of the rimiducid from the plasma. The ISS contains a compound of similar structure to rimiducid or rimiducid analog but of different molecular weight in 100% acetonitrile. An internal standard is used during LCMS quantification to ensure accuracy of quantitation. This extraction procedure is performed for all blood draws at each time point. A standard curve is generated by making solutions of known concentrations of rimiducid or rimiducid analog in 100% DMSO. These solutions are made at 20 times the final target concentration of the resulting LCMS standard, as 2.5 µL of DMSO standard is added to 47.5 µL of plasma from an untreated animal. This step is done to simulate the same ISS rimiducid extraction procedure that is performed with the plasma from the treated animals. After all blood is drawn, all plasma processed, and all rimiducid or rimiducid analog extracted with ISS, the samples are analyzed by liquid chromatography mass spectrometry (LCMS). The rimiducid or rimiducid analog peaks and the internal standard peaks are quantified using a mass spectrometer. After peak quantification, a ratio of analyte (rimiducid or rimiducid analog) to internal standard (IS) is calculated. To generate a standard curve, analyte:IS ratios are plotted (y-axis) versus the concentrations of the known standards (x-axis) and a linear curve is fitted. The concentration of rimiducid from animals dosed with rimiducid or rimiducid analog formulations is then calculated using the standard curve generated from analyte:IS ratios of known standard samples. Example 8: Formulation Dispersion Testing SEDDS formulations and oral formulations disperse within their aqueous environment forming an emulsion, a property referred to as particle dispersion. Dispersion testing is performed on rimiducid or rimiducid analog formulations with two test outcomes: (1) rimiducid solubility after dispersion and (2) dispersion particle size. Rimiducid or rimiducid analog solubility is analyzed qualitatively by diluting the rimiducid or rimiducid analog formulations 1:100 in phosphate-buffered saline (PBS), pH = 7.4. The dispersions are then mixed on a magnetic stir plate using a magnetic stir bar for 1 hour. After 1 hour, the dispersions are qualitatively observed for drug precipitation and observations are recorded. Stirring continues for an additional 72 hours and observations of any precipitation are noted every 24 hours. Rimiducid or rimiducid analog dispersion particle size is analyzed quantitatively by measuring the particle size, post-dispersion, using dynamic light scattering (DLS) technology, which measures the particle size and homogeneity of particle in solution. Rimiducid or rimiducid analog formulations are diluted 1:100 in PBS, pH = 7.4, and stirred on a magnetic stir plate using a magnetic stir bar for 1 hour. After 1 hour, the particle sizes of the dispersions are measured using DLS. Stirring continues for an additional 72 hours and dispersion particle size measurements are carried out every 24 hours. Example 9: Rimiducid and rimiducid analog self-emulsifying drug delivery systems (SEDDS) Blank formulations (not containing rimiducid or rimiducid analog) are synthesized by mixing components followed by stirring on a magnetic stir plate with a magnetic stir bar for 1 hour. Refer to Table 1 below for examples of SEDDS formulation components and their weight percentages (wt%) in the SEDDS formulation. The formulations typically contain water miscible and water immiscible components, the water miscible components are mixed separately and then added to the water immiscible component(s) in the final mixture step. For the excipients listed in Table 1, for example, polysorbate 80, polyethoxylated castor oil (PECO), PEG400, linoleoyl macrogol glycerides, glyceryl monocaprylate, propylene glycol monocaprylate, propylene glycol dicaprylate, PEG-8 caprylic / capric glycerides and ethanol are water miscible components, and MCT is a water immiscible component. For example, for a formulation containing 25% MCT oil, 40% Polysorbate 80, 25% PECO, and 10% ethanol, a mixture containing the polysorbate 80, PECO, and ethanol is first prepared and then added to MCT oil to prepare a blank formulation. The blank formulation then is added to the multimerizer active ingredient (e.g., rimiducid or rimiducid analog). Table 1. SEDDS formulation components. S J % % % % Propylene Glycol -- -- -- -- -- -- 0-50% 0-50% -- % The following specific formulations in Table 2 containing the compound of Formula B (rimiducid) were prepared according to the foregoing SEDDS formulation preparation process, and dispersion results were obtained utilizing the foregoing dispersion testing process. SEDDS formulations 1 (including formulations 1, 1a and 1b), 2, 3, 4, 5, 6, 7, 8 and 9 in Table 2 correspond to SEDDS formulations A, A, D, E, E, G, E, J and F in Table 1, respectively. Table 2. SEDDS formulations D m % % Polysorbate 23.33 23.75 22.5% 20% -- -- -- -- -- -- -- 80 % % - .5 % % - - .5 % Diameter, nm) FIG.10A is a graph showing pharmacokinetic (PK) data after subcutaneous (SC) injection in mice of Formulation A. Rimiducid (RIM), formulated in Formulation A, was administered, at a dose level of 20 mg / kg, to 12-week-old, female Balb / c mice subcutaneously (SC) on the back of the neck (n=3). At pre- determined time points of 2-, 4-, and 24-hour post SC RIM administration, retro-orbital bleeds were used to sample blood from the mice. The whole blood was processed to plasma and analyzed for RIM plasma levels as previously described. Post-plasma analysis, Graphpad Prism software was used to plot and analyze plasma levels of rimiducid (Figure 10A). FIG.10B is a graph showing pharmacokinetic (PK) data after subcutaneous (SC) injection in mice of Formulation D. Rimiducid (RIM), formulated in Formulation D, was administered, at a dose level of 20 mg / kg, to 12-week-old, female Balb / c mice subcutaneously (SC) on the back of the neck (n=3). At pre- determined time points of 2-, 4-, and 24-hour post SC RIM administration, retro-orbital bleeds were used to sample blood from the mice. The whole blood was processed to plasma and analyzed for RIM plasma levels as previously described. Post-plasma analysis, Graphpad Prism software was used to plot and analyze plasma levels of rimiducid (Figure 10B). Example 10: Characterization of SEDDS Formulation A containing rimiducid SEDDS Formulations 1, 1a and 1b described in Table 2 of Example 9 were characterized as representatives of SEDDS Formulation A described in Table 1 of Example 9. SEDDS Formulation 1, 1a and 1b contained the compound of Formula B (rimiducid) as the active ingredient. Solubility of rimiducid in the representative SEDDS Formulation 1, 1a and 1b was about 50, 100, and 200 mg / ml, respectively, as determined according to the process described in Example 6, which was about a 10, 20, or 40-fold solubility enhancement over the 5 mg / mL amount of rimiducid utilized clinically (Iuliucci et al., J Clin Pharmacol 41:870-879 (2001)) and the 5 mg / mL amount of rimiducid formulated in 25% Solutol HS15 / Kolliphor®HS15 (CAS# 70142-34-6; U.S. Patent No.11718656). Particles in SEDDS Formulation A representatives were assessed according to the process described in Example 8. Mean particle diameter and polydispersity was determined for different rimiducid amounts in a 1:100 dispersion in phosphate buffered saline, as shown in FIG.1. Mean particle size and polydispersity are summarized in the following Table 3. Table 3: Particle size parameters for representative SEDDS Formulation A 5 Pharmacokinetic parameters for the SEDDS Formulation 1, 1a and 1b were assessed in rats and dogs according to the processes described in Example 7. In rats, SEDDS Formulation 1, 1a and 1b were administered as a single intramuscular dose of 50, 100, or 200 mg / ml rimiducid, at a 10, 20, or 40 mg / kg rimiducid dose level, respectively, and 0.2 mL / kg formulation dose volume, and blood rimiducid levels were assessed over time as shown in FIG.2A. In dogs, SEDDS Formulation 1 was administered as a single intramuscular dose of 50 mg / mL rimiducid, at a 1 mg / kg rimiducid dose level and 0.02 mL / kg formulation dose volume, and blood rimiducid levels were assessed over time as shown in FIG.2B. Pharmacokinetic parameters for administration of rimiducid in the representative Formulation A determined from the study are summarized in the following Table 4. Pharmacokinetic data in rats revealed that optimal rimiducid bioavailability was afforded by a post- dispersion particle size lower than 40 nm, or a rimiducid wt% at or below 5% in SEDDS Formulation A, according to the comparison of AUC / Dose. Table 4: Pharmacokinetic parameters for representative SEDDS Formulation A ose ) The stability of Formulations 1a and 1d were tested. Formulation 1d was made in accordance with Formula D (see Table 1). Stability was tested at two temperatures (25^ and 40^) and at two relative humidity (RH) levels of 60% and 75%. The results are shown in Table 5. The tests show both Formulations were stable for at least three months. Rimiducid concentrations were measured for each formulation at each specified time point using high-performance liquid chromatography (HPLC). Briefly, a set of samples with known rimiducid concentrations were analyzed by HPLC and their peak areas (absorbance, arbitrary units) were plotted versus rimiducid concentration to establish a standard curve. Assay percentage (Assay %, Table 5) for each rimiducid formulation was then calculated by using the peak area from each rimiducid formulation and the previously generated rimiducid standard curve. The final calculated rimiducid concentration (Assay) was then compared to its expected value to calculate the Assay %. Particle Diameter (nm) was measured using dynamic light scattering. Table 5: Stability data r Example 11: Characterization of SEDDS Formulation D containing rimiducid Representative formulations containing 5, 10 or 20 wt% of the compound of Formula B (rimiducid) as the active ingredient were prepared according to SEDDS Formulation D described in Table 1 of Example 9, and characterized. These representatives of SEDDS Formulation D are referred to as SEDDS Formulation D1, D2 and D3, respectively. Solubility of rimiducid in the representative SEDDS Formulation D1, D2, and D3 was about 50, 100, and 200 mg / ml, respectively, as determined according to the process described in Example 6, which was about a 10, 20, or 40-fold solubility enhancement over the 5 mg / mL amount of rimiducid utilized clinically (Iuliucci et al., J Clin Pharmacol 41:870-879 (2001)) and the 5 mg / mL amount of rimiducid formulated in 25% Solutol HS15 / Kolliphor®HS15 (CAS# 70142-34-6; U.S. Patent No.11718656). Particles in SEDDS Formulation D representatives were assessed according to the process described in Example 8. Mean particle diameter and polydispersity was determined for different rimiducid concentrations in a 1:100 dispersion in phosphate buffered saline, as shown in FIG.3. Mean particle size and polydispersity are summarized in the following Table 6. Table 6: Particle size parameters for representative SEDDS Formulation D 3 Pharmacokinetic parameters for the representatives of SEDDS Formulation D were assessed in rats and dogs according to the processes described in Example 7. In rats, SEDDS Formulation D1, D2 and D3 were administered as a single intramuscular dose of 50, 100, or 200 mg / ml rimiducid, at a 10, 20 or 40 mg / kg rimiducid dose level, respectively, and 0.2 mL / kg formulation dose volume and blood rimiducid levels were assessed over time as shown in FIG.4A. In dogs, SEDDS Formulation D1 was administered as a single intramuscular dose of 50 mg / mL rimiducid, at a 1 mg / kg rimiducid dose level and 0.02 mL / kg formulation dose volume, and blood rimiducid levels were assessed over time as shown in FIG.4B. Pharmacokinetic parameters for administration of rimiducid in the representative SEDDS Formulation D determined from the study are summarized in the following Table 7. Pharmacokinetic data in rats revealed that optimal rimiducid bioavailability was afforded by a post-dispersion particle size lower than 50 nm, or a rimiducid wt% at or below 5% in SEDDS Formulation D, according to the comparison of AUC / Dose. Table 7: Pharmacokinetic parameters for representative SEDDS Formulation D ose ) (~50 µL) D2 100 R 20 02 259 8 6395 3198 Example 12: Rimiducid analog oral formulations Blank formulations (not containing rimiducid analog) are synthesized by mixing all components followed by stirring on a magnetic stir plate with a magnetic stir bar. Refer to Table 8 below for rimiducid analog oral formulation components and their weight percentages (wt%). Following synthesis of blank formulations, rimiducid analog is weighted into a glass vial and blank formulation is added to the vial to generate a formulation with the final desired rimiducid analog concentration. The rimiducid analog formulations then are stirred on a magnetic stir plate overnight at ambient temperature.

[0004] Table 8. Rimiducid analog oral formulation components. * * * The entirety of each patent, patent application, publication and document referenced herein is incorporated by reference. Citation of patents, patent applications, publications and documents is not an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these publications or documents. Their citation is not an indication of a search for relevant disclosures. All statements regarding the date(s) or contents of the documents are based on available information and are not an admission as to their accuracy or correctness. The technology has been described with reference to specific implementations. The terms and expressions that have been utilized herein to describe the technology are descriptive and not necessarily limiting. Certain modifications made to the disclosed implementations can be considered within the scope of the technology. Certain aspects of the disclosed implementations suitably may be practiced in the presence or absence of certain elements not specifically disclosed herein. Each of the terms “comprising,” “consisting essentially of,” and “consisting of” may be replaced with either of the other two terms. A pharmaceutical composition or component therein “consisting essentially of” a particular agent (“agent x”) can include one or more other agents (e.g., including “agent y”) that do not materially affect the basic and novel characteristics of agent x. Other agents (e.g., including “agent y”) that do not materially affect the basic and novel characteristics of agent x typically alter the solubility of an active ingredient (e.g., rimiducid, rimiducid family compound or rimiducid analog) in the pharmaceutical composition by 5% or less. The term “a” or “an” can refer to one of or a plurality of the elements it modifies (e.g., “a reagent” can mean one or more reagents) unless it is contextually clear either one of the elements or more than one of the elements is described. The term “about” as used herein refers to a value within 10% of the underlying parameter (i.e., plus or minus 10%; e.g., a weight of “about 100 grams” can include a weight between 90 grams and 110 grams). Use of the term “about” at the beginning of a listing of values modifies each of the values (e.g., “about 1, 2 and 3” refers to “about 1, about 2 and about 3”). When a listing of values is described, the listing includes all intermediate values and all fractional values thereof (e.g., the listing of values “80%, 85% or 90%” includes the intermediate value 86% and the fractional value 86.4%). When a listing of values is followed by the term “or more,” the term “or more” applies to each of the values listed (e.g., the listing of “80%, 90%, 95%, or more” or “80%, 90%, 95% or more” or “80%, 90%, or 95% or more” refers to “80% or more, 90% or more, or 95% or more”). When a listing of values is described, the listing includes all ranges between any two of the values listed (e.g., the listing of “80%, 90% or 95%” includes ranges of “80% to 90%,” “80% to 95%” and “90% to 95%”). Certain implementations of the technology are set forth in the claim(s) that follow(s).

Claims

What is claimed is:

1. A self-emulsifying drug delivery system comprising: about 5% to about 20% (wt / wt) rimiducid or pharmaceutically acceptable salt thereof; about 10% to about 40% (wt / wt) of medium chain triglycerides (MCT) excipient; about 20% to about 60% (wt / wt) of a polyethoxylated castor oil (PECO) excipient; and 0 to about 10% (wt / wt) of an ethanol excipient.

2. The system as recited in claim 1, further comprising about 10 to about 50% (wt / wt) of a polysorbate excipient.

3. The system as recited in claim 2, wherein the system consists of the rimiducid, the MCT excipient, the PECO excipient and the polysorbate excipient.

4. The system as recited in claim 2, wherein the system consists of the rimiducid, the MCT excipient, the PECO excipient, the polysorbate excipient, and an aqueous buffered saline.

5. The system as recited in claim 4, wherein the rimiducid is present at a concentration of about 50 mg per mL.

6. The system as recited in claim 2, wherein the system consists of about 10% of the rimiducid, about 22.5% (wt / wt) of the MCT excipient, about 45% (wt / wt) of the PECO excipient, and about 22.5% (wt / wt) of the polysorbate excipient.

7. The system as recited in claim 2, wherein the system consists of about 10% (wt / wt) of the rimiducid, about 22.5% (wt / wt) of the MCT excipient, about 45% (wt / wt) of the PECO excipient, about 22.5% (wt / wt) of the polysorbate excipient, the system being suspended in aqueous buffered saline.

8. The system as recited in claim 7, wherein the rimiducid is present at a concentration of about 50 mg per mL.

9. The system as recited in claim 1, further comprising about 5% to about 50% (wt / wt) of a linoleoyl macrogol glyceride excipient and about 15% to about 20% of a glyceryl monocaprylate excipient.

10. The system as recited in claim 10, wherein the PECO excipient is present at a concentration of about 15% to about 50% (wt / wt) and the MCT excipient is present at a concentration of about 10% to about 35% (wt / wt).

11. The system as recited in claim 10, wherein the system consists of the rimiducid, the MCT excipient, the PECO excipient, the linoleoyl macrogol glyceride excipient, and the glyceryl monocaprylate excipient.

12. The system as recited in claim 10, wherein the system consists of the rimiducid, the MCT excipient, the PECO excipient, the linoleoyl macrogol glyceride excipient, and the glyceryl monocaprylate excipient, the system is suspended in aqueous buffered saline.

13. The system as recited in claim 12, wherein the rimiducid is present at a concentration of about 50 mg per mL.

14. The system as recited in any one of the claims 1-13, wherein the MTC excipient comprises triglycerides that include C6, C8, C10 and C12 fatty acids.

15. The system as recited in any one of claims 1-13, wherein the rimiducid is a compound of Formula A O O Formula A.

16. The system as recited in any one of claims 1-13, wherein the rimiducid is a compound of Formula B B. 17.the system as recited in any one of claims 1-16; an aqueous solvent; wherein the system forms a liquid emulsion containing particles or a liquid dispersion containing particles.

18. The pharmaceutical composition as recited in claim 17, wherein the particles have a mean diameter of about 500 nanometers (nm) or less.

19. The pharmaceutical composition as recited in claim 18, wherein the mean diameter is about 200 nm or less.

20. The pharmaceutical composition as recited in claim 18, wherein the mean diameter is about 100 nm or less.

21. The pharmaceutical composition as recited in claim 20, wherein the aqueous solvent is a buffered saline.

22. The pharmaceutical composition as recited in claim 20, wherein the aqueous solvent is a phosphate buffered saline (PBS).

23. A method for administering a pharmaceutical composition, the method comprising: administering the pharmaceutical composition of claim 17 to cells of a subject in need of treatment, the cells comprising a fusion protein; waiting for the fusion protein to bind with the pharmaceutical composition, wherein the fusion protein comprises a polypeptide that binds to the rimiducid, thereby forming a bound composition.

24. The method as recited in claim 23, wherein the subject is in need of treatment of a cell proliferative condition.

25. The method as recited in claim 24, wherein the cell proliferative condition is a cancer.

26. The method as recited in claim 23, wherein the subject is in need of treatment of a skin condition.

27. The method as recited in claim 26, wherein the skin condition is chosen from skin lesion, actinic keratosis, skin carcinoma and Bowen’s disease.

28. The method as recited in claim 23, wherein the subject is in need of treatment of a pathogen condition.

29. The method as recited in claim 28, wherein the pathogen condition is a viral condition or bacterial condition.

Images